CN117729923A - Combination therapy for the treatment of abnormal cell growth - Google Patents
Combination therapy for the treatment of abnormal cell growth Download PDFInfo
- Publication number
- CN117729923A CN117729923A CN202280026743.9A CN202280026743A CN117729923A CN 117729923 A CN117729923 A CN 117729923A CN 202280026743 A CN202280026743 A CN 202280026743A CN 117729923 A CN117729923 A CN 117729923A
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- cancer
- administered
- kras
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title abstract description 82
- 230000002159 abnormal effect Effects 0.000 title abstract description 26
- 230000010261 cell growth Effects 0.000 title abstract description 19
- 238000002648 combination therapy Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 314
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 269
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims abstract description 229
- 239000003112 inhibitor Substances 0.000 claims abstract description 186
- 201000011510 cancer Diseases 0.000 claims abstract description 176
- -1 CDK4/6 inhibitors Substances 0.000 claims abstract description 159
- 230000009977 dual effect Effects 0.000 claims abstract description 145
- 108040008097 MAP kinase activity proteins Proteins 0.000 claims abstract description 65
- 102000019149 MAP kinase activity proteins Human genes 0.000 claims abstract description 65
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims abstract description 65
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims abstract description 65
- 229940121647 egfr inhibitor Drugs 0.000 claims abstract description 60
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims abstract description 59
- 229940124302 mTOR inhibitor Drugs 0.000 claims abstract description 58
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims abstract description 58
- 239000003197 protein kinase B inhibitor Substances 0.000 claims abstract description 57
- 229940124647 MEK inhibitor Drugs 0.000 claims description 220
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 claims description 162
- 230000035772 mutation Effects 0.000 claims description 120
- 150000001875 compounds Chemical class 0.000 claims description 92
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 77
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 73
- 150000003839 salts Chemical class 0.000 claims description 69
- 102100030708 GTPase KRas Human genes 0.000 claims description 66
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 66
- 229940126271 SOS1 inhibitor Drugs 0.000 claims description 52
- 206010069755 K-ras gene mutation Diseases 0.000 claims description 50
- 229940126638 Akt inhibitor Drugs 0.000 claims description 49
- 102200006531 rs121913529 Human genes 0.000 claims description 46
- 102200006538 rs121913530 Human genes 0.000 claims description 45
- 229960001686 afatinib Drugs 0.000 claims description 30
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 28
- UCJZOKGUEJUNIO-IINYFYTJSA-N (3S,4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound C[C@@H]1OCC2(CCN(CC2)C2=CN=C(SC3=C(Cl)C(N)=NC=C3)C(N)=N2)[C@@H]1N UCJZOKGUEJUNIO-IINYFYTJSA-N 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 229940125999 RMC-4550 Drugs 0.000 claims description 22
- 229940126685 KRAS G12R Drugs 0.000 claims description 21
- IKUYEYLZXGGCRD-ORAYPTAESA-N [3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl]methanol Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C(=NC(=C(N=1)C)C1=C(C(=CC=C1)Cl)Cl)CO)C IKUYEYLZXGGCRD-ORAYPTAESA-N 0.000 claims description 21
- 102200006537 rs121913529 Human genes 0.000 claims description 21
- 102200006539 rs121913529 Human genes 0.000 claims description 21
- 102200006540 rs121913530 Human genes 0.000 claims description 21
- 102200006541 rs121913530 Human genes 0.000 claims description 21
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 20
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 20
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 19
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 17
- 229960005167 everolimus Drugs 0.000 claims description 17
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 17
- 229960004390 palbociclib Drugs 0.000 claims description 17
- 201000002528 pancreatic cancer Diseases 0.000 claims description 17
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims description 16
- HXAUJHZZPCBFPN-QGZVFWFLSA-N 4-[[(1s)-2-(azetidin-1-yl)-1-[4-chloro-3-(trifluoromethyl)phenyl]ethyl]amino]quinazoline-8-carboxamide Chemical compound C([C@@H](NC1=C2C=CC=C(C2=NC=N1)C(=O)N)C=1C=C(C(Cl)=CC=1)C(F)(F)F)N1CCC1 HXAUJHZZPCBFPN-QGZVFWFLSA-N 0.000 claims description 14
- 229940125795 BI-3406 Drugs 0.000 claims description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 14
- 208000026310 Breast neoplasm Diseases 0.000 claims description 14
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 13
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 13
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 13
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 13
- 229960002930 sirolimus Drugs 0.000 claims description 13
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 12
- 102000016914 ras Proteins Human genes 0.000 claims description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 8
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 8
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 8
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 8
- 229960001433 erlotinib Drugs 0.000 claims description 8
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 8
- 229960004891 lapatinib Drugs 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 230000001394 metastastic effect Effects 0.000 claims description 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 7
- 229960001972 panitumumab Drugs 0.000 claims description 7
- 229940126029 BDTX-189 Drugs 0.000 claims description 6
- 102100039788 GTPase NRas Human genes 0.000 claims description 6
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 6
- 229940124640 MK-2206 Drugs 0.000 claims description 6
- HIBPKFXWOPYJPZ-UHFFFAOYSA-N N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-7-(2-morpholin-4-ylethoxy)quinazolin-6-yl]prop-2-enamide Chemical compound ClC1=C(OCC2=NC=CC=C2)C=CC(NC2=NC=NC3=CC(OCCN4CCOCC4)=C(NC(=O)C=C)C=C23)=C1 HIBPKFXWOPYJPZ-UHFFFAOYSA-N 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 229960004641 rituximab Drugs 0.000 claims description 6
- HGYTYZKWKUXRKA-MRXNPFEDSA-N 1-[4-[3-amino-5-[(4S)-4-amino-2-oxa-8-azaspiro[4.5]decan-8-yl]pyrazin-2-yl]sulfanyl-3,3-difluoro-2H-indol-1-yl]ethanone Chemical compound NC=1C(=NC=C(N=1)N1CCC2([C@@H](COC2)N)CC1)SC1=C2C(CN(C2=CC=C1)C(C)=O)(F)F HGYTYZKWKUXRKA-MRXNPFEDSA-N 0.000 claims description 5
- 101100387225 Buchnera aphidicola subsp. Baizongia pistaciae (strain Bp) asd gene Proteins 0.000 claims description 5
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims description 5
- 101100523539 Mus musculus Raf1 gene Proteins 0.000 claims description 5
- 229940126002 RMC-4630 Drugs 0.000 claims description 5
- HISJAYUQVHMWTA-BLLLJJGKSA-N [6-(2-amino-3-chloropyridin-4-yl)sulfanyl-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl]methanol Chemical compound NC1=NC=CC(=C1Cl)SC1=C(N=C(C(=N1)CO)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)C HISJAYUQVHMWTA-BLLLJJGKSA-N 0.000 claims description 5
- 229960005395 cetuximab Drugs 0.000 claims description 5
- 229960004679 doxorubicin Drugs 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 4
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims description 4
- 206010027406 Mesothelioma Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 4
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 4
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 4
- 229960002584 gefitinib Drugs 0.000 claims description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- WZIIUILMMRGPJL-UHFFFAOYSA-N n-(4-methoxyphenyl)-n,2,6-trimethylfuro[2,3-d]pyrimidin-4-amine;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1N(C)C1=NC(C)=NC2=C1C=C(C)O2 WZIIUILMMRGPJL-UHFFFAOYSA-N 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 229960000241 vandetanib Drugs 0.000 claims description 4
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 4
- NZDSLYATTDIDPH-UHFFFAOYSA-N vevorisertib Chemical compound C1CC(N(C)C(C)=O)CCN1C1=CC=CC(C=2N=C3N(C=4C=CC(=CC=4)C4(N)CCC4)C(C=4C(=NC=CC=4)N)=NC3=CC=2)=C1 NZDSLYATTDIDPH-UHFFFAOYSA-N 0.000 claims description 4
- BVRGQPJKSKKGIH-PUAOIOHZSA-N (2R)-2-[5-[5-chloro-2-(oxan-4-ylamino)pyrimidin-4-yl]-3-oxo-1H-isoindol-2-yl]-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide Chemical compound ClC=1C(=NC(=NC=1)NC1CCOCC1)C1=CC=C2CN(C(C2=C1)=O)[C@@H](C(=O)N[C@H](CO)C1=CC(=CC(=C1)OC)F)C BVRGQPJKSKKGIH-PUAOIOHZSA-N 0.000 claims description 3
- FSXCKIBROURMFT-VGSWGCGISA-N (3ar,6ar)-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]-1-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrole-5-carboxamide Chemical compound C=12C=C(NC(=O)N3C[C@@H]4N(C)CC[C@@H]4C3)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 FSXCKIBROURMFT-VGSWGCGISA-N 0.000 claims description 3
- HVIGNZUDBVLTLU-MRXNPFEDSA-N (6R)-7-[(3,4-difluorophenyl)methyl]-6-(methoxymethyl)-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C[C@@H]2COC)C=C(N=3)C2=NC(=NC=C2C)NC2=CC=NN2C)=O)C=CC=1F HVIGNZUDBVLTLU-MRXNPFEDSA-N 0.000 claims description 3
- AMADCPJVPLUGQO-UHFFFAOYSA-N 1-[3-(2,3-dichlorophenyl)-2H-pyrazolo[3,4-b]pyrazin-6-yl]-4-methylpiperidin-4-amine Chemical compound ClC1=C(C=CC=C1Cl)C1=NNC2=NC(=CN=C21)N1CCC(CC1)(N)C AMADCPJVPLUGQO-UHFFFAOYSA-N 0.000 claims description 3
- VLULRUCCHYVXOH-UHFFFAOYSA-N 11-benzyl-7-[(2-methylphenyl)methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one Chemical compound CC1=CC=CC=C1CN1C(=O)C(CN(CC=2C=CC=CC=2)CC2)=C2N2CCN=C21 VLULRUCCHYVXOH-UHFFFAOYSA-N 0.000 claims description 3
- JBGYKRAZYDNCNV-UHFFFAOYSA-N 2-[4-(1-aminocyclobutyl)phenyl]-3-phenylimidazo[1,2-b]pyridazine-6-carboxamide Chemical compound N12N=C(C(=O)N)C=CC2=NC(C=2C=CC(=CC=2)C2(N)CCC2)=C1C1=CC=CC=C1 JBGYKRAZYDNCNV-UHFFFAOYSA-N 0.000 claims description 3
- WSOHOUHPUOAXIN-UHFFFAOYSA-N 2-n-[4-(4-methylpiperazin-1-yl)phenyl]-9-propan-2-yl-8-n-pyridin-3-ylpurine-2,8-diamine Chemical compound N=1C2=CN=C(NC=3C=CC(=CC=3)N3CCN(C)CC3)N=C2N(C(C)C)C=1NC1=CC=CN=C1 WSOHOUHPUOAXIN-UHFFFAOYSA-N 0.000 claims description 3
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 claims description 3
- UWXSAYUXVSFDBQ-CYBMUJFWSA-N 4-n-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-n-[(4r)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine Chemical compound C[C@@H]1COC(NC=2C=C3C(NC=4C=C(Cl)C(OCC=5SC=CN=5)=CC=4)=NC=NC3=CC=2)=N1 UWXSAYUXVSFDBQ-CYBMUJFWSA-N 0.000 claims description 3
- ADGGYDAFIHSYFI-UHFFFAOYSA-N 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1 ADGGYDAFIHSYFI-UHFFFAOYSA-N 0.000 claims description 3
- GMYLVKUGJMYTFB-UHFFFAOYSA-N 5-ethyl-3-[2-methyl-6-(1h-1,2,4-triazol-5-yl)pyridin-3-yl]-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical compound N1=C2N(CC)C(=O)CNC2=NC=C1C(C(=N1)C)=CC=C1C1=NN=CN1 GMYLVKUGJMYTFB-UHFFFAOYSA-N 0.000 claims description 3
- YGUFCDOEKKVKJK-UHFFFAOYSA-N 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine Chemical compound NC1(CCN(CC1)C1=CN=C(C(=N1)N)C1=C(C(=CC=C1)Cl)Cl)C YGUFCDOEKKVKJK-UHFFFAOYSA-N 0.000 claims description 3
- SGJLSPUSUBJWHO-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperidin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1C1CCNCC1 SGJLSPUSUBJWHO-UHFFFAOYSA-N 0.000 claims description 3
- ALDUQYYVQWGTMR-GJFSDDNBSA-N 6-ethyl-3-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-[(3R)-1-prop-2-enoylpyrrolidin-3-yl]oxypyrazine-2-carboxamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CCc1nc(C(N)=O)c(Nc2ccc(cc2)N2CCC(CC2)N2CCN(C)CC2)nc1O[C@@H]1CCN(C1)C(=O)C=C ALDUQYYVQWGTMR-GJFSDDNBSA-N 0.000 claims description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 3
- 239000005730 Azoxystrobin Substances 0.000 claims description 3
- GHKOONMJXNWOIW-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OCC(F)(F)F)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OCC(F)(F)F)C)C GHKOONMJXNWOIW-UHFFFAOYSA-N 0.000 claims description 3
- BPMZUKYFIDPLEA-UHFFFAOYSA-N CN(CCOC1=C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC(C=C)=O)C Chemical compound CN(CCOC1=C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC(C=C)=O)C BPMZUKYFIDPLEA-UHFFFAOYSA-N 0.000 claims description 3
- WEGLOYDTDILXDA-OAHLLOKOSA-N CNCc1ccccc1-c1csc(c1)[C@@H](C)Nc1nc(C)nc2cc(OC)c(OC)cc12 Chemical compound CNCc1ccccc1-c1csc(c1)[C@@H](C)Nc1nc(C)nc2cc(OC)c(OC)cc12 WEGLOYDTDILXDA-OAHLLOKOSA-N 0.000 claims description 3
- AIFGVDXMHWGOGJ-DIVCQZSQSA-N C[C@@]1(O)C[C@@](N)(C1)C1=CC=C(C=C1)C1=C(N2COC3=C(C=NC=C3)C2=N1)C1=CC=CC=C1 Chemical compound C[C@@]1(O)C[C@@](N)(C1)C1=CC=C(C=C1)C1=C(N2COC3=C(C=NC=C3)C2=N1)C1=CC=CC=C1 AIFGVDXMHWGOGJ-DIVCQZSQSA-N 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims description 3
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 claims description 3
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 claims description 3
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 claims description 3
- RIHUDRGMCALEAK-HXUWFJFHSA-N FC1(CN(CC[C@H]1OC=1C=C2C(=NC=NC2=CC=1OC)NC1=C(C(=CC=C1)C#C)F)C)F Chemical compound FC1(CN(CC[C@H]1OC=1C=C2C(=NC=NC2=CC=1OC)NC1=C(C(=CC=C1)C#C)F)C)F RIHUDRGMCALEAK-HXUWFJFHSA-N 0.000 claims description 3
- 102100029974 GTPase HRas Human genes 0.000 claims description 3
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims description 3
- 101000771237 Homo sapiens Serine/threonine-protein kinase A-Raf Proteins 0.000 claims description 3
- KPQQGHGDBBJGFA-QNGWXLTQSA-N MK-8353 Chemical compound C([C@@](C1)(SC)C(=O)NC=2C=C3C(C=4C=NC(OC(C)C)=CC=4)=NNC3=CC=2)CN1CC(=O)N(CC=1)CCC=1C(C=C1)=CC=C1C=1N=CN(C)N=1 KPQQGHGDBBJGFA-QNGWXLTQSA-N 0.000 claims description 3
- PWHIUQBBGPGFFV-GOSISDBHSA-N N-[(1S)-2-amino-1-(3-chloro-5-fluorophenyl)ethyl]-1-[5-methyl-2-(oxan-4-ylamino)pyrimidin-4-yl]imidazole-4-carboxamide Chemical compound NC[C@H](C1=CC(=CC(=C1)F)Cl)NC(=O)C=1N=CN(C=1)C1=NC(=NC=C1C)NC1CCOCC1 PWHIUQBBGPGFFV-GOSISDBHSA-N 0.000 claims description 3
- GUYKCXXNIKKSBC-UHFFFAOYSA-N N-[2-chloro-5-[4-(3-chloro-4-fluoroanilino)quinazolin-6-yl]pyridin-3-yl]methanesulfonamide Chemical compound ClC1=NC=C(C=C1NS(=O)(=O)C)C=1C=C2C(=NC=NC2=CC=1)NC1=CC(=C(C=C1)F)Cl GUYKCXXNIKKSBC-UHFFFAOYSA-N 0.000 claims description 3
- HXBRBOYWXDLHDC-UHFFFAOYSA-N N-[2-oxo-3-[1-[[4-(5-oxo-3-phenyl-6H-1,6-naphthyridin-2-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-5-yl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC2=C(NC(N2C2CCN(CC2)CC2=CC=C(C=C2)C2=NC=3C=CNC(C=3C=C2C2=CC=CC=C2)=O)=O)C=C1 HXBRBOYWXDLHDC-UHFFFAOYSA-N 0.000 claims description 3
- BTMKEDDEMKKSEF-QGZVFWFLSA-N N-[5-[[4-[5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino]-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=C(C=C(C(=C1)NC1=NC=CC(=N1)NC1=C(C=C(C(=C1)Cl)F)C(C)(C)O)OC)N1C[C@@H](CC1)N(C)C BTMKEDDEMKKSEF-QGZVFWFLSA-N 0.000 claims description 3
- LVPBYQVQBZLDAU-DZIBYMRMSA-N N-methyl-3-[2-[(3S)-3-methylmorpholin-4-yl]-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)pyrido[2,3-d]pyrimidin-7-yl]benzamide Chemical compound C12COCC(CC1)N2C=1C2=C(N=C(N=1)N1[C@H](COCC1)C)N=C(C=C2)C=1C=C(C(=O)NC)C=CC=1 LVPBYQVQBZLDAU-DZIBYMRMSA-N 0.000 claims description 3
- MKCYPWYURWOKST-INIZCTEOSA-N NC1=NC=NC2=C1C(=C1C(=C[C@@H](CN21)NC(C=C)=O)C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C(=C[C@@H](CN21)NC(C=C)=O)C)C=1C=NC2=CC=CC=C2C=1 MKCYPWYURWOKST-INIZCTEOSA-N 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 229940127258 RMC-5552 Drugs 0.000 claims description 3
- 102100029437 Serine/threonine-protein kinase A-Raf Human genes 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 claims description 3
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 230000004075 alteration Effects 0.000 claims description 3
- WFDXOXNFNRHQEC-GHRIWEEISA-N azoxystrobin Chemical compound CO\C=C(\C(=O)OC)C1=CC=CC=C1OC1=CC(OC=2C(=CC=CC=2)C#N)=NC=N1 WFDXOXNFNRHQEC-GHRIWEEISA-N 0.000 claims description 3
- 229940070173 bimiralisib Drugs 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 229960005073 erlotinib hydrochloride Drugs 0.000 claims description 3
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000014509 gene expression Effects 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 3
- 229960003881 letrozole Drugs 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- WBKHQQZRHCECKK-UHFFFAOYSA-N n-(3-ethynylphenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 WBKHQQZRHCECKK-UHFFFAOYSA-N 0.000 claims description 3
- YFQJOPFTGMHYNV-YDALLXLXSA-N n-[(2s)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)thiophene-2-carboxamide;hydrochloride Chemical compound Cl.CN1N=CC(Cl)=C1C1=C(Cl)SC(C(=O)N[C@H](CN)CC=2C=C(F)C=CC=2)=C1 YFQJOPFTGMHYNV-YDALLXLXSA-N 0.000 claims description 3
- UTDAKQMBNSHJJB-JWGURIENSA-N n-[(z)-6,7-dihydro-5h-quinolin-8-ylideneamino]-4-pyridin-2-ylpiperazine-1-carbothioamide Chemical compound C/1CCC2=CC=CN=C2C\1=N/NC(=S)N(CC1)CCN1C1=CC=CC=N1 UTDAKQMBNSHJJB-JWGURIENSA-N 0.000 claims description 3
- PFYLLYYLCPZDMP-UHFFFAOYSA-N n-[1-amino-3-(2,4-dichlorophenyl)propan-2-yl]-2-[2-(methylamino)pyrimidin-4-yl]-1,3-thiazole-5-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CN=2)C(=O)NC(CN)CC=2C(=CC(Cl)=CC=2)Cl)=N1 PFYLLYYLCPZDMP-UHFFFAOYSA-N 0.000 claims description 3
- OAMVGUFHZPRXOM-UHFFFAOYSA-N n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfinylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 OAMVGUFHZPRXOM-UHFFFAOYSA-N 0.000 claims description 3
- 229940126426 narazaciclib Drugs 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 3
- 229960000688 pomalidomide Drugs 0.000 claims description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical group [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 3
- 201000003708 skin melanoma Diseases 0.000 claims description 3
- 229960002613 tamsulosin Drugs 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 229960000235 temsirolimus Drugs 0.000 claims description 3
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims description 3
- 229950003873 triciribine Drugs 0.000 claims description 3
- HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 claims description 3
- 229950006605 varlitinib Drugs 0.000 claims description 3
- 229940043785 zortress Drugs 0.000 claims description 3
- UELYDGOOJPRWGF-SRQXXRKNSA-N (2r,3r)-3-[2-[4-(cyclopropylsulfonimidoyl)anilino]-5-(trifluoromethyl)pyrimidin-4-yl]oxybutan-2-ol Chemical compound C1=C(C(F)(F)F)C(O[C@H](C)[C@H](O)C)=NC(NC=2C=CC(=CC=2)[S@](=N)(=O)C2CC2)=N1 UELYDGOOJPRWGF-SRQXXRKNSA-N 0.000 claims description 2
- DKNUPRMJNUQNHR-UHFFFAOYSA-N 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1OC(C=1)=CC=CC=1NC(=O)NC=1C=C(C(C)(C)C(F)(F)F)ON=1 DKNUPRMJNUQNHR-UHFFFAOYSA-N 0.000 claims description 2
- ZWHNLSHDLKIXOG-UHFFFAOYSA-N 4,7-dichloro-3-[2-(4-cyclopropylphenyl)-2-oxoethyl]-3-hydroxy-1H-indol-2-one Chemical compound ClC1=C2C(C(NC2=C(C=C1)Cl)=O)(O)CC(=O)C1=CC=C(C=C1)C1CC1 ZWHNLSHDLKIXOG-UHFFFAOYSA-N 0.000 claims description 2
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 claims description 2
- FWURTHAUPVXZHW-UHFFFAOYSA-N 4-methylbenzenesulfonic acid;2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 FWURTHAUPVXZHW-UHFFFAOYSA-N 0.000 claims description 2
- ODIUJYZERXVGEI-UHFFFAOYSA-N 6-benzyl-3-pyridin-4-yl-5,8-dihydro-1H-pyrazolo[4,3-g]quinazolin-7-one Chemical compound O=C1Nc2cc3[nH]nc(-c4ccncc4)c3cc2CN1Cc1ccccc1 ODIUJYZERXVGEI-UHFFFAOYSA-N 0.000 claims description 2
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 claims description 2
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 claims description 2
- UFKLYTOEMRFKAD-SHTZXODSSA-N C1C[C@@H](OC)CC[C@@H]1N1C2=NC(C=3C=NC(=CC=3)C(C)(C)O)=CN=C2NCC1=O Chemical compound C1C[C@@H](OC)CC[C@@H]1N1C2=NC(C=3C=NC(=CC=3)C(C)(C)O)=CN=C2NCC1=O UFKLYTOEMRFKAD-SHTZXODSSA-N 0.000 claims description 2
- RAXZSEGXMBWYQK-SNVBAGLBSA-N C[C@H](C1=CC=CC=C1)NC(=O)NC2=NC(=C3C=NNC3=C2)CO Chemical compound C[C@H](C1=CC=CC=C1)NC(=O)NC2=NC(=C3C=NNC3=C2)CO RAXZSEGXMBWYQK-SNVBAGLBSA-N 0.000 claims description 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000005431 Endometrioid Carcinoma Diseases 0.000 claims description 2
- 102220630353 Glycophorin-E_G13E_mutation Human genes 0.000 claims description 2
- 101000990042 Mus musculus CMRF35-like molecule 3 Proteins 0.000 claims description 2
- ZYSKXRAGBGLELB-UHFFFAOYSA-N N1(C)CCN(CC1)C1CCN(CC1)C1=C(C)C=C(C(OC)=C1)NC1=NC=C(Br)C(NC2=C(P(=O)(C)C)C3=C(C=C2)N=CC=N3)=N1 Chemical compound N1(C)CCN(CC1)C1CCN(CC1)C1=C(C)C=C(C(OC)=C1)NC1=NC=C(Br)C(NC2=C(P(=O)(C)C)C3=C(C=C2)N=CC=N3)=N1 ZYSKXRAGBGLELB-UHFFFAOYSA-N 0.000 claims description 2
- 206010035603 Pleural mesothelioma Diseases 0.000 claims description 2
- HDAJDNHIBCDLQF-RUZDIDTESA-N SCH772984 Chemical compound O=C([C@@H]1CCN(C1)CC(=O)N1CCN(CC1)C=1C=CC(=CC=1)C=1N=CC=CN=1)NC(C=C12)=CC=C1NN=C2C1=CC=NC=C1 HDAJDNHIBCDLQF-RUZDIDTESA-N 0.000 claims description 2
- 108010086229 SYN-004 Proteins 0.000 claims description 2
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- USNRYVNRPYXCSP-JUGPPOIOSA-N afatinib dimaleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 USNRYVNRPYXCSP-JUGPPOIOSA-N 0.000 claims description 2
- 229960002736 afatinib dimaleate Drugs 0.000 claims description 2
- 229940050528 albumin Drugs 0.000 claims description 2
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 claims description 2
- 201000001528 bladder urothelial carcinoma Diseases 0.000 claims description 2
- 201000006662 cervical adenocarcinoma Diseases 0.000 claims description 2
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims description 2
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims description 2
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 2
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 2
- 208000028730 endometrioid adenocarcinoma Diseases 0.000 claims description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 2
- 238000013115 immunohistochemical detection Methods 0.000 claims description 2
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- JYWCCUAHWOZSAU-MRXNPFEDSA-N n-[(1r)-1-phenylethyl]-1-(2-phenylethyl)pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C=1C=N2)=NC=NC=1N2CCC1=CC=CC=C1 JYWCCUAHWOZSAU-MRXNPFEDSA-N 0.000 claims description 2
- CGBJSGAELGCMKE-UHFFFAOYSA-N omipalisib Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 claims description 2
- 229950008089 omipalisib Drugs 0.000 claims description 2
- 229940071762 onatasertib Drugs 0.000 claims description 2
- 229950002433 roniciclib Drugs 0.000 claims description 2
- 102200006532 rs112445441 Human genes 0.000 claims description 2
- 102220014333 rs112445441 Human genes 0.000 claims description 2
- 102220197833 rs112445441 Human genes 0.000 claims description 2
- 102220053950 rs121913238 Human genes 0.000 claims description 2
- 102220198096 rs121913238 Human genes 0.000 claims description 2
- 102200006520 rs121913240 Human genes 0.000 claims description 2
- 102200006525 rs121913240 Human genes 0.000 claims description 2
- 102220197832 rs121913240 Human genes 0.000 claims description 2
- 102200006533 rs121913535 Human genes 0.000 claims description 2
- 102220014328 rs121913535 Human genes 0.000 claims description 2
- 102220197834 rs121913535 Human genes 0.000 claims description 2
- 102200007373 rs17851045 Human genes 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 3
- QKDCLUARMDUUKN-XMMPIXPASA-N 6-ethyl-3-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-[(3r)-1-prop-2-enoylpyrrolidin-3-yl]oxypyrazine-2-carboxamide Chemical compound N1=C(O[C@H]2CN(CC2)C(=O)C=C)C(CC)=NC(C(N)=O)=C1NC(C=C1)=CC=C1N(CC1)CCC1N1CCN(C)CC1 QKDCLUARMDUUKN-XMMPIXPASA-N 0.000 claims 2
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 claims 2
- 229950007440 icotinib Drugs 0.000 claims 2
- 229950009708 naquotinib Drugs 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 239000005740 Boscalid Substances 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- WYEMLYFITZORAB-UHFFFAOYSA-N boscalid Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1NC(=O)C1=CC=CN=C1Cl WYEMLYFITZORAB-UHFFFAOYSA-N 0.000 claims 1
- 229940118790 boscalid Drugs 0.000 claims 1
- 229960002427 dabrafenib mesylate Drugs 0.000 claims 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 claims 1
- 229960001320 lapatinib ditosylate Drugs 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 229950005674 modotuximab Drugs 0.000 claims 1
- AZBFJBJXUQUQLF-UHFFFAOYSA-N n-(1,5-dimethylpyrrolidin-3-yl)pyrrolidine-1-carboxamide Chemical compound C1N(C)C(C)CC1NC(=O)N1CCCC1 AZBFJBJXUQUQLF-UHFFFAOYSA-N 0.000 claims 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 1
- 229960003089 pramipexole Drugs 0.000 claims 1
- 208000037965 uterine sarcoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 32
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 abstract description 12
- 102000057028 SOS1 Human genes 0.000 abstract description 12
- 108700022176 SOS1 Proteins 0.000 abstract description 12
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 abstract description 12
- 101150100839 Sos1 gene Proteins 0.000 abstract description 12
- 239000006186 oral dosage form Substances 0.000 abstract description 7
- LMMJFBMMJUMSJS-UHFFFAOYSA-N CH5126766 Chemical compound CNS(=O)(=O)NC1=NC=CC(CC=2C(OC3=CC(OC=4N=CC=CN=4)=CC=C3C=2C)=O)=C1F LMMJFBMMJUMSJS-UHFFFAOYSA-N 0.000 description 182
- 210000004027 cell Anatomy 0.000 description 130
- 239000003814 drug Substances 0.000 description 85
- 239000003795 chemical substances by application Substances 0.000 description 73
- 235000002639 sodium chloride Nutrition 0.000 description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 58
- 125000000217 alkyl group Chemical group 0.000 description 51
- 125000003118 aryl group Chemical group 0.000 description 43
- 125000004432 carbon atom Chemical group C* 0.000 description 43
- 125000002947 alkylene group Chemical group 0.000 description 41
- 238000004458 analytical method Methods 0.000 description 38
- 229940079593 drug Drugs 0.000 description 37
- 125000000753 cycloalkyl group Chemical group 0.000 description 34
- 125000001424 substituent group Chemical group 0.000 description 34
- 201000010099 disease Diseases 0.000 description 33
- 238000003556 assay Methods 0.000 description 31
- 125000000623 heterocyclic group Chemical group 0.000 description 31
- 238000012054 celltiter-glo Methods 0.000 description 30
- 238000002560 therapeutic procedure Methods 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 26
- 230000000694 effects Effects 0.000 description 26
- 230000004044 response Effects 0.000 description 26
- 125000001072 heteroaryl group Chemical group 0.000 description 25
- 230000003833 cell viability Effects 0.000 description 24
- 208000035475 disorder Diseases 0.000 description 24
- 125000000304 alkynyl group Chemical group 0.000 description 23
- 241000282320 Panthera leo Species 0.000 description 22
- 230000006023 anti-tumor response Effects 0.000 description 22
- 230000002195 synergetic effect Effects 0.000 description 22
- 125000003342 alkenyl group Chemical group 0.000 description 20
- 125000004452 carbocyclyl group Chemical group 0.000 description 19
- 238000001516 cell proliferation assay Methods 0.000 description 18
- 125000000392 cycloalkenyl group Chemical group 0.000 description 18
- 108010082117 matrigel Proteins 0.000 description 18
- 239000012453 solvate Substances 0.000 description 18
- 238000012216 screening Methods 0.000 description 17
- 239000012472 biological sample Substances 0.000 description 16
- 238000001514 detection method Methods 0.000 description 16
- 229910052736 halogen Inorganic materials 0.000 description 16
- 150000002367 halogens Chemical class 0.000 description 16
- 229910052799 carbon Inorganic materials 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 14
- 230000004614 tumor growth Effects 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- 229940125811 TNO155 Drugs 0.000 description 13
- 125000004450 alkenylene group Chemical group 0.000 description 13
- 239000002131 composite material Substances 0.000 description 13
- 125000004122 cyclic group Chemical group 0.000 description 13
- 125000005842 heteroatom Chemical group 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 12
- 206010064571 Gene mutation Diseases 0.000 description 12
- 125000004404 heteroalkyl group Chemical group 0.000 description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 12
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 12
- 238000013515 script Methods 0.000 description 12
- 125000003545 alkoxy group Chemical group 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 11
- 238000012800 visualization Methods 0.000 description 11
- 102000043136 MAP kinase family Human genes 0.000 description 9
- 108091054455 MAP kinase family Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 125000004093 cyano group Chemical group *C#N 0.000 description 9
- 125000001183 hydrocarbyl group Chemical group 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 201000009030 Carcinoma Diseases 0.000 description 8
- 108091008611 Protein Kinase B Proteins 0.000 description 8
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 125000003710 aryl alkyl group Chemical group 0.000 description 8
- 125000005110 aryl thio group Chemical group 0.000 description 8
- 125000004104 aryloxy group Chemical group 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 150000004677 hydrates Chemical class 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 8
- 238000002626 targeted therapy Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 7
- 125000005631 S-sulfonamido group Chemical group 0.000 description 7
- 125000004414 alkyl thio group Chemical group 0.000 description 7
- 230000001028 anti-proliverative effect Effects 0.000 description 7
- 229910002091 carbon monoxide Inorganic materials 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 125000003396 thiol group Chemical class [H]S* 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- 230000003442 weekly effect Effects 0.000 description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 6
- 238000011729 BALB/c nude mouse Methods 0.000 description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 6
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 description 6
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 6
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 6
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical compound Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 229940127089 cytotoxic agent Drugs 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000001613 neoplastic effect Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 6
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 5
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 5
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 5
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000008033 biological extinction Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 125000004475 heteroaralkyl group Chemical group 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 230000004899 motility Effects 0.000 description 5
- 125000006574 non-aromatic ring group Chemical group 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 5
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 241000046053 Betta Species 0.000 description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
- 101150105104 Kras gene Proteins 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229960000590 celecoxib Drugs 0.000 description 4
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 4
- 229910052805 deuterium Inorganic materials 0.000 description 4
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 4
- 125000004438 haloalkoxy group Chemical group 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 125000005152 trihalomethanesulfonyl group Chemical group 0.000 description 4
- RGCGBFIARQENML-JOCHJYFZSA-N (3R)-1'-[3-(3,4-dihydro-2H-1,5-naphthyridin-1-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]spiro[3H-1-benzofuran-2,4'-piperidine]-3-amine Chemical compound N[C@@H]1c2ccccc2OC11CCN(CC1)c1cnc2c(n[nH]c2n1)N1CCCc2ncccc12 RGCGBFIARQENML-JOCHJYFZSA-N 0.000 description 3
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical group C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 3
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 206010066476 Haematological malignancy Diseases 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 108010016076 Octreotide Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 229940126000 RLY-1971 Drugs 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 201000005969 Uveal melanoma Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- 230000003474 anti-emetic effect Effects 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 239000002111 antiemetic agent Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229940111134 coxibs Drugs 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000001794 hormone therapy Methods 0.000 description 3
- 229960001330 hydroxycarbamide Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229960002700 octreotide Drugs 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 3
- KJRCEJOSASVSRA-UHFFFAOYSA-N propane-2-thiol Chemical compound CC(C)S KJRCEJOSASVSRA-UHFFFAOYSA-N 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 102200055464 rs113488022 Human genes 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 3
- 229960000894 sulindac Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000005423 trihalomethanesulfonamido group Chemical group 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 2
- JLOXTZFYJNCPIS-FYWRMAATSA-N (z)-3-amino-3-(4-aminophenyl)sulfanyl-2-[2-(trifluoromethyl)phenyl]prop-2-enenitrile Chemical compound C=1C=CC=C(C(F)(F)F)C=1C(\C#N)=C(/N)SC1=CC=C(N)C=C1 JLOXTZFYJNCPIS-FYWRMAATSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 description 2
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 2
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 2
- MFWNKCLOYSRHCJ-AGUYFDCRSA-N 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-3-indazolecarboxamide Chemical compound C1=CC=C2C(C(=O)NC3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-AGUYFDCRSA-N 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 2
- QFWCYNPOPKQOKV-UHFFFAOYSA-N 2-(2-amino-3-methoxyphenyl)chromen-4-one Chemical compound COC1=CC=CC(C=2OC3=CC=CC=C3C(=O)C=2)=C1N QFWCYNPOPKQOKV-UHFFFAOYSA-N 0.000 description 2
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 description 2
- MRPGRAKIAJJGMM-OCCSQVGLSA-N 2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2r,3s)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one Chemical compound OC[C@@H]1N(C)CC[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC(=CC=1)C(F)(F)F)Cl)=CC2=O MRPGRAKIAJJGMM-OCCSQVGLSA-N 0.000 description 2
- MEPDJWRMAAUPBM-UHFFFAOYSA-N 2-[4-[4-(2,3-dihydroxypropoxy)phenyl]-2,5-dioxoimidazolidin-1-yl]-n-(2-fluoro-4-iodophenyl)-3-phenylbutanamide Chemical compound C=1C=CC=CC=1C(C)C(C(=O)NC=1C(=CC(I)=CC=1)F)N(C1=O)C(=O)NC1C1=CC=C(OCC(O)CO)C=C1 MEPDJWRMAAUPBM-UHFFFAOYSA-N 0.000 description 2
- HLFGQICCFZTXTP-UHFFFAOYSA-N 2-chloro-n-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)benzamide Chemical compound ClC1=CC=CC=C1C(=O)NC1=CC2=C(C#N)C3=NC4=CC=CC=C4N=C3N2C=C1 HLFGQICCFZTXTP-UHFFFAOYSA-N 0.000 description 2
- BDFAOUQQXJIZDG-UHFFFAOYSA-N 2-methylpropane-1-thiol Chemical compound CC(C)CS BDFAOUQQXJIZDG-UHFFFAOYSA-N 0.000 description 2
- ZOEVXMKZJWZLFX-UHFFFAOYSA-N 3-(3-fluoro-2-methoxyanilino)-2-[3-(2-methoxy-2-methylpropoxy)pyridin-4-yl]-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one Chemical compound FC=1C(=C(C=CC=1)NC1=C(NC2=C1C(NCC2)=O)C1=C(C=NC=C1)OCC(C)(C)OC)OC ZOEVXMKZJWZLFX-UHFFFAOYSA-N 0.000 description 2
- RCLQNICOARASSR-SECBINFHSA-N 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 description 2
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 2
- VJNZMSLGVUSPCF-UHFFFAOYSA-N 5-bromo-2-(2-chloro-4-iodoanilino)-n-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C1CC1CONC(=O)C=1C=C(Br)C(F)=C(F)C=1NC1=CC=C(I)C=C1Cl VJNZMSLGVUSPCF-UHFFFAOYSA-N 0.000 description 2
- XXSSGBYXSKOLAM-UHFFFAOYSA-N 5-bromo-n-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide Chemical compound OCC(O)CONC(=O)C1=CC(Br)=C(F)C(F)=C1NC1=CC=C(I)C=C1F XXSSGBYXSKOLAM-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010071975 EGFR gene mutation Diseases 0.000 description 2
- 101150039808 Egfr gene Proteins 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- RFWVETIZUQEJEF-UHFFFAOYSA-N GDC-0623 Chemical compound OCCONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F RFWVETIZUQEJEF-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101100477990 Homo sapiens SOS1 gene Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 2
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 2
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 101150097381 Mtor gene Proteins 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000003019 Neurofibromatosis 1 Diseases 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 2
- SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 206010038111 Recurrent cancer Diseases 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- DVEXZJFMOKTQEZ-JYFOCSDGSA-N U0126 Chemical compound C=1C=CC=C(N)C=1SC(\N)=C(/C#N)\C(\C#N)=C(/N)SC1=CC=CC=C1N DVEXZJFMOKTQEZ-JYFOCSDGSA-N 0.000 description 2
- 208000028354 Vulto-van Silfout-de Vries syndrome Diseases 0.000 description 2
- 229950001573 abemaciclib Drugs 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 2
- 125000002785 azepinyl group Chemical group 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229960003736 bosutinib Drugs 0.000 description 2
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- LOCHFZBWPCLPAN-UHFFFAOYSA-N butane-2-thiol Chemical compound CCC(C)S LOCHFZBWPCLPAN-UHFFFAOYSA-N 0.000 description 2
- WQAQPCDUOCURKW-UHFFFAOYSA-N butanethiol Chemical compound CCCCS WQAQPCDUOCURKW-UHFFFAOYSA-N 0.000 description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 238000009096 combination chemotherapy Methods 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- 229960000616 diflunisal Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000005879 dioxolanyl group Chemical group 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 108700021358 erbB-1 Genes Proteins 0.000 description 2
- NYPJDWWKZLNGGM-RPWUZVMVSA-N esfenvalerate Chemical compound C=1C([C@@H](C#N)OC(=O)[C@@H](C(C)C)C=2C=CC(Cl)=CC=2)=CC=CC=1OC1=CC=CC=C1 NYPJDWWKZLNGGM-RPWUZVMVSA-N 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
- 229960005293 etodolac Drugs 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 2
- 229960001419 fenoprofen Drugs 0.000 description 2
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 2
- 229960004369 flufenamic acid Drugs 0.000 description 2
- 229960002390 flurbiprofen Drugs 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229950002252 isoxicam Drugs 0.000 description 2
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 229960004752 ketorolac Drugs 0.000 description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 2
- 229960002202 lornoxicam Drugs 0.000 description 2
- 229960002373 loxoprofen Drugs 0.000 description 2
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 229960003803 meclofenamic acid Drugs 0.000 description 2
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
- 229960003464 mefenamic acid Drugs 0.000 description 2
- 229960001929 meloxicam Drugs 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 2
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 2
- 229960004270 nabumetone Drugs 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 210000000441 neoplastic stem cell Anatomy 0.000 description 2
- 208000007538 neurilemmoma Diseases 0.000 description 2
- 229960001346 nilotinib Drugs 0.000 description 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 2
- 229950010203 nimotuzumab Drugs 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
- 229960002739 oxaprozin Drugs 0.000 description 2
- 125000000466 oxiranyl group Chemical group 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229950002592 pimasertib Drugs 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 229960003111 prochlorperazine Drugs 0.000 description 2
- DSKIOWHQLUWFLG-SPIKMXEPSA-N prochlorperazine maleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 DSKIOWHQLUWFLG-SPIKMXEPSA-N 0.000 description 2
- 229960003910 promethazine Drugs 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 150000005599 propionic acid derivatives Chemical class 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 102220197819 rs121913227 Human genes 0.000 description 2
- 102220197820 rs121913227 Human genes 0.000 description 2
- 102200055469 rs121913377 Human genes 0.000 description 2
- 102220014069 rs121913378 Human genes 0.000 description 2
- 150000003873 salicylate salts Chemical class 0.000 description 2
- 206010039667 schwannoma Diseases 0.000 description 2
- 229950003647 semaxanib Drugs 0.000 description 2
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 201000002314 small intestine cancer Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- 229960002871 tenoxicam Drugs 0.000 description 2
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 125000001583 thiepanyl group Chemical group 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 2
- 229960002905 tolfenamic acid Drugs 0.000 description 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 229960003688 tropisetron Drugs 0.000 description 2
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 229950003294 voruciclib Drugs 0.000 description 2
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- SADXACCFNXBCFY-IYNHSRRRSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-3-[(2r)-1-methylpyrrolidin-2-yl]prop-2-enamide Chemical compound C=12C=C(NC(=O)\C=C\[C@@H]3N(CCC3)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 SADXACCFNXBCFY-IYNHSRRRSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- 125000004815 1,2-dimethylethylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([*:2])C([H])([H])[H] 0.000 description 1
- KFHQOZXAFUKFNB-UHFFFAOYSA-N 1,3-oxathiolanyl Chemical group [CH]1OCCS1 KFHQOZXAFUKFNB-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- RBSXHDIPCIWOMG-UHFFFAOYSA-N 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-ethylsulfonylimidazo[1,2-a]pyridin-3-yl)sulfonylurea Chemical compound CCS(=O)(=O)C=1N=C2C=CC=CN2C=1S(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 RBSXHDIPCIWOMG-UHFFFAOYSA-N 0.000 description 1
- RZUOCXOYPYGSKL-GOSISDBHSA-N 1-[(1s)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]pyridin-2-one Chemical compound CN1N=CC=C1NC1=NC=CC(C2=CC(=O)N([C@H](CO)C=3C=C(F)C(Cl)=CC=3)C=C2)=N1 RZUOCXOYPYGSKL-GOSISDBHSA-N 0.000 description 1
- LPFWVDIFUFFKJU-UHFFFAOYSA-N 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one Chemical compound C=12C=C(OC3CCN(CC3)C(=O)C=C)C(OC)=CC2=NC=NC=1NC1=CC=C(Cl)C(Cl)=C1F LPFWVDIFUFFKJU-UHFFFAOYSA-N 0.000 description 1
- 125000004812 1-ethylethylene group Chemical group [H]C([H])([H])C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 125000004806 1-methylethylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MISZALMBODQYFT-URVXVIKDSA-N 125-69-9 Chemical compound Br.C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21 MISZALMBODQYFT-URVXVIKDSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- QTSZBNQPNSJXAC-UHFFFAOYSA-N 2-[[2-(4-aminophenyl)-9-methyl-6-morpholin-4-ylpurin-8-yl]methyl-methylamino]-N-hydroxypyrimidine-5-carboxamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CN(Cc1nc2c(nc(nc2n1C)-c1ccc(N)cc1)N1CCOCC1)c1ncc(cn1)C(=O)NO QTSZBNQPNSJXAC-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- LNSQWHNDOWEZII-UHFFFAOYSA-N 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1 LNSQWHNDOWEZII-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical class C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical class OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- GYLDXIAOMVERTK-UHFFFAOYSA-N 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C1=CC=C(OC(N)=N2)C2=C1 GYLDXIAOMVERTK-UHFFFAOYSA-N 0.000 description 1
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
- NFLLKCVHYJRNRH-UHFFFAOYSA-N 8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 NFLLKCVHYJRNRH-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 101150019464 ARAF gene Proteins 0.000 description 1
- 241001075517 Abelmoschus Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- VSEIDZLLWQQJGK-CHOZPQDDSA-N CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O Chemical compound CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O VSEIDZLLWQQJGK-CHOZPQDDSA-N 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108700000434 Cannabis sativa edestin Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- CHBRHODLKOZEPZ-UHFFFAOYSA-N Clotiazepam Chemical compound S1C(CC)=CC2=C1N(C)C(=O)CN=C2C1=CC=CC=C1Cl CHBRHODLKOZEPZ-UHFFFAOYSA-N 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 241000189070 Cotinga Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000272186 Falco columbarius Species 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical class OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- ZEZHPEIEEFTILY-QMMMGPOBSA-N G-573 Chemical compound C[C@H](O)CONC(=O)C=1OC2=C(F)C=NC=C2C=1NC1=CC=C(I)C=C1F ZEZHPEIEEFTILY-QMMMGPOBSA-N 0.000 description 1
- KGPGFQWBCSZGEL-ZDUSSCGKSA-N GSK690693 Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=C(C#CC(C)(C)O)N=CC=1OC[C@H]1CCCNC1 KGPGFQWBCSZGEL-ZDUSSCGKSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- 230000037364 MAPK/ERK pathway Effects 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PLUKVDOZEJBBIS-UHFFFAOYSA-N N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=C(C=C(C(=C1)NC1=NC=CC(=N1)C1=C2N(C3=CC=CC=C13)CCCC2)OC)N(C)CCN(C)C PLUKVDOZEJBBIS-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 241001025261 Neoraja caerulea Species 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 108700026224 Neurofibromatosis 2 Genes Proteins 0.000 description 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010048233 Procalcitonin Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101150062264 Raf gene Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000016624 Retinal neoplasm Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010068771 Soft tissue neoplasm Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 150000001278 adipic acid derivatives Chemical class 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000007844 allele-specific PCR Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 229940014175 aloxi Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940059707 anzemet Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 150000001509 aspartic acid derivatives Chemical class 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
- 229950010993 atrasentan Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000010572 basal-like breast carcinoma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229960004648 betamethasone acetate Drugs 0.000 description 1
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 229940094219 bonine Drugs 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 101150048834 braF gene Proteins 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 150000004652 butanoic acids Chemical class 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
- 235000008207 calcium folinate Nutrition 0.000 description 1
- 239000011687 calcium folinate Substances 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical class CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- QTFFGPOXNNGTGZ-LIFGOUTFSA-N chembl2368924 Chemical compound O.CS(O)(=O)=O.C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 QTFFGPOXNNGTGZ-LIFGOUTFSA-N 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- JROFGZPOBKIAEW-HAQNSBGRSA-N chembl3120215 Chemical compound N1C=2C(OC)=CC=CC=2C=C1C(=C1C(N)=NC=NN11)N=C1[C@H]1CC[C@H](C(O)=O)CC1 JROFGZPOBKIAEW-HAQNSBGRSA-N 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229960002271 cobimetinib Drugs 0.000 description 1
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 229940088505 compazine Drugs 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 229960001850 droxicam Drugs 0.000 description 1
- OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229960000925 efaproxiral Drugs 0.000 description 1
- BNFRJXLZYUTIII-UHFFFAOYSA-N efaproxiral Chemical compound CC1=CC(C)=CC(NC(=O)CC=2C=CC(OC(C)(C)C(O)=O)=CC=2)=C1 BNFRJXLZYUTIII-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229950002339 elsamitrucin Drugs 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 208000023437 ependymal tumor Diseases 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 210000001733 follicular fluid Anatomy 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 229940084910 gliadel Drugs 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical class OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000006607 hypermethylation Effects 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000011273 incision biopsy Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- YPJRHEKCFKOVRT-UHFFFAOYSA-N lerociclib Chemical compound C1CN(C(C)C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C2N3C4(CCCCC4)CNC2=O)C3=N1 YPJRHEKCFKOVRT-UHFFFAOYSA-N 0.000 description 1
- 229940121577 lerociclib Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229940071277 lithostat Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 238000011880 melting curve analysis Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 229950003442 methoprene Drugs 0.000 description 1
- 229930002897 methoprene Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- IRQVJPHZDYMXNW-UHFFFAOYSA-N metoclopramide dihydrochloride monohydrate Chemical compound O.[Cl-].[Cl-].CC[NH+](CC)CCNC(=O)C1=CC(Cl)=C([NH3+])C=C1OC IRQVJPHZDYMXNW-UHFFFAOYSA-N 0.000 description 1
- 229950009655 milciclib Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- RXZMYLDMFYNEIM-UHFFFAOYSA-N n,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5h-pyrazolo[4,3-h]quinazoline-3-carboxamide Chemical compound CNC(=O)C1=NN(C)C(C2=N3)=C1C(C)(C)CC2=CN=C3NC(C=C1)=CC=C1N1CCN(C)CC1 RXZMYLDMFYNEIM-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001326 naphthylalkyl group Chemical group 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 206010061311 nervous system neoplasm Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 208000002761 neurofibromatosis 2 Diseases 0.000 description 1
- 208000022032 neurofibromatosis type 2 Diseases 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- 150000002888 oleic acid derivatives Chemical class 0.000 description 1
- 229930183014 olympicin Natural products 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 229960002131 palonosetron Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000002727 particle therapy Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical class O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 125000005546 pivalic acid group Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229950009876 poziotinib Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- SUVIGLJNEAMWEG-UHFFFAOYSA-N propane-1-thiol Chemical compound CCCS SUVIGLJNEAMWEG-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 229940075576 pyrotinib Drugs 0.000 description 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical class O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229950007231 ravoxertinib Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940080693 reglan Drugs 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 229940023942 remeron Drugs 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 201000008933 retinal cancer Diseases 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229950003687 ribociclib Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 229940059160 sancuso Drugs 0.000 description 1
- 229950009216 sapanisertib Drugs 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 229950000055 seliciclib Drugs 0.000 description 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960000269 sitimagene ceradenovec Drugs 0.000 description 1
- 108010086606 sitimagene ceradenovec Proteins 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- QAZLUNIWYYOJPC-UHFFFAOYSA-M sulfenamide Chemical compound [Cl-].COC1=C(C)C=[N+]2C3=NC4=CC=C(OC)C=C4N3SCC2=C1C QAZLUNIWYYOJPC-UHFFFAOYSA-M 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000002942 systemic radioisotope therapy Methods 0.000 description 1
- 229950010924 talaporfin Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229960002197 temoporfin Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- WMXCDAVJEZZYLT-UHFFFAOYSA-N tert-butylthiol Chemical compound CC(C)(C)S WMXCDAVJEZZYLT-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- WCNFFKHKJLERFM-UHFFFAOYSA-N thiomorpholinyl sulfone group Chemical group N1(CCSCC1)S(=O)(=O)N1CCSCC1 WCNFFKHKJLERFM-UHFFFAOYSA-N 0.000 description 1
- ZCAGUOCUDGWENZ-UHFFFAOYSA-N thiomorpholinyl sulfoxide group Chemical group N1(CCSCC1)S(=O)N1CCSCC1 ZCAGUOCUDGWENZ-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 1
- 229960000977 trabectedin Drugs 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229940126307 triamcinolone acetate Drugs 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000022671 urothelial neoplasm Diseases 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229960003895 verteporfin Drugs 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- 229940074963 vevorisertib Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000001790 virustatic effect Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229950007155 zenocutuzumab Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to methods, compositions and oral dosage forms for the treatment of abnormal cell growth (e.g., cancer) using SHP2 inhibitors, SOS1 inhibitors, ERK1/2 inhibitors, CDK4/6 inhibitors, AKT inhibitors, mTOR inhibitors, pan-HER inhibitors or EGFR inhibitors in combination with MEK inhibitors or dual RAF/MEK inhibitors.
Description
Cross Reference to Related Applications
The present application claims U.S. provisional patent application Ser. No. 63/146,349 to 5.2021, U.S. provisional patent application Ser. No. 63/185,651 to 5.2021, U.S. provisional patent application Ser. No. 63/146,352 to 5.2021, U.S. provisional patent application Ser. No. 63/185,672 to 5.2021, U.S. provisional patent application Ser. No. 63/146,395 to 5.2021, U.S. provisional patent application Ser. No. 63/185,695 to 5.2021, U.S. provisional patent application Ser. No. 63/146,357 to 5.2021, U.S. provisional patent application Ser. No. 63/185,704 to 7.5.2021, U.S. provisional patent application Ser. No. 63/146,369 to 5.2.2021, and priority and benefit of U.S. provisional patent application Ser. No. 63/146,376 to 5.2.2021.
Background
Components of the RAS/RAF/MEK/ERK (MAPK) pathway represent an opportunity to treat abnormal cell growth (e.g., cancer). Selective inhibitors of certain components of the RAS/RAF/MEK/ERK pathway (e.g., RAS, RAF, MEK and ERK) are useful for treating abnormal cell growth, particularly cancer, in mammals. Targeting multiple nodes in the MAPK pathway simultaneously (vertical inhibition) may improve response (e.g., anti-tumor response, such as depth and/or duration) compared to blocking a single node in the pathway. Furthermore, the efficacy of MAPK pathway blockade may be circumvented by activation of drug resistant pathways, and thus co-targeting MAPK pathways and related parallel pathways may be desirable.
Due to the severity and breadth of diseases and conditions associated with abnormal cell growth (e.g., cancer), effective treatments and methods of treatment are needed. The compounds, compositions, combinations, and methods described herein are directed to this end.
Summary of The Invention
Simultaneous targeting of multiple nodes in the MAPK pathway (e.g., using SHP2 inhibitors, SOS1 inhibitors, ERK1/2 inhibitors, pan-HER inhibitors, or EGFR inhibitors), or co-targeting of the MAPK pathway and related parallel pathways (e.g., using CDK4/6 inhibitors, AKT inhibitors, or mTOR inhibitors) may improve responses (e.g., anti-tumor responses such as depth and/or duration). Thus, provided herein, in part, are combinations (e.g., combinations of compounds described herein, e.g., SHP2 inhibitors, SOS1 inhibitors, ERK1/2 inhibitors, CDK4/6 inhibitors, AKT inhibitors, mTOR inhibitors, pan-HER inhibitors, or EGFR inhibitors in combination with MEK inhibitors or dual RAF/MEK inhibitors) that are useful, e.g., in methods of treating abnormal cell growth (e.g., cancer) in a subject in need thereof.
Accordingly, in one aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of an SHP2 inhibitor and a MEK inhibitor, thereby treating the subject.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of an SHP2 inhibitor and a dual RAF/MEK inhibitor, thereby treating the subject.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of a SOS1 inhibitor and a MEK inhibitor, thereby treating the subject.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a SOS1 inhibitor in combination with a dual RAF/MEK inhibitor, thereby treating the subject.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of an ERK1/2 inhibitor and a MEK inhibitor, thereby treating the subject.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of an ERK1/2 inhibitor and a dual RAF/MEK inhibitor, thereby treating the subject.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a CDK4/6 inhibitor in combination with a MEK inhibitor, thereby treating the subject.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a CDK4/6 inhibitor in combination with a dual RAF/MEK inhibitor, thereby treating the subject.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of an AKT inhibitor and a MEK inhibitor, thereby treating the subject.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of an AKT inhibitor and a dual RAF/MEK inhibitor, thereby treating the subject.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of an mTOR inhibitor and a MEK inhibitor, thereby treating the subject.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a mTOR inhibitor in combination with a dual RAF/MEK inhibitor, thereby treating the subject.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of a pan-HER inhibitor and a MEK inhibitor, thereby treating the subject.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a pan-HER inhibitor in combination with a dual RAF/MEK inhibitor, thereby treating the subject.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of an EGFR inhibitor and a MEK inhibitor, thereby treating the subject.
In one aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of an EGFR inhibitor and a dual RAF/MEK inhibitor, thereby treating the subject.
In some embodiments, the dual RAF/MEK inhibitor is a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the dual RAF/MEK inhibitor is a potassium salt of a compound of formula (I). Other pharmaceutically acceptable salts of the compounds of formula (I) are contemplated in the methods of treatment disclosed herein.
Other objects and advantages will become apparent to those skilled in the art from consideration of the detailed description, examples and claims that follow.
Drawings
FIG. 1A shows an exemplary CellTiter-Glo assay for assessing cell viability of 16 KRAS G12C, G D or G12V mutant cell lines (9 NSCLCs and 7 PDACs) grown under 3D conditions in a 7 day assay for VS-6766, RMS-4550 and TNO 155.
FIG. 1B shows the IC50 for VS-6766, TNO155 and RMC-4550.
FIG. 2A shows an exemplary CTG proliferation assay using VS-6766 and TNO155 in H2122 cells.
FIG. 2B shows an exemplary synergy analysis using VS-6766 and TNO155 in H2122 cells.
Fig. 2C shows an exemplary waterfall plot summarizing the combined synergy of VS-6766+tno155 in a set of KRAS mut NSCLC and PDAC cell lines.
Fig. 3A shows an exemplary waterfall plot summarizing the combined synergy of VS-6766+ tno155 in a set of KRAS mut NSCLC and PDAC cell lines.
FIG. 3B shows exemplary data for a combination of VS-6766 and TNO155 showing an increase in anti-tumor response in H2122 cells.
FIG. 4A shows an exemplary waterfall graph summarizing the combined synergy of VS-6766+RMC-4550 in a set of KRAS mut NSCLC and PDAC cell lines.
FIG. 4B shows exemplary data for a combination of VS-6766 and RMC-4550, which shows an increase in anti-tumor response in H2122 cells.
FIG. 5A shows exemplary changes in tumor volume in H2122 tumor-bearing mice treated with VS-6766 (0.3 mg/kg QD) +/-RMC-4550 (10 mg/kg QD).
FIG. 5B shows exemplary changes in tumor volume in H2122 tumor-bearing mice treated with VS-6766 (0.3 mg/kg QD) +/-TNO155 (15 mg/kg BID).
Fig. 6A shows an exemplary CellTiter-Glo assay for assessing cell viability of 16 KRAS G12C, G D or G12V mutant cell lines (9 NSCLC and 7 PDACs) grown under 3D conditions in a 7 day assay.
FIG. 6B shows IC 50's for VS-6766 and BI 3406.
FIG. 7A shows an exemplary CTG proliferation assay using VS-6766 and BI3406 in H2122 cells.
FIG. 7B shows an exemplary synergy analysis using VS-6766 and BI3406 in H2122 cells.
FIG. 7C shows an exemplary waterfall plot summarizing the combined synergistic results of VS-6766+BI3406 in a set of KRAS mut NSCLC and PDAC cell lines.
FIG. 8A shows an exemplary waterfall plot summarizing the combined synergistic results of VS-6766+BI3406 in a set of KRAS mut NSCLC and PDAC cell lines.
FIG. 8B shows exemplary data for a combination of VS-6766 and BI3406 showing an increase in anti-tumor response in H2122 cells.
FIG. 9 shows exemplary changes in tumor volume in H2122 tumor-bearing mice treated with VS-6766 (0.3 mg/kg QD) +/-BI-3406 (50 mg/kg BID).
FIG. 10A shows an exemplary CellTiter-Glo assay for assessing cell viability of 16 KRAS G12C, G D or G12V mutant cell lines (9 NSCLCs and 7 PDACs) grown under 3D conditions in a 7 day assay for VS-6766 and LY-3214996.
FIG. 10B shows the IC50 for VS-6766 and LY-3214996.
FIG. 11A shows an exemplary CTG proliferation assay using VS-6766 and LY-3214996 in H2122 cells.
FIG. 11B shows an exemplary synergy analysis using VS-6766 and LY-3214996 in H2122 cells.
FIG. 11C shows an exemplary waterfall plot summarizing the combined synergistic results of VS-6766+LY-3214996 in a set of KRAS mut NSCLC and PDAC cell lines.
FIG. 12A shows an exemplary waterfall graph summarizing the combined synergistic results of VS-6766+LY-3214996 in a set of KRAS mut NSCLC and PDAC cell lines.
FIG. 12B shows exemplary data for a combination of VS-6766 and LY-3214996, which shows an increase in anti-tumor response in H2122 cells.
FIG. 13 shows exemplary changes in tumor volume in H2122 tumor-bearing mice treated with VS-6766 (0.3 mg/kg QD) +/-LY-3214996 (60 mg/kg QD).
Fig. 14A shows an exemplary CellTiter-Glo assay for assessing cell viability of 16 KRAS G12C, G D or G12V mutant cell lines (9 NSCLC and 7 PDACs) grown under 3D conditions in a 7 day assay for VS-6766, palbociclib and arbeli.
Fig. 14B shows IC50 s for VSVS-6766, palbociclib, and abbe's.
FIG. 15A shows an exemplary CTG proliferation assay using VS-6766 and palbociclib in A427 cells.
FIG. 15B shows an exemplary synergy analysis using VS-6766 and palbociclib in A427 cells.
Fig. 15C shows an exemplary waterfall plot summarizing the combined synergy of VS-6766+ palbociclib in a set of KRAS mut NSCLC and PDAC cell lines.
Fig. 16A shows an exemplary waterfall plot summarizing the combined synergy of VS-6766+ palbociclib in a set of KRAS mut NSCLC and PDAC cell lines.
FIG. 16B shows exemplary data for a combination of VS-6766 and palbociclib showing an increase in anti-tumor response in A427 cells.
Fig. 17A shows an exemplary waterfall plot summarizing the combined synergy of VS-6766+ abbe silli in a set of KRAS mut NSCLC and PDAC cell lines.
FIG. 17B shows exemplary data for a combination of VS-6766 and Abeli, showing an increase in anti-tumor response in A427 cells.
FIG. 18 shows exemplary changes in tumor volume in H2122 tumor-bearing mice treated with VS-6766 (0.3 mg/kg QD) +/-Abeli (25 mg/kg QD).
FIG. 19A shows an exemplary Bliss, loewe, HSA and ZIP synergy analysis for VS-6766+ arbelide in ER+ breast cancer cells.
Fig. 19B shows an exemplary Bliss synergy score for VS-6766+ abbe-cili in mcf7er+ breast cancer cells.
FIG. 19C shows an exemplary Bliss synergy score for VS-6766+ Abeli in ZR-75-1ER+ breast cancer cells.
Fig. 20A shows an exemplary CellTiter-Glo assay for assessing cell viability of 16 KRAS G12C, G D or G12V mutant cell lines (9 NSCLC and 7 PDACs) grown under 3D conditions in a 7 day assay for VS-6766, patatib (iptaseptib), M2698 and everolimus.
Fig. 20B shows IC50 s for VSVS-6766, patatine, M2698 and everolimus.
FIG. 21A shows an exemplary CTG proliferation assay using VS-6766 and M2698 in SW1573 cells.
FIG. 21B shows an exemplary synergy analysis using VS-6766 and M2698 in SW1573 cells.
Fig. 21C shows an exemplary waterfall plot summarizing the combined synergy of VS-6766+m2698 in a set of KRAS mut NSCLC and PDAC cell lines.
Fig. 22A shows an exemplary graph summarizing the combined synergistic results of VS-6766+ patadine in a set of KRAS mut NSCLC and PDAC cell lines.
Fig. 22B shows exemplary data for the combination of VS-6766 and patadine, which shows an increase in anti-tumor response in SW1573 cells.
Fig. 23A shows an exemplary graph summarizing the combined synergy of VS-6766+m2698 in a set of KRAS mut NSCLC and PDAC cell lines.
FIG. 23B shows exemplary data for a combination of VS-6766 and M2698, which shows an increase in anti-tumor response in SW1573 cells.
Fig. 24A shows an exemplary graph summarizing the combined synergy of VS-6766+ everolimus in a set of KRAS mut NSCLC and PDAC cell lines.
Fig. 24B shows exemplary data for a combination of VS-6766 and everolimus, showing an increase in anti-tumor response in SW1573 cells.
Fig. 25A shows an exemplary CellTiter-Glo assay for assessing cell viability of 16 KRAS G12C, G D or G12V mutant cell lines (9 NSCLC and 7 PDACs) grown under 3D conditions in a 7 day assay for VS-6766 and afatinib.
FIG. 25B shows the IC50 for VS-6766 and afatinib.
FIG. 26A shows an exemplary CTG proliferation assay using VS-6766 and afatinib in H2122.
FIG. 26B shows an exemplary synergy analysis using VS-6766 and afatinib in H2122.
Fig. 26C shows an exemplary waterfall plot summarizing the combined synergy of VS-6766+ afatinib in a set of KRAS mut NSCLC and PDAC cell lines.
Fig. 27A shows an exemplary graph summarizing the combined synergy of VS-6766+ afatinib in a panel of KRAS mut NSCLC and PDAC cell lines.
FIG. 27B shows exemplary data for a combination of VS-6766 and afatinib showing an increase in anti-tumor response in H2122 cells.
FIG. 28 shows exemplary changes in tumor volume in H2122 tumor-bearing mice treated with VS-6766 (0.3 mg/kg QD) +/-afatinib (10 mg/kg QD).
FIG. 29 shows exemplary changes in tumor volume and survival in H1975 (L858R/T790M) tumor-bearing mice treated with VS-6766 (0.3 mg/kg QD) +/-Ornitinib (2.5 mg/kg QD).
FIG. 30 shows exemplary changes in tumor volume and survival in H1975 octenib drug resistance (Del 19/T790M/C797S) tumor bearing mice treated with VS-6766 (0.3 mg/kg QD) +/-octenib (2.5 mg/kg QD).
Detailed Description
As generally described herein, the present disclosure provides methods and combinations of compounds (e.g., combinations of compounds described herein, e.g., SHP2 inhibitors, SOS1 inhibitors, ERK1/2 inhibitors, CDK4/6 inhibitors, AKT inhibitors, mTOR inhibitors, pan-HER inhibitors, or EGFR inhibitors in combination with MEK inhibitors or dual RAF/MEK inhibitors) that are useful for treating abnormal cell growth (e.g., cancer) in a subject in need thereof.
Definition of the definition
Chemical definition
The definition of specific functional groups and chemical terms is described in more detail below. The chemical elements being CAS according to the periodic Table of the elementsVersion Handbook of Chemistry and Physics, 75 th edition (inner page) and specific functional groups are generally defined as described herein. Furthermore, in Thomas Sorrell, organic Chemistry, university Science Books, sausalato, 1999; smith and March, march's Advanced Organic Chemistry,5 th Edition,John Wiley&Sons, inc., new York,2001; larock, comprehensive Organic Transformations, VCH Publishers, inc., new York,1989; and Carruther, some Modern Methods of Organic Synthesis,3 rd General principles of organic chemistry, as well as specific functional groups and reactivities, are described in Edition, cambridge University Press, cambridge, 1987.
The compounds described herein may contain one or more asymmetric centers and thus may exist in various isomeric forms, such as enantiomers and/or diastereomers. For example, the compounds described herein may be in the form of individual enantiomers, diastereomers, or geometric isomers, or may be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers. The isomers may be separated from the mixtures by methods known to those skilled in the art, including chiral High Pressure Liquid Chromatography (HPLC) and formation and crystallization of chiral salts; alternatively preferred isomers may be prepared by asymmetric synthesis. See, e.g., jacques et al, entantiomers, racemates and Resolutions (Wiley Interscience, new York, 1981); wilen et al Tetrahedron 33:2725 (1977); eliel, stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, tables of Resolving Agents and Optical Resolutions, page 268 (E.L.Eliel, eds., univ.of Notre Dame Press, notre Dame, IN 1972). The present invention also encompasses the compounds described herein, either as individual isomers substantially free of other isomers, or as mixtures of the various isomers.
As used herein, a pure enantiomeric compound is substantially free of other enantiomers or stereoisomers of the compound (i.e., in enantiomeric excess). In other words, the "S" form of the compound is substantially free of the "R" form of the compound, and thus is in enantiomeric excess of the "R" form. The term "enantiomerically pure" or "pure enantiomer" means that a compound comprises more than 75 wt%, more than 80 wt%, more than 85 wt%, more than 90 wt%, more than 91 wt%, more than 92 wt%, more than 93 wt%, more than 94 wt%, more than 95 wt%, more than 96 wt%, more than 97 wt%, more than 98 wt%, more than 98.5 wt%, more than 99 wt%, more than 99.2 wt%, more than 99.5 wt%, more than 99.6 wt%, more than 99.7 wt%, more than 99.8 wt%, or more than 99.9 wt% of the enantiomer. In some embodiments, the weight is based on the total weight of all enantiomers or stereoisomers of the compound.
In the compositions provided herein, enantiomerically pure compounds may be present with other active or inactive ingredients. For example, a pharmaceutical composition comprising an enantiomerically pure R-compound may comprise, for example, about 90% excipient and about 10% enantiomerically pure R-compound. In some embodiments, enantiomerically pure R-compounds in such compositions may comprise, for example, at least about 95% by weight of the R-compound and at most about 5% by weight of the S-compound, based on the total weight of the compound. For example, a pharmaceutical composition comprising an enantiomerically pure S-compound may comprise, for example, about 90% excipient and about 10% enantiomerically pure S-compound. In some embodiments, enantiomerically pure S-compounds in such compositions may comprise, for example, at least about 95% by weight of S-compound and at most about 5% by weight of R-compound, based on the total weight of the compounds. In some embodiments, the active ingredient may be formulated with little or no excipients or carriers.
The compounds described herein may also comprise one or more isotopic substitutions. For example, H may be in any isotopic form, including 1 H、 2 H (D or deuterium) and 3 h (T or tritium); c may be in any isotopic form, including 12 C、 13 C and C 14 C, performing operation; o may be in any isotopic form, including 16 O and 18 o; f may be in any isotopic form, including 18 F and F 19 F, performing the process; etc.
The following terms are intended to have the meanings presented below and to aid in understanding the description and intended scope of the invention. When describing the invention, which may include compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and methods of using such compounds and compositions, the following terms, if any, have the following meanings, unless otherwise indicated. It will also be understood that when described herein, any of the moieties defined below may be substituted with a variety of substituents, and each definition is intended to include such substituted moieties within the scope thereof as shown below.
The term "halogen atom" as used herein refers to any of the radiostabilizing atoms of column 7 of the periodic table of elements, such as fluorine, chlorine, bromine or iodine, preferably fluorine and chlorine.
The term "ester" as used herein means a compound having the formula- (R) n -a chemical moiety of COOR ', wherein R and R' are independently selected from: alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), and wherein n is 0 or 1.
The term "amide" as used herein means a compound having the formula- (R) n -C (O) NHR' or- (R) n -a chemical moiety of NHC (O) R ', wherein R and R' are independently selected from: alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), and wherein n is 0 or 1. Amides may be amino acid or peptide molecules linked to the molecules of the invention, thereby forming prodrugs.
Any amine, hydroxyl, or carboxyl side chains on the compounds disclosed herein may be esterified or amidated. The manipulation and specific groups for achieving this are known to the person skilled in the art and can be readily found in references such as Greene and Wuts, protective Groups in Organic Synthesis,3 rd Ed.,John Wiley&Sons, new York, NY,1999, the entire contents of which are incorporated herein.
The term "aromatic" as used herein refers to an aromatic group having at least one ring with a conjugated pi electron system, and includes both carbocyclic aryl (e.g., phenyl) and heterocyclic aryl (e.g., pyridine). The term includes monocyclic or fused ring polycyclic (i.e., rings sharing adjacent pairs of carbon atoms) groups. The term "carbocycle" refers to a compound containing one or more covalent ring-closing structures and the atoms forming the ring backbone are all carbon atoms. Thus, the term distinguishes carbocycles from heterocycles in which the ring backbone contains at least one atom other than carbon. The term "heteroaromatic" refers to an aromatic group containing at least one heterocyclic ring.
As used herein, "Ca to Cb" (where "a" and "b" are integers) refers to the number of carbon atoms in an alkyl, alkenyl, or alkynyl group, or the number of carbon atoms in a ring of a cycloalkyl, aryl, heteroaryl, or heterocyclyl group. That is, the ring of an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl group may contain "a" to "b" (inclusive) carbon atoms. Thus, for example, a "C1-C4 alkyl" group or a "C1-C4 alkyl" group means all alkyl groups having 1 to 4 carbons, i.e., CH 3 -、CH 3 CH 2 -、CH 3 CH 2 CH 2 -、(CH 3 ) 2 CH-、CH 3 CH 2 CH 2 CH 2 -、CH 3 CH 2 CH(CH 3 ) -and (CH) 3 ) 3 C-. Likewise, for example, a cycloalkyl group may contain a total of "a" to "b" (inclusive) atoms in the ring, e.g., a C3-C8 cycloalkyl group, 3 to 8 carbon atoms. If "a" and "b" are not specified for alkyl, cycloalkyl or cycloalkenyl, then the broadest scope described in these definitions is assumed. Similarly, "4-to 7-membered heterocyclic group" means all heterocyclic groups having a total of 4 to 7 ring atoms, such as azetidine, oxetane, oxazoline, pyrrolidine, piperidine, piperazine, morpholine, and the like. As used herein, the term "C1-C6" includes C1, C2, C3, C4, C5, and C6, as well as ranges defined by any two of the foregoing numbers. For example, C1-C6 alkyl includes C1, C2, C3, C4, C5 and C6 alkyl, C2-C6 alkyl, C1-C3 alkyl, and the like. Similarly, C3-C8 carbocyclyl or cycloalkyl each includes hydrocarbon rings containing 3, 4, 5, 6, 7 and 8 carbon atoms or ranges defined by any two numbers, such as C3-C7 cycloalkyl or C5-C6 cycloalkyl. As another example, a 3 to 10 membered heterocyclyl group includes 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, or a range defined by any two of the foregoing numbers, e.g., 4 to 6 membered or 5-to 7-membered heterocyclyl.
As used herein, "alkyl" refers to a hydrocarbon group that is fully saturated (without double or triple bonds) with a straight or branched hydrocarbon chain. As used herein, "alkyl" refers to a hydrocarbon group that is fully saturated (without double or triple bonds) with a straight or branched hydrocarbon chain. Alkyl groups may have 1 to 20 carbon atoms (whenever present herein, a numerical range such as "1 to 20" refers to each integer within a given range; e.g., "1 to 20 carbon atoms" refers to an alkyl group that may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term "alkyl", where no numerical range is specified). The alkyl group may also be a medium size alkyl group having 1 to 10 carbon atoms. The alkyl group may also be a lower alkyl group having 1 to 5 carbon atoms. The alkyl group of a compound may be designated as "C1-C4 alkyl" or similar designation. By way of example only, "C1-C4 alkyl" means that there are 1 to 4 carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of: methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, ethenyl, propenyl, butenyl, and the like.
Alkyl groups may be substituted or unsubstituted. When substituted, the substituent is one or more groups independently and independently selected from the group consisting of: alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclic, aralkyl, heteroaralkyl, (heteroalicyclic) alkyl, hydroxy, protected hydroxy, alkoxy, aryloxy, acyl, ester, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxyl, protected C-carboxyl, O-carboxyl, isocyanato, thiocyanato, nitro, silyl, sulfinyl (sulfofinyl), sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido and amino (including mono-and di-substituted amino groups) and protected derivatives thereof. When a substituent is described as "optionally substituted," the substituent may be substituted with one of the substituents described above.
"alkenyl" as used herein refers to an alkyl group containing one or more double bonds in a straight or branched hydrocarbon chain. Alkenyl groups may be unsubstituted or substituted. When substituted, the substituents may be selected from the same groups disclosed above for alkyl substitution. Alkenyl groups may have 2 to 20 carbon atoms, although the present definition also covers the occurrence of the term "alkenyl" where no numerical range is specified. Alkenyl groups may also be medium size alkenyl groups having 2 to 9 carbon atoms. Alkenyl groups may also be lower alkenyl groups having 2 to 4 carbon atoms. Alkenyl groups of compounds may be designated as "C2-C4 alkenyl" or similar designations. By way of example only, "C2-C4 alkenyl" means 2 to 4 carbon atoms in the alkenyl chain, i.e., the alkenyl chain is selected from the group consisting of: vinyl, propen-1-yl, propen-2-yl, propen-3-yl, buten-1-yl, buten-2-yl, buten-3-yl, buten-4-yl, 1-methyl-propen-1-yl, 2-methyl-propen-1-yl, 1-ethyl-ethen-1-yl, 2-methyl-propen-3-yl, but-1, 3-dienyl, but-1, 2-dienyl and but-1, 2-dien-4-yl. Exemplary alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, hexenyl, and the like.
As used herein, "alkynyl" refers to an alkyl group containing one or more triple bonds in a straight or branched hydrocarbon chain. Alkynyl groups may be unsubstituted or substituted. When substituted, the substituents may be selected from the same groups disclosed above for alkyl substitution. Alkynyl groups may have 2 to 20 carbon atoms, although the present definition also covers the occurrence of the term "alkynyl", where no numerical range is specified. Alkynyl groups may also be medium-sized alkynyl groups having 2 to 9 carbon atoms. Alkynyl groups may also be lower alkynyl groups having 2 to 4 carbon atoms. Alkynyl groups of compounds may be designated as "C2-C4 alkynyl" or similar designations. By way of example only, "C2-C4 alkynyl" means that there are 2 to 4 carbon atoms in the alkynyl chain, i.e., the alkynyl chain is selected from the group consisting of: ethynyl, propyn-1-yl, propyn-2-yl, butyn-1-yl, butyn-3-yl, butyn-4-yl and 2-butynyl. Exemplary alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like.
"heteroalkyl" as used herein refers to a straight or branched hydrocarbon chain containing one or more heteroatoms (i.e., elements other than carbon, including but not limited to nitrogen, oxygen, and sulfur) in the backbone. Heteroalkyl groups may have from 1 to 20 carbon atoms, although the present definition also covers the occurrence of the term "heteroalkyl" where no numerical range is specified. The heteroalkyl group may also be a medium size heteroalkyl group having 1 to 9 carbon atoms. The heteroalkyl group may also be a lower heteroalkyl group having 1 to 4 carbon atoms. The heteroalkyl group of a compound may be designated as "C1-C4 heteroalkyl" or a similar designation. The heteroalkyl group may contain one or more heteroatoms. By way of example only, "C1-C4 heteroalkyl" means 1 to 4 carbon atoms in the heteroalkyl chain and an additional heteroatom or heteroatoms in the backbone of the chain.
As used herein, "aryl" refers to a carbocyclic (all carbon) ring or two or more fused rings (rings sharing two adjacent carbon atoms) having a fully delocalized pi-electron system. Examples of aryl groups include, but are not limited to, benzene, naphthalene and azulene. Aryl groups may be substituted or unsubstituted. When substituted, the hydrogen atom is replaced by a substituent, which is one or more groups independently selected from the group consisting of: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclic, aralkyl, heteroaralkyl, (heteroalicyclic) alkyl, hydroxy, protected hydroxy, alkoxy, aryloxy, acyl, ester, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, protected C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido and amino (including mono-and di-substituted amino groups) and protected derivatives thereof. When substituted, substituents on the aryl groups can form non-aromatic rings fused to the aryl groups, including cycloalkyl, cycloalkenyl, cycloalkynyl, and heterocyclyl.
As used herein, "heteroaryl" refers to a monocyclic or polycyclic aromatic ring system (ring system having a fully delocalized pi electron system), one or two or more fused rings, which contain one or more heteroatoms (i.e., elements other than carbon, including but not limited to nitrogen, oxygen, and sulfur). Examples of heteroaromatic rings include, but are not limited to, furan, thiophene, phthalazine, pyrrole, oxazole, thiazole, imidazole, pyrazole, isoxazole, isothiazole, triazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, and triazine. Heteroaryl groups may be substituted or unsubstituted. When substituted, the hydrogen atom is replaced by a substituent, which is one or more groups independently selected from the group consisting of: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclic, aralkyl, heteroaralkyl, (heteroalicyclic) alkyl, hydroxy, protected hydroxy, alkoxy, aryloxy, acyl, ester, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, protected C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido and amino include mono-and di-substituted amino groups and protected derivatives thereof. When substituted, substituents on heteroaryl groups can form non-aromatic rings fused to aryl groups, including cycloalkyl, cycloalkenyl, cycloalkynyl, and heterocyclyl.
As used herein, "aralkyl" or "arylalkyl" refers to an aryl group attached through an alkylene group as a substituent. The alkylene and aryl groups of the aralkyl groups may be substituted or unsubstituted. Examples include, but are not limited to, benzyl, substituted benzyl, 2-phenylethyl, 3-phenylpropyl, and naphthylalkyl. In some cases, the alkylene is a lower alkylene.
As used herein, "heteroarylalkyl" or "heteroarylalkyl" is a heteroaryl group attached through an alkylene group as a substituent. The alkylene and heteroaryl groups of the heteroaralkyl groups may be substituted or unsubstituted. Examples include, but are not limited to, 2-thienylmethyl, 3-thienylmethyl, furylmethyl, thienylethyl, pyrrolidinyl, pyridylalkyl, isoxazolylalkyl, and imidazolylalkyl, and substituted and benzofused analogs thereof. In some cases, the alkylene is a lower alkylene.
As used herein, "alkylene" refers to a branched or straight chain fully saturated diradical chemical group containing only carbon and hydrogen, which is attached to the remainder of the molecule (i.e., an alkanediyl group) through two points of attachment. Alkylene groups may have from 1 to 20 carbon atoms, although the present definition also covers the occurrence of the term alkylene, where no numerical range is specified. The alkylene group may also be a medium size alkylene group having 1 to 9 carbon atoms. The alkylene group may also be a lower alkylene group having 1 to 4 carbon atoms. Alkylene groups may be designated as "C1-C4 alkylene" or similar designations. By way of example only, "C1-C4 alkylene" means having from 1 to 4 carbon atoms in the alkylene chain, i.e., the alkylene chain is selected from the group consisting of: methylene, ethylene-1, 1-diyl, propylene, propane-1, 1-diyl, propane-2, 2-diyl, 1-methyl-ethylene, butylene, butane-1, 1-diyl, butane-2, 2-diyl, 2-methyl-propane-1, 1-diyl, 1-methyl-propylene, 2-methyl-propylene, 1-dimethyl-ethylene, 1, 2-dimethyl-ethylene and 1-ethyl-ethylene.
As used herein, "alkenylene" refers to a straight or branched chain diradical chemical group containing only carbon and hydrogen and containing at least one carbon-carbon double bond attached to the remainder of the molecule through two points of attachment. Alkenylene groups may have 2 to 20 carbon atoms, although the present definition also covers the occurrence of the term alkenylene, where no numerical range is specified. Alkenylene may also be a medium-sized alkenylene having 2 to 9 carbon atoms. Alkenylene may also be lower alkenylene having 2 to 4 carbon atoms. Alkenylene may be designated as "C2-C4 alkenylene" or similar designation. By way of example only, "C2 alkenylene" means that there are 2 to 4 carbon atoms in the alkenylene chain, i.e., the alkenylene chain is selected from the group consisting of: ethylene, ethylene-1, 1-diyl, propylene-1, 1-diyl, prop-2-en-1, 1-diyl, 1-methyl-ethylene, but-1-ylene, but-2-ylene, but-1, 3-dienylene, but-1, 1-diyl, but-1, 3-diene-1, 1-diyl, but-2-en-1, 1-diyl, but-3-en-1, 1-diyl, l-methyl-prop-2-en-1, 1-diyl, 2-methyl-prop-2-en-1, 1-diyl, 1-ethyl-ethylene, 1, 2-dimethyl-ethylene, 1-methyl-propylene, 2-methyl-propylene, 3-methyl-propylene, 2-methyl-propylene-1, 1-diyl and 2, 2-dimethyl-ethylene-1, 1-diyl.
As used herein, "alkylene" refers to a divalent group, e.g., =cr' R ", that is attached to one carbon of another group to form a double bond, alkylene including, but not limited to, methine (=ch 2 ) And ethylene (=chch) 3 ). As used herein, "arylalkylene" refers to an alkylene in which R' and R "are aryl groups. The alkylene groups may be substituted or unsubstituted.
As used herein, "alkoxy" refers to the formula-OR, wherein R is an alkyl group as defined above, such as methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, tert-pentyloxy, and the like. Alkoxy groups may be substituted or unsubstituted.
As used herein, "alkylthio" refers to the formula-SR, wherein R is an alkyl group as defined above, such as methyl mercaptan, ethyl mercaptan, n-propyl mercaptan, 1-methyl ethyl mercaptan (isopropyl mercaptan), n-butyl mercaptan, isobutyl mercaptan, sec-butyl mercaptan, tert-butyl mercaptan, and the like. Methyl mercapto group, ethyl mercapto group, n-propyl mercapto group, 1-methyl ethyl mercapto group (isopropyl mercapto group), n-butyl mercapto group, isobutyl mercapto group, sec-butyl mercapto group, tert-butyl mercapto group, and the like. Alkylthio groups may be substituted or unsubstituted.
As used herein, "aryloxy" and "arylthio" refer to RO-and RS-, respectively, wherein R is an aryl group, such as, but not limited to, phenyl. Both aryloxy and arylthio groups may be substituted or unsubstituted.
As used herein, "acyl" refers to-C (=o) R, wherein R is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 carbocyclyl, aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein. Non-limiting examples include formyl, acetyl, propionyl, benzoyl and acryloyl.
As used herein, "cycloalkyl" refers to a fully saturated (non-double bond) mono-or polycyclic hydrocarbon ring system. When composed of two or more rings, the rings may be connected together in a fused, bridged or bolted fashion. Cycloalkyl groups may range from C3 to C10, in other embodiments, they may range from C3 to C6. Cycloalkyl groups may be unsubstituted or substituted. Exemplary cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. If substituted, unless otherwise indicated, the substituents may be alkyl groups or selected from those indicated above with respect to alkyl substitution. When substituted, substituents on cycloalkyl groups can form aromatic rings fused to cycloalkyl groups, including aryl and heteroaryl groups.
As used herein, "cycloalkenyl" refers to cycloalkyl groups containing one or more double bonds in the ring, but if multiple double bonds are present, they are not able to form a fully delocalized pi-electron system in the ring (otherwise the group would be an "aryl" group, as defined herein). When composed of two or more rings, the rings may be connected together in a fused, bridged or bolted fashion. Cycloalkenyl groups may be unsubstituted or substituted. When substituted, unless otherwise indicated, the substituents may be alkyl or selected from the groups disclosed above for alkyl substitution. When substituted, substituents on the cycloalkenyl group can form aromatic rings fused to the cycloalkenyl group, including aryl and heteroaryl groups.
As used herein, "cycloalkynyl" refers to cycloalkyl groups containing one or more triple bonds in the ring. When composed of two or more rings, the rings may be connected together in a fused, bridged or bolted fashion. The cycloalkynyl group may be unsubstituted or substituted. When substituted, unless otherwise indicated, the substituents may be alkyl or selected from the groups disclosed above for alkyl substitution. When substituted, substituents on the cycloalkynyl group can form an aromatic ring fused to the cycloalkynyl group, including aryl and heteroaryl groups.
As used herein, "heteroalicyclic" or "heteroalicyclic" refers to a stable 3-to 18-membered ring consisting of carbon atoms and 1 to 5 heteroatoms selected from nitrogen, oxygen, and sulfur. "heteroalicyclic" or "heteroalicyclic" groups may be monocyclic, bicyclic, tricyclic, or tetracyclic ring systems, which may be joined together in a fused, bridged, or spiro-linked manner; and the nitrogen, carbon and sulfur atoms in the "heteroalicyclic" or "heteroalicyclic" group may optionally be oxidized; nitrogen may optionally be quaternized; and the rings may also contain one or more double bonds, provided that they do not form a completely delocalized pi-electron system in all rings. The heteroalicyclic may be unsubstituted or substituted. When substituted, the substituents may be one or more groups independently selected from the group consisting of: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclic, aralkyl, heteroaralkyl, (heteroalicyclic) alkyl, hydroxy, protected hydroxy, alkoxy, aryloxy, acyl, ester, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, protected C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, haloalkyl, haloalkoxy, trihalomethylsulfonyl, trihalomethylsulfonylamino, and amino (including mono-and di-substituted amino groups) and protected derivatives thereof. Examples of such "heteroalicyclic" or "heteroalicyclic" include, but are not limited to, azepinyl, acridinyl, carbazolyl, cinnolinyl, dioxolanyl, imidazolinyl, morpholinyl, oxiranyl, piperidinyl A-oxide, piperidinyl, piperazinyl, pyrrolidinyl, 4-piperidinyl, pyrazolidinyl, 2-oxopyrrolidinyl, thiomorpholinyl sulfoxide, and thiomorpholinyl sulfone. When substituted, the substituents on the heteroalicyclic group may form an aromatic ring fused to the heteroalicyclic group, including aryl and heteroaryl groups.
As used herein, the term "(cycloalkenyl) alkyl" refers to cycloalkenyl groups linked via an alkylene group as a substituent. The alkylene and cycloalkenyl groups of the (cycloalkenyl) alkyl groups may be substituted or unsubstituted. In some cases, the alkylene is a lower alkylene.
As used herein, the term "(cycloalkynyl) alkyl" refers to a cycloalkynyl group attached via an alkylene group as a substituent. The alkylene groups of the (cycloalkynyl) alkyl groups and the cycloalkynyl groups may be substituted or unsubstituted. In some cases, the alkylene is a lower alkylene.
As used herein, the term "O-carboxy" refers to a "RC (=o) O-group, wherein R may be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclic, aralkyl, or (heteroalicyclic) alkyl, as defined herein. The O-carboxy group may be substituted or unsubstituted.
As used herein, the term "C-carboxy" refers to a "-C (=o) R" group, wherein R may be as defined for O-carboxy. The C-carboxyl group may be substituted or unsubstituted.
The term "trihalomethylsulfonyl" as used herein means "X 3 CSO 2 - "group wherein X is halogen.
As used herein, the term "cyano" refers to a "-CN" group.
As used herein, the term "cyanooxy" refers to an "-OCN" group.
As used herein, the term "isocyanato" refers to an "-NCO" group.
As used herein, the term "thiocyanic acid" refers to an "-SCN" group.
As used herein, the term "isothiocyanato" refers to an "-NCS" group.
As used herein, the term "sulfinyl" refers to an "-S (=o) -R" group, wherein R may be as defined for the O-carboxy group. Sulfinyl groups may be substituted or unsubstituted.
The term "sulfonyl" as used herein refers to "-SO 2 R' groups, wherein R may be as defined for the O-carboxyl group. Sulfonyl groups may be substituted or unsubstituted.
The term "S-sulfonylamino", as used herein"means" -SO 2 NRARB "groups, wherein RA and RB may be as defined for O-carboxy. The S-sulfonylamino group may be substituted or unsubstituted.
The term "N-sulfonylamino" as used herein means "-SO 2 An N (RA) (RB) "group, wherein RA and RB can be the same as defined for the O-carboxy group. Sulfonyl groups may be substituted or unsubstituted.
The term "trihalomethylsulfonylamino" as used herein means "X 3 CSO 2 An N (R) - "group, wherein X is halogen, and R may be as defined for the O-carboxy group. The trihalomethanesulfonylamino group may be substituted or unsubstituted.
As used herein, the term "O-carbamoyl" refers to an "-OC (=o) NRARB" group, wherein RA and RB may be as defined for O-carboxy. The O-carbamoyl group may be substituted or unsubstituted.
As used herein, the term "N-carbamoyl" refers to the "ROC (=o) NRA" group, wherein R and RA may be as defined for O-carboxy. The N-carbamoyl group may be substituted or unsubstituted.
As used herein, the term "O-thiocarbamoyl" refers to an "-OC (=s) -NRARB" group, wherein RA and RB may be as defined for the O-carboxyl group. The O-thiocarbamoyl group may be substituted or unsubstituted.
As used herein, the term "N-thiocarbamoyl" refers to the "ROC (=s) NRA-group, wherein R and RA may be as defined for the O-carboxyl group. The N-thiocarbamoyl group may be substituted or unsubstituted.
As used herein, the term "C-amido" refers to a "-C (=o) NRARB" group, wherein RA and RB may be as defined for O-carboxy. The C-amido group may be substituted or unsubstituted.
As used herein, the term "N-amido" refers to the "RC (=o) NRA-" group, wherein R and RA may be as defined for O-carboxy. The N-amido group may be substituted or unsubstituted.
As used herein, the term "amino" refers to an "-NRARB" group, wherein RA and RB are each independently selected from: hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 carbocyclyl, C6-C10 aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
As used herein, the term "aminoalkyl" refers to an amino group attached through an alkylene group.
As used herein, the term "ester" refers to a "-C (=o) OR" group, wherein R may be as defined for O-carboxy. The esters may be substituted or unsubstituted.
As used herein, the term "lower aminoalkyl" refers to an amino group attached through a lower alkylene group. Lower aminoalkyl groups may be substituted or unsubstituted.
As used herein, the term "lower alkoxyalkyl" refers to an alkoxy group attached through a lower alkylene group. Lower alkoxyalkyl groups may be substituted or unsubstituted.
The term "acetyl" as used herein refers to-C (=o) CH 3 A group.
As used herein, the term "perhaloalkyl" refers to an alkyl group in which all hydrogen atoms are replaced by halogen atoms.
As used herein, the term "carbocyclyl" refers to a non-aromatic ring or ring system containing only carbon atoms in the ring system backbone. When carbocyclyl is a ring system, two or more rings may be connected together in a fused, bridged or spiro manner. Carbocyclyl groups may have any degree of saturation provided that at least one ring in the ring system is not aromatic. Thus, carbocyclyl includes cycloalkyl, cycloalkenyl, and cycloalkynyl. Carbocyclyl groups may have 3 to 20 carbon atoms, although the present definition also covers the occurrence of the term "carbocyclyl", where no numerical range is specified. The carbocyclyl group may also be a medium size carbocyclyl group having 3 to 10 carbon atoms. The carbocyclyl group may also be a carbocyclyl group having 3 to 6 carbon atoms. Carbocyclyl may be designated as "C3-C6 carbocyclyl" or similar designations. Examples of carbocyclyl rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2, 3-indane, bicyclo [2.2.2] octyl, adamantyl, and spiro [4.4] nonyl.
As used herein, the term "(cycloalkyl) alkyl" refers to cycloalkyl groups attached through an alkylene group as a substituent. The alkylene and cycloalkyl groups of the (cycloalkyl) alkyl groups may be substituted or unsubstituted. Examples include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopropylethyl, cyclopropylbutyl, cyclobutylethyl, cyclopropylisopropyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cycloheptylmethyl, and the like. In some cases, the alkylene is a lower alkylene.
As used herein, the term "cycloalkyl" refers to a fully saturated carbocyclyl ring or ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
As used herein, the term "cycloalkenyl" refers to a carbocyclic ring or ring system having at least one double bond, wherein no ring in the ring system is aromatic. One example is cyclohexenyl.
As used herein, the term "heterocyclyl" refers to three-, four-, five-, six-, seven-, and eight-or more membered rings in which the carbon atoms together with 1 to 3 heteroatoms form the ring. However, the heterocyclyl may optionally contain one or more unsaturated bonds that are positioned in a manner that does not result in an aromatic pi-electron system. The heteroatoms are independently selected from oxygen, sulfur, and nitrogen. The heterocyclyl group may also contain one or more carbonyl or thiocarbonyl functional groups, such that definition includes oxo and thio systems, such as lactams, lactones, cyclic imides, cyclic thioimides, cyclic carbamates, and the like. "heterocyclyl" may refer to a non-aromatic ring or ring system containing at least one heteroatom in the ring backbone. The heterocyclic groups may be linked together in a fused, bridged or spiro manner. The heterocyclyl group may have any degree of saturation, provided that at least one ring in the ring system is not aromatic. Heteroatoms may be present in non-aromatic or aromatic rings in the ring system. Heterocyclyl groups may have 3 to 20 ring members (i.e., the number of atoms comprising the ring backbone, including carbon atoms and heteroatoms), although the present definition also covers the occurrence of the term "heterocyclyl" wherein no numerical range is specified. The heterocyclyl may also be a medium sized heterocyclyl having 3 to 10 ring members. The heterocyclyl may also be a heterocyclyl having 3 to 6 ring members. Heterocyclyl groups may be designated as "3-6 membered heterocyclyl" or similar designations. In a preferred six-membered monocyclic heterocyclyl, the heteroatoms are selected from one to three of O, N or S, and in a preferred five-membered monocyclic heterocyclyl, the heteroatoms are selected from one or two of O, N or S. Examples of heterocyclyl rings include, but are not limited to, azepinyl, acridinyl, carbazolyl, cinnolinyl, dioxolanyl, imidazolinyl, imidazolidinyl, morpholinyl, oxiranyl, oxacycloheptyl (oxapanyl), thiepanyl (thiepanyl), piperidinyl, piperazinyl, dioxopiperazinyl, pyrrolidinyl, pyrrolidonyl, 4-piperidone, pyrazolinyl, pyrazolidinyl, 1, 3-dioxanyl (dioxanyl), 1, 3-dioxanyl, 1, 4-dioxanyl, 1, 3-oxathianyl, 1, 4-oxathiadienyl, 1, 4-oxathianyl, 2// -l, 2-oxazinyl, trioxane (trioxane yl), hexahydro-l, 3, 5-triazinyl, 1, 3-dioxolyl, 1, 3-dithiolane (dithiolyl), 1, 3-dithiolane (dithiolanyl), isoxazolinyl, isoxazolidinyl, oxazolinyl, oxazolidinyl, oxazolidone, thiazolinyl, thiazolidinyl, 1, 3-oxathiolanyl, indolinyl, isoindolinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydro-l, 4-thiazinyl, thiomorpholinyl, dihydrobenzofuranyl, benzimidazolidinyl and tetrahydroquinoline.
As used herein, the term "(heterocyclyl) alkyl" refers to a heterocyclyl attached through an alkylene group as a substituent. Examples include, but are not limited to, imidazolinylmethyl and indolinylethyl.
The substituted group is based on or derived from an unsubstituted parent group in which one or more hydrogen atoms are exchanged with another atom or group. When a group is considered "substituted" unless otherwise indicated, the group is substituted with one or more substituents independently selected from the group consisting of: C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C3-C7 carbocyclyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 halo)Alkoxy), C3-C7-carbocyclyl-C1-C6-alkyl (optionally substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), 5-10-membered heterocyclyl-C1-C6-alkyl (optionally substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), aryl (optionally substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy) aryl (C1-C6) alkyl (optionally substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), 5-to 10-membered heteroaryl (C1-C6) alkyl (optionally substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), halogen, cyano, hydroxy, C1-C6 alkoxy (C1-C6) alkyl (i.e., ether), aryloxy, mercapto (mercapto), halo (C1-C6) alkyl (e.g. -CF) 3 ) Halo (C1-C6) alkoxy (e.g. -OCF 3 ) C1-C6 alkylthio, arylthio, amino (C1-C6) alkyl, nitro, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxyl, O-carboxyl, acyl, cyanooxy, isocyanato, thiocyanato, isothiocyanato, sulfinyl, sulfonyl and oxo (= O). When a group is described as "optionally substituted," the group may be substituted with the substituents described above.
In some embodiments, a substituted group is substituted with one or more substituents independently and independently selected from the group consisting of: C1-C4 alkyl, amino, hydroxy and halogen.
It should be appreciated that certain radical naming conventions may include single radicals or dual radicals, depending on the context. For example, where a substituent requires two points of attachment to the remainder of the molecule, it is understood that the substituent is a diradical. For example, substituents identified as alkyl groups requiring two points of attachment include bisFree radicals, e.g. -CH 2 -、-CH 2 CH 2 -、-CH 2 CH(CH 3 )CH 2 -and the like. Other radical naming conventions clearly indicate that the radical is a diradical, such as "alkylene" or "alkenylene".
Unless otherwise indicated, when a substituent is considered "optionally substituted" it is meant that the substituent is a group that may be substituted with one or more groups independently and independently selected from: alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanic, isothiocyanato, nitro, silyl, trihalomethanesulfonyl and amino (including mono-and di-substituted amino groups) and protected derivatives thereof. Protecting groups that can form protective derivatives of the above substituents are known to those skilled in the art and can be found in references such as Greene and Wuts, described above.
Other definitions
"about" and "approximately" generally mean an acceptable degree of error in the measured quantity taking into account the nature or accuracy of the measurement. Exemplary degrees of error are within 20 percent (%) of a given value or range of values, typically within 10%, more typically within 5%.
As used herein, "pharmaceutically acceptable salts" refers to those salts that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, berge et al, J.pharmaceutical Sciences (1977) 66: pharmaceutically acceptable salts are described in detail in 1-19. Pharmaceutically acceptable salts of the compounds of the invention include those derived from suitable inorganic and organic acids and bases. Pharmaceutically acceptable non-toxic acid additionExamples of salts are salts of amino groups with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid, or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid, or by using other methods used in the art, for example ion exchange. Other pharmaceutically acceptable salts include adipic acid salts, alginates, ascorbates, aspartic acid salts, benzenesulfonic acid salts, benzoic acid salts, bisulfate salts, boric acid salts, butyric acid salts, camphoric acid salts, citric acid salts, cyclopentanepropionic acid salts, digluconate, dodecylsulfuric acid salts, ethanesulfonic acid salts, formic acid salts, fumaric acid salts, glucoheptonate, glycerophosphate, gluconic acid salts, hemisulfate, heptanoic acid salts, caproic acid salts, hydroiodic acid salts, 2-hydroxy-ethanesulfonic acid salts, lactobionic acid salts, lactic acid salts, lauric acid salts, lauryl sulfuric acid salts, malic acid salts, maleic acid salts, malonic acid salts, methanesulfonic acid salts, 2-naphthalenesulfonic acid salts, nicotinic acid salts, nitrate, oleic acid salts, oxalic acid salts, palmitic acid salts, pamoic acid salts, pectic acid salts, persulfates, 3-phenylpropionic acid salts, phosphates, picrate, pivalic acid salts, propionic acid salts, stearates, succinic acid salts, sulfuric acid salts, tartaric acid salts, thiocyanate salts, p-toluenesulfonic acid salts, undecanoate, valeric acid salts, and the like. Pharmaceutically acceptable salts derived from suitable bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N + (C 1–4 Alkyl group 4 And (3) salt. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Additional pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations, where appropriate, formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates, and aryl sulfonates.
As used herein, a "pharmaceutically acceptable carrier" refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that can be used in the compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as phosphates), glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts), colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and lanolin.
As used herein, a "subject" contemplated for administration includes, but is not limited to, humans (i.e., males or females of any age group, such as pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle aged adults, or elderly) and/or non-human animals, such as mammals, such as primates (e.g., cynomolgus, rhesus), cows, pigs, horses, sheep, goats, rodents, cats, and/or dogs. In certain embodiments, the subject is a human. In certain embodiments, the subject is a non-human animal. The terms "human," "patient," and "subject" are used interchangeably herein.
Diseases, disorders, and conditions are used interchangeably herein.
As used herein and unless otherwise specified, the terms "treat" (treat, treating and treatment) encompass the effect that occurs when a subject suffers from a specified disease, disorder or condition, which reduces the severity of the disease, disorder or condition or delays or reduces the progression of the disease, disorder or condition (also referred to as "therapeutic treatment").
In general, an "effective amount" of a compound refers to an amount sufficient to elicit the desired biological response. As will be appreciated by those of skill in the art, the effective amount of the compounds of the present invention may vary depending on factors such as: the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, the age, weight, health, and condition of the subject.
As used herein, unless otherwise indicated, a "therapeutically effective amount" of a compound is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder, or condition, or to delay or minimize one or more symptoms associated with the disease, disorder, or condition. A therapeutically effective amount of a compound refers to an amount of a therapeutic agent alone or in combination with other therapies that provides a therapeutic benefit in the treatment of a disease, disorder or condition. The term "therapeutically effective amount" may encompass an amount that improves overall treatment, reduces or avoids symptoms or causes of a disease or disorder, or enhances the therapeutic efficacy of another therapeutic agent.
As used herein, "prophylactic treatment" encompasses actions that occur before a subject begins to suffer from a particular disease, disorder, or condition.
As used herein, unless otherwise indicated, a "prophylactically effective amount" of a compound is an amount sufficient to prevent a disease, disorder, or condition, or one or more symptoms associated with a disease, disorder, or condition, or to prevent recurrence thereof. A prophylactically effective amount of a compound refers to an amount of a therapeutic agent alone or in combination with other agents that provides a prophylactic benefit in preventing a disease, disorder, or condition. The term "prophylactically effective amount" may encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
As used herein, the term "oral dosage form" refers to a composition or medium for administration of an agent to a subject. Generally, oral dosage forms are administered orally, however, "oral dosage forms" are intended to encompass any substance that is administered to a subject and absorbed through a membrane of the gastrointestinal tract, such as the mucosa, including, for example, the mouth, esophagus, stomach, small intestine, large intestine, and colon. For example, "oral dosage form" encompasses solutions administered into the stomach through a feeding tube.
As used herein in the context of a drug administration cycle, "cycle" refers to a period of time during which a drug is administered and may further include a rest period during which the drug is not administered to a subject. In some embodiments, 1 cycle is 4 weeks (e.g., three weeks of administration followed by one week of discontinuation).
"KRAS mutations" are mutations in the KRAS gene (i.e., nucleic acid mutations) or KRAS protein (i.e., amino acid mutations) that result in aberrant KRAS protein function associated with increased and/or constitutive activity by favoring the active GTP binding state of KRAS protein. Mutations may be located at conserved sites favoring GTP binding and constitutively active Kras protein. In some cases, the mutation is located at one or more of codons 12, 13 and 16 of the KRAS gene. For example, a KRAS mutation may be at codon 12 of the KRAS gene, e.g., as a single point substitution mutation at codon 12 (i.e., a KRAS G12X mutation) (e.g., a KRAS G12V mutation resulting from a single nucleotide change (c.35G > T) and resulting in substitution of glycine (G) at position 12 with valine (V). Exemplary KRAS G12X mutations include, but are not limited to, KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C.
"RAF mutation" is a mutation in the RAF gene. A "BRAF mutation" is a mutation in the BRAF gene. An "ARAF mutation" is a mutation in the ARAF gene. A "CRAF mutation" is a mutation in the CRAF gene.
Therapeutic method
Combinations of compounds described herein (e.g., SHP2 inhibitors, SOS1 inhibitors, ERK1/2 inhibitors, CDK4/6 inhibitors, AKT inhibitors, mTOR inhibitors, pan-HER inhibitors, or EGFR inhibitors in combination with MEK inhibitors or dual RAF/MEK inhibitors) and pharmaceutical compositions thereof are generally useful in methods of treating abnormal cell growth such as cancer.
Accordingly, in one aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of an SHP2 inhibitor and a MEK inhibitor, thereby treating the subject. In some embodiments, the method further comprises administering an additional agent.
In another aspect, disclosed herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of an SHP2 inhibitor and a dual RAF/MEK inhibitor (e.g., VS-6766), thereby treating the subject. In some embodiments, the method further comprises administering an additional agent.
In some embodiments of the methods described herein, the duration of response to an SHP2 inhibitor may be reduced by administering to a subject in need thereof a combination of an SHP2 inhibitor and a MEK inhibitor. In some embodiments, the duration of response to an SHP2 inhibitor may be reduced by administering to a subject in need thereof a combination of an SHP2 inhibitor and a RAF/MEK inhibitor (e.g., VS-6766). In some embodiments, the combinations described herein can improve the depth and/or duration of a response (e.g., an anti-tumor response) in a subject.
The contemplated subjects of the methods described herein can be identified (e.g., by screening, e.g., sequencing) as having SHP2 mutations.
The methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., a KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering a MEK inhibitor in combination with a SHP2 inhibitor, optionally with an additional agent, to the subject.
The methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C) by administering to the subject a dual RAF/MEK inhibitor (e.g., VS-6766) in combination with a SHP2 inhibitor, optionally with an additional agent.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of a SOS1 inhibitor and a MEK inhibitor, thereby treating the subject. In some embodiments, the method further comprises administering an additional agent.
In another aspect, disclosed herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a SOS1 inhibitor in combination with a dual RAF/MEK inhibitor (e.g., VS-6766), thereby treating the subject. In some embodiments, the method further comprises administering an additional agent.
In some embodiments of the methods described herein, the duration of response to a SOS1 inhibitor may be reduced by administering a combination of a SOS1 inhibitor and a MEK inhibitor to a subject in need thereof. In some embodiments, the duration of response to a SOS1 inhibitor may be reduced by administering to a subject in need thereof a combination of a SOS1 inhibitor and a RAF/MEK inhibitor (e.g., VS-6766). In some embodiments, the combinations described herein can improve the depth and/or duration of a response (e.g., an anti-tumor response) in a subject.
The contemplated subject of the methods described herein can be identified (e.g., by screening, e.g., sequencing) as having SOS1 mutations.
The methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., a KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering a MEK inhibitor in combination with a SOS1 inhibitor, optionally with an additional agent, to the subject.
The methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C) by administering to the subject a dual RAF/MEK inhibitor (e.g., VS-6766) in combination with an SOS1 inhibitor, optionally with an additional agent.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of an ERK1/2 inhibitor and a MEK inhibitor, thereby treating the subject. In some embodiments, the method further comprises administering an additional agent.
In another aspect, disclosed herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of an ERK1/2 inhibitor and a dual RAF/MEK inhibitor (e.g., VS-6766), thereby treating the subject. In some embodiments, the method further comprises administering an additional agent.
In some embodiments of the methods described herein, the duration of response to an ERK1/2 inhibitor may be reduced by administering to a subject in need thereof a combination of an ERK1/2 inhibitor and a MEK inhibitor. In some embodiments, the duration of response to an ERK1/2 inhibitor may be shortened by administering to a subject in need thereof a combination of an ERK1/2 inhibitor and a RAF/MEK inhibitor (e.g., VS-6766). In some embodiments, the combinations described herein can improve the depth and/or duration of a response (e.g., an anti-tumor response) in a subject.
Contemplated subjects of the methods described herein can be identified (e.g., by screening, e.g., sequencing) as having an ERK1/2 mutation.
The methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., a KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering a MEK inhibitor in combination with an ERK1/2 inhibitor, optionally with an additional agent, to the subject.
The methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C) by administering to the subject a dual RAF/MEK inhibitor (e.g., VS-6766) in combination with an ERK1/2 inhibitor, optionally with an additional agent.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a CDK4/6 inhibitor in combination with a MEK inhibitor, thereby treating the subject. In some embodiments, the method further comprises administering an additional agent.
In another aspect, disclosed herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a CDK4/6 inhibitor in combination with a dual RAF/MEK inhibitor (e.g., VS-6766) or a pharmaceutically acceptable salt thereof, thereby treating the subject. In some embodiments, the method further comprises administering an additional agent.
In some embodiments of the methods described herein, the duration of response to a CDK4/6 inhibitor may be reduced by administering to a subject in need thereof a combination of a CDK4/6 inhibitor and a MEK inhibitor. In some embodiments, the duration of response to a CDK4/6 inhibitor may be shortened by administering to a subject in need thereof a combination of a CDK4/6 inhibitor and a RAF/MEK inhibitor (e.g., VS-6766). In some embodiments, the combinations described herein can improve the depth and/or duration of a response (e.g., an anti-tumor response) in a subject.
Contemplated subjects of the methods described herein may be identified (e.g., by screening, e.g., sequencing) as having CDK4/6 mutations.
The methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., a KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering a MEK inhibitor in combination with a CDK4/6 inhibitor, optionally with an additional agent, to the subject.
The methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C) by administering to the subject a dual RAF/MEK inhibitor (e.g., VS-6766) in combination with a CDK4/6 inhibitor, optionally with an additional agent.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of an AKT inhibitor and a MEK inhibitor, thereby treating the subject. In some embodiments, the method further comprises administering an additional agent.
In another aspect, disclosed herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of an AKT inhibitor and a dual RAF/MEK inhibitor (e.g., VS-6766), thereby treating the subject. In some embodiments, the method further comprises administering an additional agent.
In some embodiments of the methods described herein, the duration of response to an AKT inhibitor may be reduced by administering to a subject in need thereof a combination of an AKT inhibitor and a MEK inhibitor. In some embodiments, the duration of response to an AKT inhibitor may be shortened by administering to a subject in need thereof a combination of an AKT inhibitor and a RAF/MEK inhibitor (e.g., VS-6766). In some embodiments, the combinations described herein can improve the depth and/or duration of a response (e.g., an anti-tumor response) in a subject.
The contemplated subjects of the methods described herein can be identified (e.g., by screening, e.g., sequencing) as having AKT mutations.
The methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., a KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering a MEK inhibitor in combination with an AKT inhibitor, optionally with an additional agent, to the subject.
The methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C) by administering a dual RAF/MEK inhibitor (e.g., VS-6766) in combination with an AKT inhibitor, optionally with an additional agent, to the subject.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of an mTOR inhibitor and a MEK inhibitor, thereby treating the subject. In some embodiments, the method further comprises administering an additional agent.
In another aspect, disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject a mTOR inhibitor in combination with a dual RAF/MEK inhibitor (e.g., VS-6766) or a pharmaceutically acceptable salt thereof, thereby treating the subject. In some embodiments, the method further comprises administering an additional agent.
In some embodiments of the methods described herein, the duration of response to an mTOR inhibitor may be reduced by administering to a subject in need thereof a combination of an mTOR inhibitor and a MEK inhibitor. In some embodiments, the duration of response to an mTOR inhibitor may be reduced by administering to a subject in need thereof a combination of an mTOR inhibitor and a RAF/MEK inhibitor (e.g., VS-6766). In some embodiments, the combinations described herein can improve the depth and/or duration of a response (e.g., an anti-tumor response) in a subject.
The contemplated subjects of the methods described herein can be identified (e.g., by screening, e.g., sequencing) as having an mTOR mutation.
The methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., a KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering a MEK inhibitor in combination with an mTOR inhibitor, optionally with an additional agent, to the subject.
The methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C) by administering to the subject a dual RAF/MEK inhibitor (e.g., VS-6766) in combination with an mTOR inhibitor, optionally with an additional agent.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of a pan-HER inhibitor and a MEK inhibitor, thereby treating the subject. In some embodiments, the method further comprises administering an additional agent.
In another aspect, disclosed herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a pan-HER inhibitor in combination with a dual RAF/MEK inhibitor (e.g., VS-6766) or a pharmaceutically acceptable salt thereof, thereby treating the subject. In some embodiments, the method further comprises administering an additional agent.
In some embodiments of the methods described herein, the duration of response to a pan-HER inhibitor may be reduced by administering to a subject in need thereof a combination of a pan-HER inhibitor and a MEK inhibitor. In some embodiments, the duration of response to a pan-HER inhibitor may be shortened by administering to a subject in need thereof a combination of a pan-HER inhibitor and a RAF/MEK inhibitor (e.g., VS-6766). In some embodiments, the combinations described herein can improve the depth and/or duration of a response (e.g., an anti-tumor response) in a subject.
The contemplated subject of the methods described herein can be identified (e.g., by screening, e.g., sequencing) as having a pan-HER mutation.
The methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., a KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering a MEK inhibitor in combination with a pan-HER inhibitor, optionally with an additional agent, to the subject.
The methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C) by administering a dual RAF/MEK inhibitor (e.g., VS-6766) in combination with a pan-HER inhibitor, optionally with an additional agent, to the subject.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of an EGFR inhibitor and a MEK inhibitor, or a pharmaceutically acceptable salt thereof, thereby treating the subject. In some embodiments, the method further comprises administering an additional agent.
In another aspect, disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an EGFR inhibitor in combination with a dual RAF/MEK inhibitor (e.g., VS-6766) or a pharmaceutically acceptable salt thereof, thereby treating the subject. In some embodiments, the method further comprises administering an additional agent.
In some embodiments of the methods described herein, the duration of response to an EGFR inhibitor can be reduced by administering to a subject in need thereof a combination of an EGFR inhibitor and a MEK inhibitor. In some embodiments, the duration of response to an EGFR inhibitor can be reduced by administering to a subject in need thereof a combination of an EGFR inhibitor and a RAF/MEK inhibitor (e.g., VS-6766). In some embodiments, the combinations described herein can improve the depth and/or duration of a response (e.g., an anti-tumor response) in a subject.
The contemplated subjects of the methods described herein can be identified (e.g., by screening, e.g., sequencing) as having EGFR mutations.
The methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., a KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering a MEK inhibitor in combination with an EGFR inhibitor, optionally with an additional agent, to the subject.
The methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C) by administering a dual RAF/MEK inhibitor (e.g., VS-6766) in combination with an EGFR inhibitor, optionally with an additional agent, to the subject.
Src homologous phosphatase 2 (SHP 2) inhibitors
Examples of SHP2 inhibitors include, but are not limited to:
TNO-155 (Novartis AG) having the following structure:
SHP099 having the structure:
RMC-4630 (Revolution Medicines) having the structure:
RMC-4550 (Revolution Medicines) having the structure:
IACS-13909 having the structure:
JAB-3068 (Jacobio Pharmaceuticals Co Ltd) having the structure:
JAB-3312 (Jacobio Pharmaceuticals Co Ltd); RLY-1971 (Relay Therapeutics Inc); BBP-398 (Navire Pharma Inc); ERAS-601 (ERASCA); HBI-2376 (HUYA Bioscience International LLC); ICP-189 (InnoCare Pharma Ltd), BR790 (Shanghai Blueray Biopharma); ETS-001 (Shanghai ETERN Biopharma); PF-07284892 (Pfizer); RX-SHP2i (Redx Pharma); SH3809 (Nanjing Sanhome Pharmaceutical); TAS-ASTX (Taiho Oncology); X-37-SHP2 (X-37); and hydrates, solvates and pharmaceutically acceptable salts thereof.
In some embodiments, the SHP2 inhibitor is ERAS-601, TNO-155, SHP099, RMC-4630, RMC-4550, IACS-13909, JAB-3068, JAB-3312, RLY-1971, BBP-398, HBI-2376, or ICP-189, or a hydrate, solvate, or pharmaceutically acceptable salt thereof.
In some embodiments, the SHP2 inhibitor is ERAS-601, JAB-3068, RMC-4630, TNO-155, JAB-3312, RLY-1971, BBP-398, HBI-2376, ICP-189 or RMC-4550, or a hydrate, solvate or pharmaceutically acceptable salt thereof.
In some embodiments, the SHP2 inhibitor is administered at least once a week. In some embodiments, the SHP2 inhibitor is administered at least once a day. In some embodiments, the SHP2 inhibitor is administered once daily. In some embodiments, the SHP2 inhibitor is administered twice daily. In some embodiments, the SHP2 inhibitor is administered orally.
In some embodiments, the SHP2 inhibitor is administered at a dose of about 0.1mg to about 5000mg, e.g., about 1mg to about 3000mg, about 1mg to about 1000mg, about 1mg to about 500mg, about 1mg to about 100mg, about 10mg to about 2000mg, e.g., about 100mg to about 2000mg, about 100mg to about 1500mg, about 100mg to about 1000mg, about 100mg to about 800mg, about 100mg to about 600mg, about 100mg to about 400mg, about 100mg to about 200mg, about 200mg to about 2000mg, about 200mg to about 1500mg, about 200mg to about 1000mg, about 200mg to about 800mg, about 200mg to about 600mg, about 200mg to about 400mg, about 400mg to about 2000mg, about 400mg to about 1500mg, about 400mg to about 1000mg, about 400mg to about 800mg, about 400mg to about 600mg, about 600mg to about 2000mg, about 600mg to about 1500mg, about 600mg to about 1000mg, about 600mg to about 800mg, about 800mg to about 2000mg, about 800mg to about 1500mg, about 800mg to about 1000mg, about 600mg to about 2000mg, about 600mg to about 1500mg, about 600mg to about 1000mg, about 600mg to about 800 mg. In some embodiments, the SHP2 inhibitor is administered at about 1mg per administration. In some embodiments, the SHP2 inhibitor is administered at about 5mg per administration. In some embodiments, the SHP2 inhibitor is administered at about 10mg per administration. In some embodiments, the SHP2 inhibitor is administered at about 50mg per administration. In some embodiments, the SHP2 inhibitor is administered at about 100mg per administration. In some embodiments, the SHP2 inhibitor is administered at about 200mg per administration. In some embodiments, the SHP2 inhibitor is administered at about 300mg per administration. In some embodiments, the SHP2 inhibitor is administered at about 400mg per administration. In some embodiments, the SHP2 inhibitor is administered at about 500mg per administration. In some embodiments, the SHP2 inhibitor is administered at about 600mg per administration. In some embodiments, the SHP2 inhibitor is administered at about 700mg per administration. In some embodiments, the SHP2 inhibitor is administered at about 800mg per administration. In some embodiments, the SHP2 inhibitor is administered at about 900mg per administration. In some embodiments, the SHP2 inhibitor is administered at about 1000mg per administration.
SOS1 inhibitors
Examples of SOS1 inhibitors include, but are not limited to:
BI-3406 having the structure:
BAY-293 having the structure:
RMC-5845(Revolution Medicines);SDGR-5(Schrodinger LLC);BI-1701963(Boehringer Ingleheim);BMS-SCHand SDGR 5->And hydrates, solvates and pharmaceutically acceptable salts thereof.
In some embodiments, the SOS1 inhibitor is BI-3406, BAY-293, RMC-5845 (Revolution Medicines), SDGR-5 (Schrodinger LLC) or BI-1701963 (Boehringer Ingleheim), or a hydrate, solvate, or pharmaceutically acceptable salt thereof.
In some embodiments, the SOS1 inhibitor is SDGR-5 (Schrodinger LLC) or BI-1701963 (Boehringer Ingleheim), or a hydrate, solvate, or pharmaceutically acceptable salt thereof.
In some embodiments, the SOS1 inhibitor is administered at least once a week. In some embodiments, the SOS1 inhibitor is administered at least once daily. In some embodiments, the SOS1 inhibitor is administered once daily. In some embodiments, the SOS1 inhibitor is administered twice daily. In some embodiments, the SOS1 inhibitor is administered orally.
In some embodiments, the SOS1 inhibitor is administered at a dose of about 0.1mg to about 5000mg, e.g., about 1mg to about 3000mg, about 1mg to about 1000mg, about 1mg to about 500mg, about 1mg to about 100mg, about 10mg to about 2000mg, e.g., about 100mg to about 2000mg, about 100mg to about 1500mg, about 100mg to about 1000mg, about 100mg to about 800mg, about 100mg to about 600mg, about 100mg to about 400mg, about 100mg to about 200mg, about 200mg to about 2000mg, about 200mg to about 1500mg, about 200mg to about 1000mg, about 200mg to about 800mg, about 200mg to about 600mg, about 200mg to about 400mg, about 400mg to about 2000mg, about 400mg to about 1500mg, about 400mg to about 1000mg, about 400mg to about 800mg, about 400mg to about 600mg, about 600mg to about 2000mg, about 600mg to about 1500mg, about 600mg to about 1000mg, about 600mg to about 800mg, about 800mg to about 2000mg, about 800mg to about 1500mg, about 800mg to about 1000mg, about 600mg to about 2000mg, about 600mg to about 1500mg, about 600mg to about 1000mg, about 600mg to about 800 mg. In some embodiments, the SOS1 inhibitor is administered at about 1mg per administration. In some embodiments, the SOS1 inhibitor is administered at about 5mg per administration. In some embodiments, the SOS1 inhibitor is administered at about 10mg per administration. In some embodiments, the SOS1 inhibitor is administered at about 50mg per administration. In some embodiments, the SOS1 inhibitor is administered at about 100mg per administration. In some embodiments, the SOS1 inhibitor is administered at about 200mg per administration. In some embodiments, the SOS1 inhibitor is administered at about 300mg per administration. In some embodiments, the SOS1 inhibitor is administered at about 400mg per administration. In some embodiments, the SOS1 inhibitor is administered at about 500mg per administration. In some embodiments, the SOS1 inhibitor is administered at about 600mg per administration. In some embodiments, the SOS1 inhibitor is administered at about 700mg per administration. In some embodiments, the SOS1 inhibitor is administered at about 800mg per administration. In some embodiments, the SOS1 inhibitor is administered at about 900mg per administration. In some embodiments, the SOS1 inhibitor is administered at about 1000mg per administration.
ERK1/2 inhibitors
Examples of ERK1/2 inhibitors include, but are not limited to:
ASTX-029 (Astex Pharmaceuticals) having the following structure:
LY-3214996 (Eli Lilly and Co) having the structure:
ulitinib (ulixertiinib) having the structure:
ASN-007 (Asana Biosciences) having the structure:
ATG-017 (Antegene Corp) having the following structure:
MK-8353 (Merck) having the structure:
ravoxertiinib having the structure:
AZ6197 (AstraZeneca) having the structure:
BPI-27336 (Betta Pharmaceuticals Co Ltd); JSI-1187 (JS InnoPharm Ltd); HH-2710 (Shanghai Haihe Biopharma Co Ltd); JRP-890 (Prous Institute for Biomedical Research SA); JRF-108 (Chengdu Jinrui Foundation Biotechnology Co Ltd); BI ERKi (Boehringer Ingelheim); CC-90003 (BMS); ERAS-007 (Erasca); HMPL-295 (Hutchmed); IPN-ERK (Ipsen); KO-947 (Kura Oncology); LTT462 (Novartis); SCH772984 (Astex Pharmaceuticals); TK216 (Oncternal Therapeutics), and hydrates, solvates and pharmaceutically acceptable salts thereof.
In some embodiments, the ERK1/2 inhibitor is ASTX-029 (Astex Pharmaceuticals), HH-2710 (Shanghai Haihe Biopharma Co Ltd), LY-3214996 (Eli Lilly and Co), ulitinib, ASN-007 (Asana BioSciences), ATG-017 (Antegene Corp), BPI-27336 (Betta Pharmaceuticals Co Ltd), JSI-1187 (JS Innovarm Ltd, shanghai), MK-8353 (Merck), JRP-890 (Prous Institute for Biomedical Research SA), JRF-108 (Chengdu Jinrui Foundation Biotechnology Co Ltd), or ravoxertinib, or a hydrate, solvate, or pharmaceutically acceptable salt thereof.
In some embodiments, the ERK1/2 inhibitor is administered at least once a week. In some embodiments, the ERK1/2 inhibitor is administered at least once daily. In some embodiments, the ERK1/2 inhibitor is administered once daily. In some embodiments, the ERK1/2 inhibitor is administered twice daily. In some embodiments, the ERK1/2 inhibitor is administered orally.
In some embodiments, the ERK1/2 inhibitor is administered at about 0.1mg to about 5000mg, e.g., about 1mg to about 3000mg, about 1mg to about 1000mg, about 1mg to about 500mg, about 1mg to about 100mg, about 10mg to about 2000mg, e.g., about 100mg to about 2000mg, about 100mg to about 1500mg, about 100mg to about 1000mg, about 100mg to about 800mg, about 100mg to about 600mg, about 100mg to about 400mg, about 100mg to about 200mg, about 200mg to about 2000mg, about 200mg to about 1500mg, about 200mg to about 1000mg, about 200mg to about 800mg, about 200mg to about 600mg, about 200mg to about 400mg, about 400mg to about 2000mg, about 400mg to about 1500mg, about 400mg to about 400mg, about 400mg to about 800mg, about 400mg to about 600mg, about 600mg to about 2000mg, about 1500mg to about 600mg, about 600mg to about 600mg, about 1500mg to about 600mg, about 600mg to about 800mg, about 600mg, about 1500mg to about 600mg, about 600mg to about 600 mg. In some embodiments, the ERK1/2 inhibitor is administered at about 1mg per administration. In some embodiments, the ERK1/2 inhibitor is administered at about 5mg per administration. In some embodiments, the ERK1/2 inhibitor is administered at about 10mg per administration. In some embodiments, the ERK1/2 inhibitor is administered at about 50mg per administration. In some embodiments, the ERK1/2 inhibitor is administered at about 100mg per administration. In some embodiments, the ERK1/2 inhibitor is administered at about 200mg per administration. In some embodiments, the ERK1/2 inhibitor is administered at about 300mg per administration. In some embodiments, the ERK1/2 inhibitor is administered at about 400mg per administration. In some embodiments, the ERK1/2 inhibitor is administered at about 500mg per administration. In some embodiments, the ERK1/2 inhibitor is administered at about 600mg per administration. In some embodiments, the ERK1/2 inhibitor is administered at about 700mg per administration. In some embodiments, the ERK1/2 inhibitor is administered at about 800mg per administration. In some embodiments, the ERK1/2 inhibitor is administered at about 900mg per administration. In some embodiments, the ERK1/2 inhibitor is administered at about 1000mg per administration.
CDK4/6 inhibitors
Examples of CDK4/6 inhibitors include, but are not limited to:
palbociclib (Palbociclib) having the structure:
rebamacinib (Ribociclib) having the structure:
abemaciclib (Abemaciclib) having the structure:
SHR-6390 (Jiangsu Hengrui Medicine Co Ltd) having the structure:
luo Xili (Lerociclib) having the following structure:
azoxystrobin (Milciclib) having the following structure:
PF-06873600 (Pfizer Inc) having the following structure:
ON-123300 (HanX Biopharmaceuticals Inc) having the structure:
SRX-3177 (SignalRx Pharmaceuticals Inc) having the structure:
roniciclib (Bayer) having the following structure:
RMC-4550 (Revolution Medicines Inc) having the structure:
GLR-2007 (Gan and Lee Pharmaceuticals); RP-CDK4/6 (Rhizen Pharmaceuticals); TQB 3303 (Chia Tai Tianqing Pharmaceutical); troracilli (trilacillib) (G1 Therapeutics); FCN-437c (Fochon Pharmaceutical Ltd); XZP-3287 (Sihuan Pharmaceutical Holdings Group Ltd); BEBT-209 (Guangzhou BeBetter Medicine Technology Co Ltd); BPI-16350 (Betta Pharmaceuticals Co Ltd); CS-3002 (CStone Pharmaceuticals Co Ltd); HS-10342 (Jiangsu Hansoh Pharmaceutical Group Co Ltd); TY-302 (Tetranov International Inc); voruciclib; BPI-1178 (Beta Pharma Inc.); NUV-422 (nuchange Bio Inc); AU-294 (Aucentra Therapeutics Pty Ltd); ETH-155008 (Shengke Pharmaceuticals Ltd, jiangsu); HEC-80797 (HEC Pharm Co Ltd); JS-104 (Rizen Biosciences Co Ltd, suzhou); PF-07220060 (Pfizer Inc.); and VS-2370 (ViroStatics srl), and hydrates, solvates and pharmaceutically acceptable salts thereof.
In some embodiments, the CDK4/6 inhibitor is SHR-6390, FCN-437c, lai Luo Xili, azoxystrobin, PF-06873600, XZP-3287, BEBT-209, BPI-16350, CS-3002, HS-10342, ON-123300, TY-302, voruciclib, BPI-1178, NUV-422, AU-294, ETH-155008, HEC-80797, JS-104, PF-07220060, RMC-4550, SRX-3177, VS-2370, palbociclib, rabociclib succinate (e.g., rabociclib succinate), letrozole+Rabociclib succinate, or a solvate, hydrate, or pharmaceutically acceptable salt thereof.
In some embodiments, the CDK4/6 inhibitor is ETH-155008, HEC-80797, JS-104, PF-07220060, RMC-4550, SRX-3177, VS-2370, palbociclib, rebabociclib (e.g., rebabociclib succinate), letrozole+rebabociclib succinate, or arbicimide, or a solvate, hydrate, or pharmaceutically acceptable salt thereof.
In some embodiments, the CDK4/6 inhibitor is administered at least once a week. In some embodiments, the CDK4/6 inhibitor is administered at least once daily. In some embodiments, the CDK4/6 inhibitor is administered once daily. In some embodiments, the CDK4/6 inhibitor is administered twice daily. In some embodiments, the CDK4/6 inhibitor is administered orally.
In some embodiments, the CDK4/6 inhibitor is administered at a dose of about 0.1mg to about 5000mg, e.g., about 1mg to about 3000mg, about 1mg to about 1000mg, about 1mg to about 500mg, about 1mg to about 100mg, about 10mg to about 2000mg, e.g., about 100mg to about 2000mg, about 100mg to about 1500mg, about 100mg to about 1000mg, about 100mg to about 800mg, about 100mg to about 600mg, about 100mg to about 400mg, about 100mg to about 200mg, about 200mg to about 2000mg, about 200mg to about 1500mg, about 200mg to about 1000mg, about 200mg to about 800mg, about 200mg to about 600mg, about 200mg to about 400mg, about 400mg to about 2000mg, about 400mg to about 1500mg, about 400mg to about 1000mg, about 400mg to about 800mg, about 400mg to about 600mg, about 600mg to about 2000mg, about 600mg to about 1500mg, about 600mg to about 1000mg, about 600mg to about 800mg, about 800mg to about 2000mg, about 800mg to about 1500mg, about 800mg to about 1000mg, about 600mg to about 2000mg, about 600mg to about 1500mg, about 600mg to about 1000mg, about 600mg to about 800 mg. In some embodiments, the CDK4/6 inhibitor is administered at about 1mg per administration. In some embodiments, the CDK4/6 inhibitor is administered at about 5mg per administration. In some embodiments, the CDK4/6 inhibitor is administered at about 10mg per administration. In some embodiments, the CDK4/6 inhibitor is administered at about 50mg per administration. In some embodiments, the CDK4/6 inhibitor is administered at about 100mg per administration. In some embodiments, the CDK4/6 inhibitor is administered at about 200mg per administration. In some embodiments, the CDK4/6 inhibitor is administered at about 300mg per administration. In some embodiments, the CDK4/6 inhibitor is administered at about 400mg per administration. In some embodiments, the CDK4/6 inhibitor is administered at about 500mg per administration. In some embodiments, the CDK4/6 inhibitor is administered at about 600mg per administration. In some embodiments, the CDK4/6 inhibitor is administered at about 700mg per administration. In some embodiments, the CDK4/6 inhibitor is administered at about 800mg per administration. In some embodiments, the CDK4/6 inhibitor is administered at about 900mg per administration. In some embodiments, the CDK4/6 inhibitor is administered at about 1000mg per administration.
AKT inhibitors
Examples of AKT inhibitors include, but are not limited to:
capigaservib; patadine; afuresertib hydrochloride; miransertib mesylate; qu Meiti Nidimethyl sulfoxide+Youpultib (uprosisertib); euthane color; borussertib; LY-2503029 (Eli Lilly and Co); COTI-2 (Cotinga Pharmaceuticals Inc); MK-2206+semetinib sulfate (Merck & Co Inc.); PTX-200 (Prescient Therapeutics Ltd); ARQ-751 (Vevorisertib, merck & Co Inc.); ALM-301 (Almac Discovery Ltd); DC-120 (Guangzhou Institute of Biomedicine and Health); FXY-1 (Krisani Bio Sciences Pvt Ltd); JRP-890 (Prous Institute for Biomedical Research SA); KS-99 (Pennsylvania State University); NISC-6 (Pennsylvania State University); RX-0201 (Zhejiang Haichang Biotechnology Co Ltd); RX-0301 (Zhejiang Haichang Biotechnology Co Ltd);
m2698 (Merck) having the following structure:
MK-2206 (Merck & Co Inc) has the following structure:
ONC-201 (Ohara Pharmaceutical Co Ltd) having the structure:
TAS-117 (Taiho Pharmaceutical Co Ltd) having the structure:
AT-13148 (Astex Pharmaceuticals Inc) having the structure:
BAY-1125976 (Bayer AG) having the structure:
and
GSK690693 having the structure:
and hydrates, solvates and pharmaceutically acceptable salts thereof.
In some embodiments, the AKT inhibitor is capigaservib, pataserib, LY-2503029, afuresertib hydrochloride, COTI-2, miranserinb mesylate, MK-2206, MK-2206+ semantenib sulfate, ONC-201, PTX-200, TAS-117, trimetinib dimethyl sulfoxide+Uprivet, uprivet, ARQ-751, AT-13148, M2698, ALM-301, BAY-1125976, borussertib, DC-120, FXY-1, JRP-890, KS-99, NISC-6, RX-0201, or RX-0301, or a hydrate, solvate, or pharmaceutically acceptable salt thereof.
In some embodiments, the AKT inhibitor is administered at least once a week. In some embodiments, the AKT inhibitor is administered at least once daily. In some embodiments, the AKT inhibitor is administered once daily. In some embodiments, the AKT inhibitor is administered twice daily. In some embodiments, the AKT inhibitor is administered orally.
In some embodiments, the AKT inhibitor is administered at about 0.1mg to about 5000mg, e.g., about 1mg to about 3000mg, about 1mg to about 1000mg, about 1mg to about 500mg, about 1mg to about 100mg, about 10mg to about 2000mg, e.g., about 100mg to about 2000mg, about 100mg to about 1500mg, about 100mg to about 1000mg, about 100mg to about 800mg, about 100mg to about 600mg, about 100mg to about 400mg, about 100mg to about 200mg, about 200mg to about 2000mg, about 200mg to about 1500mg, about 200mg to about 1000mg, about 200mg to about 800mg, about 200mg to about 600mg, about 200mg to about 400mg, about 400mg to about 2000mg, about 400mg to about 1500mg, about 400mg to about 1000mg, about 400mg to about 800mg, about 600mg to about 600mg, about 600mg to about 1500mg, about 600mg to about 600mg, about 600mg to about 800 to about 600mg, about 800 to about 600mg, about 600mg to about 600mg, about 1500 mg. In some embodiments, the AKT inhibitor is administered at about 1mg per administration. In some embodiments, the AKT inhibitor is administered at about 5mg per administration. In some embodiments, the AKT inhibitor is administered at about 10mg per administration. In some embodiments, the AKT inhibitor is administered at about 50mg per administration. In some embodiments, the AKT inhibitor is administered at about 100mg per administration. In some embodiments, the AKT inhibitor is administered at about 200mg per administration. In some embodiments, the AKT inhibitor is administered at about 300mg per administration. In some embodiments, the AKT inhibitor is administered at about 400mg per administration. In some embodiments, the AKT inhibitor is administered at about 500mg per administration. In some embodiments, the AKT inhibitor is administered at about 600mg per administration. In some embodiments, the AKT inhibitor is administered at about 700mg per administration. In some embodiments, the AKT inhibitor is administered at about 800mg per administration. In some embodiments, the AKT inhibitor is administered at about 900mg per administration. In some embodiments, the AKT inhibitor is administered at about 1000mg per administration.
mTOR inhibitors
Examples of mTOR inhibitors include, but are not limited to: everolimus; zortress; sirolimus; temsirolimus; albumin-bound sirolimus; dactylisib tosylate; the onahasertib; DTRMWXHS-12+everolimus+pomalidomide (Zhejiang DTRM Biopharma LLC); bimiralisib; monetel; sapanantib (sapanisertib); paclitaxel + sirolimus + tamsulosin (Co-D Therapeutics Inc); sirolimus; vitacocrine (vistuertib); diutan (detosertib); ompaliib; prabetahistine mesylate (purinostat mesylate) d; NSC-765844 (National Cancer Institute US); OSU-53 (Ohio State University); OT-043 (Onco Therapies Inc); PQR-514 (PIQUR Therapeutics AG); QR-213 (Qrono Inc); SN-202 (Sichuan Sinovation Bio-technology Co Ltd); SPR-965 (Sphaera Pharma Pte Ltd); TAM-03 (Mount Tam Biotechnologies Inc); FP-208 (Beijing Foreland Pharma Co Ltd); HEC-68498 (HEC Pharm Co Ltd); LXI-15029 (Shandong Luoxin Pharmaceutical Group Stock Co Ltd); PTX-367 (Palvella Therapeutics LLC); WXFL-10030390 (Shanghai Jiatan Pharmaceutical Technology Co Ltd); XP-105 (Xynomic Pharmaceuticals Holdings Inc); AL-58805 (Advenchen Laboratories LLC); AL-58922 (Advenchen Laboratories LLC); AUM-302 (AUM Biosciences Pte Ltd); CA-102 (Curigin Co Ltd); CA-103 (Curigin Co Ltd); CT-365 (HEC Pharm Co Ltd); DFN-529 (Diffusion Pharmaceuticals Inc); DHM-25 (University of Rennes I);
RMC-5552 (Revolution Medicines Inc) having the structure:
CC-115 (Bristol-Myers Squibb Co) having the following structure:
ME-344 (MEIPhara Inc) having the following structure:
FT-1518 (FTG Bio LLC) having the structure:and
OSI-027 having the following structure:
and hydrates, solvates and pharmaceutically acceptable salts thereof.
In some embodiments, the mTOR inhibitor is everolimus, zortress, sirolimus, temsirolimus, albumin-bound sirolimus, dactolisib tosylate, onatasertib, DTRMWXHS-12+ everolimus+pomalidomide, bimiralisib, CC-115, monetel, sha Pase, sirolimus, valatide, diepastil, FP-208, HEC-68498, LXI-15029, ME-344, PTX-367, WXFL-10030390, XP-105, paclitaxel+sirolimus+tamsulosin, AL-58805, AL-58922, AUM-302, CA-102, CA-103, CT-365, DFN-529, DHM-25, FT-1518, NSC-765844, omipalisib, OSU-53, OT-043, R-514, prazistat mesylate, QR-213, RMC-5552, SN-202, SPR-965, TAM-03, or OSI-7, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof. In some embodiments, the mTOR inhibitor is everolimus, or a pharmaceutically acceptable salt thereof.
In some embodiments, the mTOR inhibitor is administered at least once a week. In some embodiments, the mTOR inhibitor is administered at least once daily. In some embodiments, the mTOR inhibitor is administered once daily. In some embodiments, the mTOR inhibitor is administered twice daily. In some embodiments, the mTOR inhibitor is administered orally.
In some embodiments, the mTOR inhibitor is administered at about 0.1mg to about 5000mg, e.g., about 1mg to about 3000mg, about 1mg to about 1000mg, about 1mg to about 500mg, about 1mg to about 100mg, about 10mg to about 2000mg, e.g., about 100mg to about 2000mg, about 100mg to about 1500mg, about 100mg to about 1000mg, about 100mg to about 800mg, about 100mg to about 600mg, about 100mg to about 400mg, about 100mg to about 200mg, about 200mg to about 2000mg, about 200mg to about 1500mg, about 200mg to about 1000mg, about 200mg to about 800mg, about 200mg to about 600mg, about 200mg to about 400mg, about 400mg to about 2000mg, about 400mg to about 1500mg, about 400mg to about 1000mg, about 600mg to about 1500mg, about 600mg to about 1000mg, about 600mg to about 600mg, about 600mg to about 800 to about 600mg, about 1500mg to about 600mg, about 800 to about 600 mg. In some embodiments, the mTOR inhibitor is administered at about 1mg per administration. In some embodiments, the mTOR inhibitor is administered at about 5mg per administration. In some embodiments, the mTOR inhibitor is administered at about 10mg per administration. In some embodiments, the mTOR inhibitor is administered at about 50mg per administration. In some embodiments, the mTOR inhibitor is administered at about 100mg per administration. In some embodiments, the mTOR inhibitor is administered at about 200mg per administration. In some embodiments, the mTOR inhibitor is administered at about 300mg per administration. In some embodiments, the mTOR inhibitor is administered at about 400mg per administration. In some embodiments, the mTOR inhibitor is administered at about 500mg per administration. In some embodiments, the mTOR inhibitor is administered at about 600mg per administration. In some embodiments, the mTOR inhibitor is administered at about 700mg per administration. In some embodiments, the mTOR inhibitor is administered at about 800mg per administration. In some embodiments, the mTOR inhibitor is administered at about 900mg per administration. In some embodiments, the mTOR inhibitor is administered at about 1000mg per administration.
pan-HER inhibitors
Examples of pan-HER inhibitors include, but are not limited to:
ZW49 (zymewirks), PB 357 (Pfizer), MP 0274 (Molecular Partners), VRN 07 (Volronoi), saprotinib, zenocuzumab (zenocutuzumab), wave Ji Tini (poziotinib), mo Bo tinib (mobocertiinib), valitinib, pyrroltinib (pyrotinib), lapatinib, afatinib (afatinib), lenatinib or dacatinib, and
BDTX 189 with the following structure:
and hydrates, solvates and pharmaceutically acceptable salts thereof.
In some embodiments, the pan-HER inhibitor is ZW49, PB 357, MP 0274, VRN 07, BDTX 189, saprotinib, zetolizumab, wave Ji Tini, mo Bo tinib, valitinib, pyrroltinib, lapatinib, afatinib, lenatinib, or dacatinib, or a hydrate, solvate, or pharmaceutically acceptable salt thereof. In some embodiments, the pan-HER inhibitor is afatinib or a pharmaceutically acceptable salt thereof.
In some embodiments, the pan-HER inhibitor is administered at least once a week. In some embodiments, the pan-HER inhibitor is administered at least once daily. In some embodiments, the pan-HER inhibitor is administered once daily. In some embodiments, the pan-HER inhibitor is administered twice daily. In some embodiments, the pan-HER inhibitor is administered orally.
In some embodiments, the pan-HER inhibitor is administered at a dose of about 0.1mg to about 5000mg, e.g., about 1mg to about 3000mg, about 1mg to about 1000mg, about 1mg to about 500mg, about 1mg to about 100mg, about 10mg to about 2000mg, e.g., about 100mg to about 2000mg, about 100mg to about 1500mg, about 100mg to about 1000mg, about 100mg to about 800mg, about 100mg to about 600mg, about 100mg to about 400mg, about 100mg to about 200mg, about 200mg to about 2000mg, about 200mg to about 1500mg, about 200mg to about 1000mg, about 200mg to about 800mg, about 200mg to about 600mg, about 200mg to about 400mg, about 400mg to about 2000mg, about 400mg to about 1500mg, about 400mg to about 1000mg, about 400mg to about 800mg, about 400mg to about 600mg, about 600mg to about 2000mg, about 600mg to about 1500mg, about 600mg to about 1000mg, about 600mg to about 800mg, about 800mg to about 2000mg, about 800mg to about 1500mg, about 800mg to about 1000mg, about 600mg to about 2000mg, about 600mg to about 1500mg, about 600mg to about 1000mg, about 600mg to about 800 mg. In some embodiments, the pan-HER inhibitor is administered at about 1mg per administration. In some embodiments, the pan-HER inhibitor is administered at about 5mg per administration. In some embodiments, the pan-HER inhibitor is administered at about 10mg per administration. In some embodiments, the pan-HER inhibitor is administered at about 50mg per administration. In some embodiments, the pan-HER inhibitor is administered at about 100mg per administration. In some embodiments, the pan-HER inhibitor is administered at about 200mg per administration. In some embodiments, the pan-HER inhibitor is administered at about 300mg per administration. In some embodiments, the pan-HER inhibitor is administered at about 400mg per administration. In some embodiments, the pan-HER inhibitor is administered at about 500mg per administration. In some embodiments, the pan-HER inhibitor is administered at about 600mg per administration. In some embodiments, the pan-HER inhibitor is administered at about 700mg per administration. In some embodiments, the pan-HER inhibitor is administered at about 800mg per administration. In some embodiments, the pan-HER inhibitor is administered at about 900mg per administration. In some embodiments, the pan-HER inhibitor is administered at about 1000mg per administration.
EGFR inhibitors
Exemplary EGFR inhibitors include, but are not limited to:
ASK-120067 (Jiangsu Aosaikang Pharmaceutical Co Ltd) having the structure:
AST-2818 (Allist Shanghai Pharmaceutical Technology Co Ltd) having the following structure:
BI-4020 having the structure:
BDTX-189 (Black Diamond Therapeutics Inc) with the following structure:
BPI-7711 (Beta Pharma Inc) having the structure:
NRC-2694 (Natco Pharma Ltd) having the following structure:
SKLB-1028 (CSPC Pharmaceutical Group Ltd) having the structure:
TAS-6417 (Cullinan Oncology LLC) having the structure:
BAY-2476568 (Bayer) having the structure:
doxorubicin+erlotinib, rituximab+zatoxib, evighib maleate, ABP-1119 (AB Pharma Ltd), ABP-1130 (AB Pharma Ltd), afatinib, african afatinib, AG-101 (Arrogene Inc), AL-6802 (Jiangsu Simcere Pharmaceutical Co Ltd), ametinib mesylate, AM-105 (AbClon Inc), amelimumab, E Mo Tuo monoclonal antibody (amivanamab), AMX-3009 (Arromax Pharmatech Co Ltd), APL-1898 (Shangaai) Co Ltd), BBT-176 (Bridge Biotherapeutics Inc), BEBT-108 (Guangzhou BeBetter Medicine Technology Co Ltd), BEBT-109 (Guangzhou BeBetter Medicine Technology Co Ltd), BH-2922 (Beijing Hanmi Pharmaceutical Co Ltd), BLU-4810 (Blueprint Medicines Corp), BMX-002 (Biomunex Pharmaceuticals), BO-1978, BO-15086 (Betta Pharmaceuticals Co Ltd), buganinib (brinib), C-005 (C005), cexib (BIC-29), BIC-29 (BIB), C-95 (35), BIB-29 (35), C-95 (35), and Mawear-95 (BIP-35 (35), BIP-35 (BIP-35), CLwear-35 (BIP-29), CLwear-35 (BI), CLwear-95 (CLwear-35) Darafenib mesylate+panitumumab+trimetinib dimethyl sulfoxide, dacatinib, DBPR-112, rituximab (depatuzumab), DGD-1202 (MAIABiotechnology Inc), doxitinib mesylate, DZD-9008 (Dizal (Jiangsu) Pharmaceutical Co Ltd), EO-1001 (Senz Oncology Pty Ltd), ai Peiti, erlotinib (e.g. erlotinib hydrochloride), ES-072 (Apollomics Inc), FCN-411 (Fochon Pharma Inc), FHND-9041 (Jiangsu Zhengda Fenghai Pharmaceutical Co Ltd), FLAG-001 (Flag Therapeutics Inc), FLAG-003 (Flag Therapeutics Inc), fmAb-2 (Biocon Ltd), GB-263 (Genor BioPharma Co Ltd), GC-1118A (GC Pharma), gefitinib, GS-03+octtinib (Osimtinib), HA-12128 (CSPC Pharmaceutical Group Ltd), HMPL-309 (Hutchison MediPharma Ltd), HMPL-813 (Hutchison MediPharma Ltd), HS-Zhejiang Hisun Pharmaceutical Co Ltd), ecritinib hydrochloride, JMT-101 (JMP) and KN-411 (Fochon Pharma Inc), FHND-9041 (Jiangsu Zhengda Fenghai Pharmaceutical Co Ltd), FLAG-001 (Flag Therapeutics Inc), FLAG-003 (Flag Therapeutics Inc), FMAB-2 (Biocon Ltd), GB-263 (Genor BioPharma Co Ltd), GC-1118 (GC-03+Ksupport, ksupport device (XuanZhu Pharma Co Ltd), ksupport device (Ksupport device) and method for treating cancer with the drug delivery of the drug, lagranatinib (larotinib), lasatinib, liforafenib maleate, MCLA-129 (MeruNV), MCLA-158 (MeruNV), MDC-22 (Medicon Pharmaceuticals Inc), mo Bo tinib, mRX-7 (MiReven Pty Ltd), MTX-211 (Mekanistic Therapeutics LLC), MVC-101 (Maverick Therapeutics Inc), naquotinib mesylate, toxituzumab, lenatinib, nimotuzumab, NT-004 (NewGen Therapeutics Inc), NT-113 (NewGen Therapeutics Inc), OBX-1012 (Oncobix Co Ltd), otemtinib hydrochloride, octtinib (e.g., oxitinib mesylate), panitumumab, PB-4639, wave Ji Tini, pyrroltinib, QL-Qilu Pharmaceutical Co Ltd), QL-1203 (Qilu Pharmaceutical Co Ltd), RX-105 (ageranib, teva Pharmaceutical Industries Ltd), SAH-EJ1 (Arizona Cancer Therapeutics LLC), pratinib mesylate, TQ-200 (TQ-35), stratinib (TQ-48), stratinib (Shenzhen Targetrx Inc), TQ-48), ltimacyb (TQ-52 ) and TQ-48, TQvalatinib (TQ-52) and TQ-52-35 (TQb) are included UBP-1215 (Chi Cheung (Shanghai) Biomedical Co Ltd), vandetanib, varlitinib, VRN-071918 (Voronoi Group), VRN-6 (Voronoi Group), WBP-297 (Hualan Biological Engineering Inc), WJ-13404 (Wigen Biomedicine Technology (Shanghai) Co Ltd), WSD-0922 (Wayshine Biopharma Inc), XZP-5809 (Sihuan Pharmaceutical Holdings Group Ltd), inflitinib, YZJ-0318 (Yangtze River Pharmaceutical Group), ZNE-4 (Zentalis Pharmaceuticals Inc), zolitinib, ZR-2002 (McGill University) or ZSP-0391 (Guangdong Zhongsheng Pharmaceutical Co Ltd), JS-111 (Shanghai Junshi Biosciennce), LL-191 (Capella Therapeutics), ORIC-114 (Oric Pharmaceuticals), DS-2087b (Daiichi Sankyo), and hydrates, solvates and pharmaceutically acceptable salts thereof.
In some embodiments of the present invention, in some embodiments, EGFR inhibitors are doxorubicin+erlotinib, rituximab+zatoxib, eretinide maleate, ABP-1119, ABP-1130, afatinib dimaleate, AG-101, AL-6802, armetinib mesylate, AM-105, amelimumab, E Mo Tuoshan anti, AMX-3009, APL-1898, ASK-120067, AST-2818, BBT-176, BDTX-189, BEBT-108, BEBT-109, BH-2922, BLU-4810, BMX-002, BO-1978, BPI-15086, BPI-7711, bugatinib, C-005, cetuximab, CK-101, CLM-29, CLM-3, CMAB-017, CR-13626, CSHEGF-29, D-6, D2C 7-PVSRIPO 031 Darafenib mesylate+panitumumab+trimetinib dimethyl sulfoxide, dacatinib, DBPR-112, rituximab, DGD-1202, doxitinib mesylate, DZD-9008, EO-1001, ai Peiti, erlotinib (e.g. erlotinib hydrochloride), ES-072, FCN-411, FHND-9041, FLAG-001, FLAG-003, FAb-2, GB-263, GC-1118A, gefitinib, GS-03+Oritinib, HA-12128, HMPL-309, HMPL-813, HS-627, ecritinib hydrochloride, JRF-101, JRF-103, JZB-29, KBP-5209, KNP-501, KU-004, lapatinib (e.g. lapatinib ditoluenesulfonate), latinib, ratinib, lifanib maleate, MCLA-129, MCLA-158, MDC-22, mo Bo, mRX-7, MTX-211, MVC-101, naquotinib mesylate, nazatinib mesylate, cetuximab, lenatinib, nimotuzumab, NRC-2694, NT-004, NT-113, OBX-1012, omutinib hydrochloride, octtinib (e.g., octtinib mesylate), panitumumab, PB-357, bo Ji Tini, pyrroltinib, QL-1105, QL-1203, RXDX-105, SAH-EJ1, saprottinib, SCT-200 selatinib di-p-toluenesulfonate, cerotinib, SKLB-1028, SKLB-1206, SPH-118811, SYN-004, TAS-6417, tervaltinib p-toluenesulfonate, TGRX-360, tobrazib, TQB-3804, UBP-1215, vandetanib, varlitinib, VRN-071918, VRN-6, WBP-297, WJ-13404, WSD-0922, XZP-5809, inlitinib (yinlitinib), YZJ-0318, ZNE-4, zoribitinib, ZR-2002, ZSP-0391, ORIC-114, DS-2087b, JS-111, LL-191, BI-4020 or BAY-2476568, or a hydrate, solvate, or pharmaceutically acceptable salt thereof. In some embodiments, the EGFR inhibitor is afatinib, or a pharmaceutically acceptable salt thereof. In some embodiments, the EGFR inhibitor is octreotide or a pharmaceutically acceptable salt thereof.
In some embodiments, the EGFR inhibitor is administered at least once a week. In some embodiments, the EGFR inhibitor is administered at least once daily. In some embodiments, the EGFR inhibitor is administered once daily. In some embodiments, the EGFR inhibitor is administered twice daily. In some embodiments, the EGFR inhibitor is administered orally.
In some embodiments, the EGFR inhibitor is administered at about 0.1mg to about 5000mg, e.g., about 1mg to about 3000mg, about 1mg to about 1000mg, about 1mg to about 500mg, about 1mg to about 100mg, about 10mg to about 2000mg, e.g., about 100mg to about 2000mg, about 100mg to about 1500mg, about 100mg to about 1000mg, about 100mg to about 800mg, about 100mg to about 600mg, about 100mg to about 400mg, about 100mg to about 200mg, about 200mg to about 2000mg, about 200mg to about 1500mg, about 200mg to about 1000mg, about 200mg to about 800mg, about 200mg to about 600mg, about 200mg to about 400mg, about 400mg to about 2000mg, about 400mg to about 1500mg, about 400mg to about 1000mg, about 600mg to about 1500mg, about 600mg to about 1000mg, about 600mg to about 600mg, about 1500mg to about 800 to about 600mg, about 800 to about 600 mg. In some embodiments, the EGFR inhibitor is administered at about 1mg per administration. In some embodiments, the EGFR inhibitor is administered at about 5mg per administration. In some embodiments, the EGFR inhibitor is administered at about 10mg per administration. In some embodiments, the EGFR inhibitor is administered at about 50mg per administration. In some embodiments, the EGFR inhibitor is administered at about 100mg per administration. In some embodiments, the EGFR inhibitor is administered at about 200mg per administration. In some embodiments, the EGFR inhibitor is administered at about 300mg per administration. In some embodiments, the EGFR inhibitor is administered at about 400mg per administration. In some embodiments, the EGFR inhibitor is administered at about 500mg per administration. In some embodiments, the EGFR inhibitor is administered at about 600mg per administration. In some embodiments, the EGFR inhibitor is administered at about 700mg per administration. In some embodiments, the EGFR inhibitor is administered at about 800mg per administration. In some embodiments, the EGFR inhibitor is administered at about 900mg per administration. In some embodiments, the EGFR inhibitor is administered at about 1000mg per administration.
MEK inhibitors
The MEK inhibitor may be a small molecule or biological inhibitor of the mitogen-activated protein kinase (MAPK) enzymes MEK1 and/or MEK2 (e.g., MAPK/ERK pathway).
Examples of MEK inhibitors include, but are not limited to:
trimetinib (also known as mekinest, GSK 1120212) having the following structure:
cobicitinib (cobimeinib) (also known as GDC-0973, xl 518) having the following structure:
bemetinib having the structure:
CI-1040 (also referred to as PD 184352) having the structure:
PD-325901 having the structure:
semantenib (also known as AZD 6244) having the following structure:
MEK162 having the structure:
AZD8330 having the structure:
TAK-733 having the structure:
GDC-0623 having the following structure:
rafacitinib (also known as RDEA119; BAY 869766) having the following structure:
pimasertib (also called AS 4987555) having the following structure:
RO 4987555 (also referred to as CH 4987555) having the following structure:
CInQ-03 having the following structure:
g-573 having the structure:
PD184161 having the following structure:
PD318088 having the following structure:
PD98059 having the following structure:
RO5068760 having the following structure:
SL327 having the following structure:
U0126 having the structure:
WX-554 (Wilex); and HL-085 (Shanghai Kechow Pharma), and pharmaceutically acceptable salts thereof.
In some embodiments, the MEK inhibitor is selected from: trametinib, cobicitinib, bemetinib, semetinib, PD-325901, CI-1040, MEK162, AZD8330, GDC-0623, refatinib, pimasertib, WX-554, HL-085, CH 4987555, TAK-733, CInQ-03, G-573, PD184161, PD318088, PD98059, RO5068760, U0126 and SL327, or pharmaceutically acceptable salts thereof.
In some embodiments, the MEK inhibitor is administered at least once a week (e.g., once a week, twice a week, three times a week, four times a week, five times a week, or six times a week). In some embodiments, the MEK inhibitor is administered once a week. In some embodiments, the MEK inhibitor is administered twice a week. In some embodiments, the MEK inhibitor is administered once daily. In some embodiments, the MEK inhibitor is administered twice daily. In some embodiments, the MEK inhibitor is administered for at least three weeks. In some embodiments, the MEK inhibitor is administered periodically (as a cycle) for three weeks, then discontinued for one week (three weeks after administration of the MEK inhibitor and then one week without administration of the MEK inhibitor). In some embodiments, the cycle is repeated at least once. In other embodiments, the MEK inhibitor is administered continuously (e.g., without discontinuation for one week).
In some embodiments, the MEK inhibitor is administered at about 0.1mg to about 100mg, e.g., about 0.1mg to about 50mg, about 0.1mg to about 10mg, about 0.1mg to about 5mg, about 0.1mg to about 4mg, about 0.1mg to about 3mg, about 0.1mg to about 2mg, about 0.1mg to about 1mg, about 1mg to about 10mg, about 1mg to about 20mg, about 1mg to about 40mg, about 1mg to about 60mg, about 1mg to about 80mg, about 1mg to about 100mg, about 10mg to about 100mg, about 20mg to about 100mg, about 40mg to about 100mg, about 60mg to about 100mg, or about 80mg to about 100mg per administration. In some embodiments, the MEK inhibitor is administered at about 0.5mg to about 10mg per administration. In some embodiments, the MEK inhibitor is administered at about 0.1mg, 0.2mg, 0.5mg, 1mg, 1.5mg, 3mg, 4mg, 5mg, 10mg, 15mg, 20mg, 25mg, 30mg, 35mg, 40mg, 45mg, 50mg, 65mg, 70mg, 75mg, 80mg, 85mg, 90mg, 95mg, or 100mg per administration. In some embodiments, the MEK inhibitor is administered at about 4mg per administration. In some embodiments, the MEK inhibitor is administered at about 3.2mg per administration.
In some embodiments, the MEK inhibitor is administered orally.
In some embodiments, the MEK inhibitor is administered prior to the administration of the SHP2 inhibitor, SOS1 inhibitor, ERK1/2 inhibitor, CDK4/6 inhibitor, AKT inhibitor, mTOR inhibitor, pan-HER inhibitor, or EGFR inhibitor. In some embodiments, the MEK inhibitor is administered after the SHP2 inhibitor, SOS1 inhibitor, ERK1/2 inhibitor, CDK4/6 inhibitor, AKT inhibitor, mTOR inhibitor, pan-HER inhibitor, or EGFR inhibitor is administered. In some embodiments, the MEK inhibitor is administered concurrently with the SHP2 inhibitor, SOS1 inhibitor, ERK1/2 inhibitor, CDK4/6 inhibitor, AKT inhibitor, mTOR inhibitor, pan-HER inhibitor, or EGFR inhibitor.
Dual RAF/MEK inhibitors
In some embodiments, the dual RAF/MEK inhibitor is a compound of formula (I):
in some embodiments, the compound of formula (I) is:
which is also referred to herein as compound 1 or VS-6766 in free form.
In some embodiments, the dual RAF/MEK inhibitor is a pharmaceutically acceptable salt of a compound of formula (I). In some embodiments, the dual RAF/MEK inhibitor is a potassium salt of a compound of formula (I), also known as VS-6766. Other pharmaceutically acceptable salts of the compounds of formula (I) are contemplated herein.
The compounds of formula (I) and pharmaceutically acceptable salts thereof are dual RAF/MEK inhibitors that confer vertical inhibition of the MAPK pathway. In contrast to other MEK inhibitors, the compounds of formula (I) and pharmaceutically acceptable salts thereof are potent allosteric inhibitors of MEK kinase activity, which promote dominant negative RAF/MEK complexes, preventing the phosphorylation of MEK by wild-type RAF, V600E BRAF and CRAF. This mechanism allows compounds of formula (I) and pharmaceutically acceptable salts thereof to block MEK signaling without the occurrence of compensatory activation of MEK that appears to limit the efficacy of other inhibitors.
In some embodiments, the dual RAF/MEK inhibitor is a compound having the structure of formula (II):
Including pharmaceutically acceptable salts thereof, wherein:
ring A is
R 1 、R 2 、R 3 And R is 4 Each independently selected from: H. deuterium, hydroxy, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate (sulfonate), optionally substituted O-thiocarbamoyl, optionally substituted N-carbamoyl, optionally substituted O-carbamoyl, optionally substituted urea, optionally substituted C1 to C6 alkoxy, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C10 aryl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C10 heteroaryl, and L; r is R 6 Selected from: H. deuterium, hydroxy, halogen, cyano, nitro, optionally substituted amino, optionally substituted C1 to C6 alkoxy, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl and optionally substituted C2 to C6 alkynyl;
x is C (R) 5 ) 2 ,CH(R 5 ),CH 2 ,-O-,
L is-Z 1 -Z 2 or-Z 1 -Z 2 -Z 3 ;
Z 1 、Z 2 And Z 3 Independently selected from: -CH 2 -、-O-、-S-、S=O、-SO 2 -、C=O、-CO 2 -、-NO 2 、-NH-、-CH 2 CCH、-CH 2 CN、-NR 5 R 5’ 、-NH(CO)-、-(CO)NH-、-(CO)NR 5 R 5’ -、-NH-SO 2 -、-SO 2 -NH-、-R 5 CH 2- 、-R 5 O-、-R 5 S-、R 5 -S=O、-R 5 SO 2- 、R 5 -C=O、-R 5 CO 2- 、-R 5 NH-、-R 5 NH(CO)-、-R 5 (CO)NH-、-R 5 NH-SO 2- 、-R 5 SO 2 -NH-、-NHCH 2 CO-、-CH 2 R 5 -、-OR 5 -、-SR 5 -、S=O-R 5 、-SO 2 R 5 -、C=O-R 5 、-CO 2 R 5 -、-NHR 5 -、-NH(CO)R 5 -、-(CO)NHR 5 -、-NH-SO 2 R 5 -、-SO 2 -NHR 5 -, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C10 aryl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C10 heteroaryl, -CH 2 - (optionally substituted aryl), -CH 2 - (optionally substituted C3 to C8 cycloalkyl) and-CH 2 - (optionally substituted C3 to C10 heteroaryl); each R 5 And R is 5’ Independently selected from: H. deuterium, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 carbocyclyl, optionally substituted C6 to C10 aryl, optionally substituted C3 to C8 heterocyclyl and optionally substituted C3 to C10 heteroaryl; and
y is CH 2 NH or O, provided that R 1 not-O-pyrimidinyl.
In some embodiments, the dual RAF/MEK inhibitor is a compound selected from the compounds in table I:
table I.
In some embodiments, the dual RAF/MEK inhibitor is IMM-1-104 (Immuneering) or a pharmaceutically acceptable salt thereof.
In some embodiments, the dual RAF/MEK inhibitor is administered at least once a week (e.g., once a week, twice a week, three times a week, four times a week, five times a week, or six times a week). In some embodiments, the dual RAF/MEK inhibitor is administered once a week. In some embodiments, the dual RAF/MEK inhibitor is administered twice a week. In some embodiments, the dual RAF/MEK inhibitor is administered once daily. In some embodiments, the dual RAF/MEK inhibitor is administered twice daily. In some embodiments, the dual RAF/MEK inhibitor is administered for at least three weeks. In some embodiments, the dual RAF/MEK inhibitor is administered periodically (as a cycle) for three weeks, then discontinued for one week (three weeks of dual RAF/MEK inhibitor administration, then one week of no dual RAF/MEK inhibitor administration). In some embodiments, the cycle is repeated at least once. In other embodiments, the dual RAF/MEK inhibitor is administered continuously (e.g., without discontinuation for one week).
In some embodiments, the dual RAF/MEK inhibitor is administered at about 0.1mg to about 100mg, e.g., about 0.1mg to about 50mg, about 0.1mg to about 10mg, about 0.1mg to about 5mg, about 0.1mg to about 4mg, about 0.1mg to about 3mg, about 0.1mg to about 2mg, about 0.1mg to about 1mg, about 1mg to about 10mg, about 1mg to about 20mg, about 1mg to about 40mg, about 1mg to about 60mg, about 1mg to about 80mg, about 1mg to about 100mg, about 10mg to about 100mg, about 20mg to about 100mg, about 40mg to about 100mg, about 60mg to about 100mg, or about 80mg to about 100mg per administration. In some embodiments, the dual RAF/MEK inhibitor is administered at about 0.5mg to about 10mg per administration. In some embodiments, the dual RAF/MEK inhibitor is administered at about 0.1mg, 0.2mg, 0.5mg, 1mg, 1.5mg, 3mg, 4mg, 5mg, 10mg, 15mg, 20mg, 25mg, 30mg, 35mg, 40mg, 45mg, 50mg, 65mg, 70mg, 75mg, 80mg, 85mg, 90mg, 95mg, or 100mg per administration. In some embodiments, the dual RAF/MEK inhibitor is administered at about 4mg per administration. In some embodiments, the dual RAF/MEK inhibitor is administered at about 3.2mg per administration.
In some embodiments, dual RAF/MEK inhibitors (e.g., VS-6766) are administered at about 4mg twice weekly. In some embodiments, the dual RAF/MEK inhibitor (e.g., VS-6766) is administered at about 3.2mg twice weekly.
In some embodiments, the dual RAF/MEK inhibitor is administered orally.
In some embodiments, the dual RAF/MEK inhibitor is administered periodically for three weeks followed by a discontinuation of the administration for one week (three weeks of administration of the dual RAF/MEK inhibitor followed by one week of no administration of the dual RAF/MEK inhibitor). In some embodiments, the cycle is repeated at least once. In some embodiments, the cycle is repeated at least twice. In some embodiments, the cycle is repeated at least three times. In some embodiments, the dual RAF/MEK inhibitor is administered twice a week. In some embodiments, the dual RAF/MEK inhibitor is administered at about 0.5mg to about 10mg (e.g., about 4mg or about 3.2 mg) per administration. In some embodiments, the dual RAF/MEK inhibitor is administered at about 0.1mg to about 5mg per administration. In some embodiments, the dual RAF/MEK inhibitor is administered at about 1mg to about 5mg per administration. In some embodiments, the dual RAF/MEK inhibitor is administered at about 2mg to about 4mg per administration.
In some embodiments, the dual RAF/MEK inhibitor is administered in a twice-a-week cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor at a dose of about 0.5mg to about 10mg per administration for three weeks, followed by no administration of the dual RAF/MEK inhibitor for one week. In some embodiments, the dual RAF/MEK inhibitor is administered in a twice-a-week cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor at a dose of about 1mg to about 5mg per administration for three weeks, followed by no administration of the dual RAF/MEK inhibitor for one week. In some embodiments, the dual RAF/MEK inhibitor is administered in a twice-a-week cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor at a dose of about 2mg to about 4mg per administration for three weeks, followed by no administration of the dual RAF/MEK inhibitor for one week. In some embodiments, the dual RAF/MEK inhibitor is administered in a twice-a-week cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor at a dose of 3.2mg per administration for three weeks, followed by no administration of the dual RAF/MEK inhibitor for one week. In some embodiments, the dual RAF/MEK inhibitor is administered in a twice-a-week cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor at a dose of 4mg per administration for three weeks, followed by no administration of the dual RAF/MEK inhibitor for one week. In some embodiments, the cycle is repeated at least once.
In some embodiments, the dual RAF/MEK inhibitor is administered in a three-week cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor at a dose of about 0.8mg to about 10mg per administration for three weeks, followed by no administration of the dual RAF/MEK inhibitor for one week. In some embodiments, the dual RAF/MEK inhibitor is administered in a three-week cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor at a dose of about 1mg to about 5mg per administration for three weeks, followed by no administration of the dual RAF/MEK inhibitor for one week. In some embodiments, the dual RAF/MEK inhibitor is administered in a three-week cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor at a dose of about 2mg to about 4mg per administration for three weeks, followed by no administration of the dual RAF/MEK inhibitor for one week. In some embodiments, the dual RAF/MEK inhibitor is administered in a three-week cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor at a dose of 3.2mg per administration for three weeks, followed by no administration of the dual RAF/MEK inhibitor for one week. In some embodiments, the dual RAF/MEK inhibitor is administered in a three-week cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor at a dose of 4mg per administration for three weeks, followed by no administration of the dual RAF/MEK inhibitor for one week. In some embodiments, the cycle is repeated at least once.
In other embodiments, the dual RAF/MEK inhibitor is administered continuously (i.e., without a period of time (e.g., one week), wherein the dual RAF/MEK inhibitor is not administered). In some embodiments, the dual RAF/MEK inhibitor is administered once a week. In some embodiments, the dual RAF/MEK inhibitor is administered twice a week. In some embodiments, the dual RAF/MEK inhibitor is administered three times per week.
In some embodiments, the dual RAF/MEK inhibitor is administered prior to administration of the SHP2 inhibitor, SOS1 inhibitor, ERK1/2 inhibitor, CDK4/6 inhibitor, AKT inhibitor, mTOR inhibitor, pan-HER inhibitor, or EGFR inhibitor. In some embodiments, the dual RAF/MEK inhibitor is administered after administration of the SHP2 inhibitor, SOS1 inhibitor, ERK1/2 inhibitor, CDK4/6 inhibitor, AKT inhibitor, mTOR inhibitor, pan-HER inhibitor, or EGFR inhibitor. In some embodiments, the dual RAF/MEK inhibitor is administered concurrently with the SHP2 inhibitor, SOS1 inhibitor, ERK1/2 inhibitor, CDK4/6 inhibitor, AKT inhibitor, mTOR inhibitor, pan-HER inhibitor, or EGFR inhibitor.
Diseases and disorders
The methods provided herein are believed to be useful in the treatment of abnormal cell growth (e.g., cancer). For example, the cancer may include, but is not limited to, ovarian cancer, non-small cell lung cancer (e.g., NSCLC adenocarcinoma), endometrioid cancer, pancreatic adenocarcinoma, colorectal adenocarcinoma, or lung adenocarcinoma.
The methods provided herein are also expected to be useful for treating cancers identified as having a KRAS mutation, e.g., a KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C). In some embodiments, the cancer is characterized by having a KRAS mutation (e.g., a KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)).
In some embodiments, the cancer is identified as having one or more KRAS mutations. In some embodiments, the KRAS mutation is a KRAS G12X mutation. In some embodiments, the KRAS mutation is a KRAS G12V mutation. In some embodiments, the KRAS mutation is a KRAS G12D mutation. In some embodiments, the KRAS mutation is a KRAS G12A mutation. In some embodiments, the KRAS mutation is a KRAS G12R mutation. In some embodiments, the KRAS mutation is a KRAS G12S mutation. In some embodiments, the KRAS mutation is a KRAS G12C mutation. In some embodiments, the KRAS mutation is a KRAS G13X mutation. In some embodiments, the KRAS mutation is a KRAS G13V mutation. In some embodiments, the KRAS mutation is a KRAS G13D mutation. In some embodiments, the KRAS mutation is a KRAS G13A mutation. In some embodiments, the KRAS mutation is a KRAS G13R mutation. In some embodiments, the KRAS mutation is a KRAS G13S mutation. In some embodiments, the KRAS mutation is a KRAS G13E mutation. In some embodiments, the KRAS mutation is a KRAS G12 dup mutation. In some embodiments, the KRAS mutation is a KRAS G13C mutation. In some embodiments, the KRAS mutation is a KRAS Q61X mutation. In some embodiments, the KRAS mutation is a KRAS Q61H mutation. In some embodiments, the KRAS mutation is a KRAS Q61K mutation. In some embodiments, the KRAS mutation is a KRAS Q61L mutation. In some embodiments, the KRAS mutation is a KRAS Q61R mutation. In some embodiments, the KRAS mutation is a KRAS Q61P mutation. In some embodiments, the KRAS mutation is a KRAS Q61E mutation.
The methods provided herein are also expected to be useful for treating cancers identified as having RAS pathway mutations (e.g., KRAS, NRAS, or HRAS).
In some embodiments, the cancer is identified as having a HRAS mutation.
In some embodiments, the cancer is identified as having NRAS mutation.
In some embodiments, the cancer is identified as having a RAF mutation.
In some embodiments, the cancer is identified as having a BRAF mutation. In some embodiments, the BRAF mutation is a BRAF V600 mutation. In some embodiments, the BRAF V600 is mutated to one or more BRAF V600E, BRAF V600K, BRAF V600D, BRAF V600R, or BRAF V600M mutations. In some embodiments, the BRAF V600 mutation is a BRAF V600E mutation. In some embodiments, the BRAF V600 mutation is a BRAF V600K mutation. In some embodiments, the BRAF V600 mutation is a BRAF V600D mutation. In some embodiments, the BRAF V600 mutation is a BRAF V600R mutation. In some embodiments, the BRAF V600 mutation is a BRAF V600M mutation.
In some embodiments, the cancer is identified as having an ARAF mutation.
In some embodiments, the cancer is identified as having a CRAF mutation.
In some embodiments, the cancer is identified as having a MEK1 and/or MEK2 mutation.
In some embodiments, the cancer is identified as having NF1 alterations, KRAS amplification, and/or NRAS amplification.
In some embodiments, the cancer is identified as having positive phosphorylated ERK protein expression (e.g., > 10%, > 20% or > 30% of cells) by immunohistochemical detection.
In some embodiments, the cancer is identified as having an EGFR change.
Abnormal cell growth
As used herein, abnormal cell growth refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition), unless otherwise indicated. This includes the following abnormal growths: (1) A proliferating tumor cell (tumor), for example, by expressing a mutated tyrosine kinase or overexpressing a receptor tyrosine kinase; (2) Benign and malignant cells of other proliferative diseases, for example, in which abnormal tyrosine kinase activation occurs; (3) Any tumor that proliferates through, for example, receptor tyrosine kinases; (4) For example any tumor that proliferates by aberrant serine/threonine kinase activation; and (5) benign and malignant cells of other proliferative diseases, such as serine/threonine kinase activation in which abnormalities occur. Abnormal cell growth may refer to the following cell growth: epithelial cells (e.g., carcinoma, adenocarcinoma); interstitial (e.g., sarcomas (e.g., leiomyosarcoma, ewing's sarcoma)); hematopoietic system (e.g., lymphoma, leukemia, myelodysplastic (e.g., premalignant)); or other (e.g., melanoma, mesothelioma, and other tumors of unknown origin).
Neoplastic disease
Abnormal cell growth may refer to neoplastic disease. A "neoplastic disease" is a disease or disorder characterized by cells having the ability to autonomously grow or replicate, for example, by an abnormal state or condition characterized by the growth of proliferative cells. Abnormal masses or "neo-organisms" of tissue due to abnormal cell growth or division may be benign, premalignant (carcinoma in situ) or malignant (cancer).
Exemplary neoplastic diseases include: carcinomas, sarcomas, metastatic diseases (e.g. tumors originating from the prostate, colon, lung, breast and liver), hematopoietic neoplastic diseases, e.g. leukemias, metastatic tumors. The amount of the compound treated is effective to ameliorate at least one symptom of the neoplastic disease, such as reduced cell proliferation, reduced tumor mass, and the like.
Cancer of the human body
The inventive methods of the present invention are useful for the prevention and treatment of cancers, including, for example, solid tumors, soft tissue tumors, and metastases thereof. The disclosed methods are also useful for treating non-solid cancers. Exemplary solid tumors include malignant tumors of different organ systems (e.g., sarcomas, adenocarcinomas, and carcinomas), such as those of the lung, breast, lymph, gastrointestinal tract (e.g., colon), and genitourinary tract (e.g., kidney, urothelium, or testicular tumor), pharynx, prostate, and ovary. Exemplary adenocarcinomas include colorectal cancer, renal cell carcinoma, liver cancer (e.g., hepatocellular carcinoma), non-small cell carcinoma of the lung, pancreatic cancer (e.g., metastatic pancreatic cancer), and small intestine cancer.
The cancer may include Esophageal Squamous Cell Carcinoma (ESCC); gastrointestinal stromal tumor (GIST); head and neck cancer, squamous cell carcinoma, bladder cancer; colorectal cancer; pancreatic ductal carcinoma; triple Negative Breast Cancer (TNBC), mesothelioma; neurofibromatosis; for example, type 2 neurofibromatosis, type 1 neurofibromatosis; renal cancer; lung cancer, non-small cell lung cancer; liver cancer; thyroid cancer; ovarian cancer; breast cancer; tumors of the nervous system; a schwannoma; meningioma; schwannoma disease; auditory neuroma; adenoid cystic carcinoma; ventricular tube membranoma; a ependymal tumor, or any other tumor exhibiting reduced merlin expression and/or mutation, and/or NF-2 gene deletion and/or promoter hypermethylation. In some embodiments, the cancer is renal cancer.
Cancers may include cancers characterized by comprising cancer stem cells, cancer-associated mesenchymal cells, or tumor-initiating cancer cells. Cancers may include cancers that have been characterized as enriched for cancer stem cells, cancer-associated mesenchymal cells, or tumor-forming cancer cells (e.g., tumors or metastatic tumors enriched for cells undergoing epithelial-to-mesenchymal transformation).
The cancer may be a primary tumor, i.e. an anatomical site located at the beginning of tumor growth. The cancer may also be metastatic, i.e. at least a second anatomical site is present in addition to the anatomical site where tumor growth begins. The cancer may be a recurrent cancer, i.e., a cancer that recurs after treatment and after a period of time in which the cancer is undetectable. Recurrent cancer may be anatomically located near the primary tumor, e.g., anatomically close to the primary tumor; in the area of the primary tumor, for example in the lymph nodes near the primary tumor; or away from the primary tumor, e.g., anatomically away from the area of the primary tumor.
Cancers may also include, for example, but are not limited to, epithelioid cancer, breast cancer, lung cancer, pancreatic cancer, colorectal cancer (e.g., metastatic colorectal cancer, e.g., metastatic KRAS mutant), prostate cancer, head and neck cancer, melanoma (e.g., locally advanced or metastatic malignant cutaneous melanoma with NRAS mutations), acute myelogenous leukemia, and glioblastoma. Exemplary breast cancers include triple negative breast cancer, basal-like breast cancer, claudin-low breast cancer, invasive, inflammatory, metaplastic and advanced HER-2 positive or ER-positive cancers, which are resistant to treatment.
The cancer may also include cancers with SHP2 mutations, SOS1 mutations, ERK1/2 mutations, CDK 4/6 mutations, AKT mutations, mTOR mutations, pan-HER mutations, or EGFR alterations.
The cancer may also include lung adenocarcinoma, colorectal carcinoma, uveal melanoma, ovarian carcinoma, endometrioid carcinoma, bladder urothelial carcinoma, breast invasive lobular carcinoma, cervical squamous cell carcinoma, cutaneous melanoma, cervical adenocarcinoma, hepatocellular carcinoma, pancreatic carcinoma, bipolar pleural mesothelioma, renal clear cell carcinoma, gastric adenocarcinoma, tubular gastric adenocarcinoma, uterine carcinomatosis, or uterine malignant mixed Mullerian tumor.
Other cancers include, but are not limited to, uveal melanoma, brain cancer, abdominal cancer, esophageal cancer, gastrointestinal cancer, glioma, liver cancer, tongue cancer, neuroblastoma, osteosarcoma, ovarian cancer, retinoblastoma, nephroblastoma, multiple myeloma, skin cancer, lymphoma, hematological cancer, and bone marrow cancer (e.g., advanced hematological malignancy, leukemia, such as acute myelogenous leukemia (e.g., primary or secondary), acute lymphoblastic leukemia, T-cell leukemia, hematological malignancy, advanced myeloproliferative disease, myelodysplastic syndrome, recurrent or refractory multiple myeloma, advanced myeloproliferative disease), retinal cancer, bladder cancer, cervical cancer, renal cancer, endometrial cancer, meningioma, lymphoma, skin cancer, uterine cancer, lung cancer, non-small cell lung cancer, nasopharyngeal carcinoma, neuroblastoma, solid tumors, hematological malignancy, cancer, squamous cell carcinoma, brain cancer, vulval carcinoma, vulval sarcoma, intestinal cancer, oral cavity cancer, endocrine carcinoma, seminal carcinoma, testicular cancer, diffuse cancer of the thyroid gland, diffuse cell, diffuse cancer, malignant tumor, and malignant tumor-associated cancer of the thyroid gland, and malignant tumor-like, carcinoma.
In some embodiments, the tumor is a solid tumor. In some embodiments, the solid tumor is locally advanced or metastatic. In some embodiments, the solid tumor is refractory (e.g., resistant) to standard post-treatment.
In some embodiments, the cancer is lung cancer (e.g., non-small cell lung cancer (NSCLC), e.g., KRAS mutated NSCLC; metastatic cancer), bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer (e.g., unresectable lower ovarian cancer, advanced or metastatic ovarian cancer), rectal cancer, cancer of the anal region, gastric cancer, colon cancer, breast cancer (e.g., triple negative breast cancer (e.g., breast cancer that does not express the genes of estrogen receptor, progesterone receptor, and Her 2/neu)), uterine cancer, fallopian tube cancer, endometrioid cancer, cervical cancer, vaginal cancer, vulval cancer, hodgkin's disease, cancer of the esophagus (esophageal cancer), small intestine cancer, cancer of the endocrine system, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, renal cancer or ureteral cancer, renal cell carcinoma, renal pelvis cancer, tumors of the Central Nervous System (CNS), primary CNS lymphoma, spinal column tumor, brain stem glioma, pituitary adenoma, mesothelioma (e.g., malignant mesothelioma, such as may be resected by surgery), or a combination of one or more of the above). In some embodiments, the cancer is metastatic. In some embodiments, the abnormal cell growth is locally recurrent (e.g., the subject has a locally recurrent disease, e.g., cancer).
The methods described herein may reduce, ameliorate, or completely eliminate the disorder and/or its associated symptoms, to prevent its deterioration, to slow the rate of progression, or to minimize its recurrence rate (i.e., avoid recurrence) after the disorder is initially eliminated. The appropriate dosage and treatment regimen may vary depending upon the particular compound, combination and/or pharmaceutical composition employed and the mode of delivery of the compound, combination and/or pharmaceutical composition. In some embodiments, the methods increase the average survival, increase the average length of progression-free survival, and/or decrease the rate of recurrence of a subject treated with a combination described herein in a statistically significant manner.
Other therapies
In some embodiments, the methods and compositions described herein are administered with additional therapies (e.g., cancer treatment). In one embodiment, a mixture or pharmaceutical composition of one or more compounds may be administered to a subject in need thereof, along with a combination as described herein. In yet another embodiment, one or more compounds or compositions (e.g., pharmaceutical compositions) may be administered with a combination as described herein for the treatment or prevention of various diseases, including, for example, cancer, diabetes, neurodegenerative diseases, cardiovascular disease, coagulation, inflammation, flushing, obesity, aging, stress, and the like. In various embodiments, combination therapies comprising a compound or pharmaceutical composition described herein may refer to (1) pharmaceutical compositions comprising one or more compounds in combination with a combination described herein; and (2) co-administering one or more compounds or pharmaceutical compositions described herein with a combination described herein, wherein the compounds or pharmaceutical compositions described herein are not yet formulated in the same composition. In some embodiments, the combinations described herein are administered with additional treatments (e.g., additional cancer treatments). In some embodiments, the additional treatment (e.g., additional cancer treatment) may be administered simultaneously (e.g., at the same time), in the same or separate compositions, or sequentially. Sequential administration refers to administration of one treatment immediately prior to (e.g., less than 5, 10, 15, 30, 45, 60 minutes; 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 48, 72, 96 or more hours; 4, 5, 6, 7, 8, 9 or more days; 1, 2, 3, 4, 5, 6, 7, 8 or more weeks prior to administration of another, e.g., second treatment (e.g., compound or therapy). The order of administration of the first and second compounds or therapies may also be reversed.
Exemplary cancer treatments include, for example: chemotherapy, targeted therapies such as antibody therapy, immunotherapy and hormone therapy. Examples of each of these treatments are provided below.
Chemotherapy treatment
In some embodiments, the combination described herein is administered with chemotherapy. Chemotherapy is the treatment of cancer with drugs that can destroy cancer cells. "chemotherapy" generally refers to cytotoxic drugs that, in contrast to targeted therapies, generally affect rapidly dividing cells. Chemotherapeutic agents interfere with cell division in a variety of possible ways, e.g., replication of DNA or isolation of newly formed chromosomes. While a degree of specificity may be produced by many cancer cells failing to repair DNA damage, most normal cells are typically able to repair, most forms of chemotherapy target all rapidly dividing cells and are not specific to cancer cells.
Examples of chemotherapeutic agents for cancer treatment include, for example, antimetabolites (e.g., folic acid, purine and pyrimidine derivatives) and alkylating agents (e.g., nitrogen mustards, nitrosoureas, platinum, alkyl sulfonates, hydrazines, triazenes, aziridines, spindle toxins, cytotoxic agents, topoisomerase inhibitors, and the like). Exemplary agents include aclarubicin, actinomycin, alithetin, altreton, altretamine, aminopterin, aminolevulinic acid, amrubicin, amsacrine, anagrelide, arsenic trioxide, asparaginase, atrasentan, belothiocan, bexarotene, endamstine, bleomycin, bortezomib, busulfan, camptothecine, capecitabine, carboplatin, carboquinone, carmofur, carmustine, celecoxib chlorambucil, nitrogen mustard, cisplatin, cladribine, clofarabine, crisantaaspase, cyclophosphamide, cytarabine, dacarbazine, actinomycin D, daunorubicin, decitabine, dimecoxin docetaxel, doxorubicin, etoposide (Efaproxiral), i Li Simo, elsamitrucin, enocitabine, epirubicin, estramustine, etoposide, floxuridine, fludarabine, fluorouracil (5 FU), fotemustine, gemcitabine, gliadel implants, hydroxyurea (hydroxyarbamide), hydroxyurea (Hydroxyurea), idarubicin, ifosfamide, irinotecan, ilofirofen, ixabepilone, raloxine, calcium folinate, doxorubicin liposomes, daunorubicin liposomes, lonimine, lomustine, thioanthrone, mannsuloshu, masorol, melphalan, mercaptopurine, mesna, methotrexate, minovalerate, dibromomannitol, mitoguazone, mitotane, mitomycin, mitoxantrone, nedaplatin, nimustine, olympicin, oxabane, pennistin, piramide, pirarubicin, agamycin, pramipenem, sodium, phenomycin, procalcitonin, procarbazine, and the like, rapamycin, lubitecan, sapatacitabine, semustine, celecoxib Ma Ji (sitimagene ceradenovec), satraplatin (straaplatin), streptozotocin, talaporfin, tegafur-uracil, temoporfin, temozolomide, teniposide, temozolomide, testosterone, tetranitate (tetranitate), thiotepa, thiflulin, thioguanine, tepirfenib, topotecan, trabectedin, triamcinolone, tritlatin, retinoic acid, troxiv, triamcinolone, urapidine, valrubicin, verteporfin, vinblastine, vincristine, vindesine, vinflunine, vinorelbine, lithostat, zorubicin, and other cytostatics or cytotoxic agents described herein.
Because certain drugs are used in combination more effectively than alone, two or more drugs are often used simultaneously or sequentially. Typically, two or more chemotherapeutic agents are used as a combination chemotherapy. In some embodiments, the chemotherapeutic agent (including combination chemotherapy) may be used in combination with a combination as described herein.
Targeted therapy
In some embodiments, the combinations described herein are administered with targeted therapies. Targeted therapies consist of agents that use deregulated proteins specific for cancer cells. Small molecule targeted therapy drugs are typically inhibitors of the enzymatic domain on mutations, overexpression or other critical proteins within cancer cells. Prominent examples are tyrosine kinase inhibitors such as Axitinib (axiinib), bosutinib (Bosutinib), ceridinib (Cediranib), dasatinib (desatinib), erlotinib (erlotinib), imatinib, gefitinib, lapatinib, letatinib (lebamutinib), nilotinib (Nilotinib), semaxanib (Semaxanib), sorafenib, sunitinib and Vandetanib (vanretanib), and cyclin-dependent kinase inhibitors such as Alvocidib and Seliciclib. Monoclonal antibody therapy is another strategy in which the therapeutic agent is an antibody that specifically binds to a protein on the surface of cancer cells. Examples include the anti-HER 2/neu antibody trastuzumab commonly used for breast cancer And rituximab and tositumomab, anti-CD 20 antibodies commonly used in a variety of B cell malignancies. Other exemplary antibodies include, but are not limited to, cetuximab, panitumumab, trastuzumab, alemtuzumab, bevacizumab, edestin and gemtuzumab. Exemplary fusion proteins include, abelmoschus (Aflibeccept) and diniinterleukin (Denileukin diftitox)). In some embodiments, targeted therapies may be used in combination with the combinations described herein.
Targeted therapies may also involve small peptides as "homing devices" which can bind cell surface receptors or affect the extracellular matrix surrounding the tumor. Radionuclides attached to these peptides (e.g., RGD) eventually kill cancer cells if the nuclides decay in the vicinity of the cells. One example of such a therapy includes
Immunotherapy
In some embodiments, the combination described herein is administered with an immunotherapy. Cancer immunotherapy refers to a variety of therapeutic strategies aimed at inducing the patient's autoimmune system against tumors.
Modern methods of generating immune responses against tumors include intracapsular BCG immunotherapy against superficial bladder cancer, and induction of immune responses in subjects with renal cell carcinoma and melanoma using interferons and other cytokines. Allogeneic hematopoietic stem cell transplantation can be considered an immunotherapy, as donor immune cells will often trigger tumors with graft-versus-tumor effects. In some embodiments, immunotherapeutic agents may be used in combination with the combinations described herein.
Hormone therapy
In some embodiments, the described combination is administered with hormonal therapy. The growth of certain cancers may be inhibited by providing or blocking certain hormones. Common examples of hormone sensitive tumors include certain types of breast and prostate cancers. Removal or blocking of estrogen or testosterone is often an important additional treatment. In certain cancers, administration of a hormonal agonist, such as a progestin, may be beneficial for treatment. In some embodiments, hormonal therapeutic agents may be used in combination with the combinations described herein.
Radiation therapy
The combinations described herein can be used in combination with directed energy or particles, or with radioisotope therapy (e.g., radiation therapy, e.g., radiooncology) to treat proliferative diseases, such as cancer, e.g., cancer associated with cancer stem cells. The combinations described herein may be administered to a subject simultaneously or sequentially with targeted energy or particle or radioisotope therapy. For example, the combinations described herein may be administered prior to, during, or after targeted energy or particles, or radioisotope therapy, or a combination thereof. Directed energy or particle therapy may include whole body irradiation, localized body irradiation, or spot irradiation. The directed energy or particles may originate from an accelerator, synchrotron, nuclear reaction, vacuum tube, laser or radioisotope. The therapy may include external-ray radiation therapy, teletherapy, brachytherapy, sealed source radiation therapy, systemic radioisotope therapy or unsealed source radiation therapy. Treatment may include ingestion of a radioisotope (e.g., radioiodine, cobalt, cesium, potassium, bromine, fluorine, carbon), or placement in proximity to the radioisotope. External-ray radiation therapy may include exposure to directed alpha particles, electrons (e.g., beta particles), protons, neutrons, positrons, or photons (e.g., radio waves, millimeter waves, microwaves, infrared, visible light, ultraviolet, X-rays, or gamma rays). The radiation may be directed to any portion of the subject in need of treatment.
Surgery
The combinations described herein can be used in combination with surgery (e.g., surgical exploration, intervention, biopsy) to treat proliferative disorders, such as cancer, e.g., cancer associated with cancer stem cells. The combinations described herein may be administered to a subject concurrently with surgery or sequentially. For example, the combinations described herein may be administered prior to surgery (preoperative), during surgery or after surgery (post-operative), or a combination thereof. The procedure may be a biopsy, in which one or more cells are collected for further analysis. The biopsy may be done, for example, with a scalpel, needle, catheter, endoscope, spatula or scissors. The biopsy may be a resected biopsy, an incision biopsy, a center biopsy or a needle biopsy, such as a needle biopsy. Surgery may involve removing local tissue suspected or identified as cancerous. For example, the process may involve removal of cancerous lesions, bumps, polyps, or moles. This operation may involve removing a large amount of tissue, such as breast, bone, skin, fat, or muscle. The procedure may involve removing a portion or all of an organ or nodule, such as a lung, throat, tongue, bladder, cervix, ovary, testis, lymph node, liver, pancreas, brain, eye, kidney, gall bladder, stomach, colon, rectum or intestine. In one embodiment, the cancer is breast cancer, e.g., triple negative breast cancer, and the surgery is mastectomy or lumpectomy.
Anti-inflammatory agent
The combinations described herein may be administered with an anti-inflammatory agent. Anti-inflammatory agents may include, but are not limited to, non-steroidal anti-inflammatory agents (e.g., salicylates (aspirin, acetylsalicylic acid), diflunisal, bissalicylates), propionic acid derivatives (ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin, loxoprofen), acetic acid derivatives (indomethacin, sulindac, etodolac, ketorolac, diclofenac, nabumetone), enolic acid (oxicam) derivatives (piroxicam, meloxicam, tenoxicam, droxic, lornoxicam, isoxicam), fenamic acid derivatives (fenamic acid esters) (mefenamic acid, meclofenamic acid, flufenamic acid), tolfenamic acid), selective COX-2 inhibitors (Coxibs) (celecoxib), sulfonanilides (nimesulide), steroids (e.g., hydrocortisone), cortisone acetate, prednisone, prednisolone, methylprednisolone, dexamethasone, triamcinolone acetate, betamethasone acetate, and the like.
Analgesic agent
Analgesics include, but are not limited to, opioids (e.g., morphine, codeine, oxycodone, hydrocodone, dihydromorphine, dolantine, buprenorphine, tramadol, venlafaxine), paracetamol and non-steroidal anti-inflammatory agents (e.g., salicylates (aspirin (acetylsalicylic acid), diflunisal, bissalicylate), propionic acid derivatives (ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin, loxoprofen), acetic acid derivatives (indomethacin, sulindac, etodolac, ketorolac, diclofenac, nabumetone), enolic acid (oxicam) derivatives (piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam, isoxicam), fenamic acid derivatives (fenamic acid esters) (mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid), selective COX-2 inhibitors (coxib) (celecoxib), sulfenamide (sulindac).
Antiemetic medicine
The combinations described herein may be administered with an antiemetic. Antiemetics may include, but are not limited to, 5-HT3 receptor antagonists (dolasetron (Anzemet), granalon (Kytril, sancuso), ondansetron (Zofran), tropisetron (Navoban), palonosetron (Aloxi), mirtazapine (Remeron), dopamine antagonists (domperidone, olanzapine, haloperidol, chlorpromazine, promethazine, prochlorperazine, methoprene (Reglan), aripride, prochlorperazine (Compazine, stemzine, buccastem, stemetil, phenotil), NK1 receptor antagonists (aprepand), anti-resistive amine drugs (cyprohexazine, benalamine, theabehenamine (Gravol), meclozine (Bonine, antivertet), promethazine, oxazine, benzodiazine, benzodiazepine, and desipram).
Combination of two or more kinds of materials
The phrase "combination" and the term "co-administer," "co-administer," or "co-provide," as used herein in the context of administering a compound described herein or a therapy described herein, refers to delivering two (or more) different compounds or therapies to a subject during a subject suffering from a disease or disorder (e.g., a disease or disorder described herein, such as cancer), e.g., after a subject is diagnosed with a disease or disorder (e.g., a disease or disorder described herein, such as cancer) and before the disease or disorder is cured or eliminated or otherwise stopped.
In some embodiments, delivery of one compound or therapy is still in progress at the beginning of the second delivery, such that there is overlap in administration. This is sometimes referred to herein as "simultaneous" or "simultaneous delivery. In other embodiments, the delivery of one compound or therapy is ended before the delivery of the other compound or therapy begins. In some embodiments in either case, the treatment (e.g., administration of a compound, composition, or treatment) is more effective due to the combined administration. For example, a second compound or therapy is more effective, e.g., an equivalent effect can be seen with less of the second compound or therapy than seen with administration of the second compound or therapy in the absence of the first compound or therapy, or the second compound or therapy reduces symptoms to a greater extent, or similar conditions can be seen with the first compound or therapy. In some embodiments, the delivery results in a greater reduction in symptoms or other parameters associated with the disorder than would be observed in the absence of one compound or therapy delivered with the other compound or therapy. The effects of the two compounds or therapies may be partially additive, fully additive, or greater than additive (e.g., synergistic). When the second is delivered, the delivery may be such that the effect of the delivered first compound or therapy is still detectable.
In some embodiments, the first compound or therapy and the second compound or therapy may be administered simultaneously (e.g., at the same time), in the same or separate compositions, or sequentially. Sequential administration refers to administration of one compound or therapy immediately prior to administration of another, e.g., less than 5, 10, 15, 30, 45, 60 minutes; 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 48, 72, 96 or more hours; 4, 5, 6, 7, 8, 9 or more days; 1, 2, 3, 4, 5, 6, 7, 8 or more weeks. The order of administration of the first and second compounds or therapies may also be reversed.
The combination described herein may be a first line treatment of abnormal cell growth (e.g., cancer), i.e., for a patient who has not previously been administered another drug intended to treat cancer; a second line treatment of cancer, i.e., it is for a subject in need thereof who has been previously administered another drug intended to treat cancer; the third or fourth treatment of cancer, i.e., it is for a subject who has previously been administered two or three other drugs intended to treat cancer.
In some embodiments, the combinations described herein provide a synergistic effect. Synergy scores can be calculated using 4 different methods (Bliss, loewe, HSA and ZIP) in combination.
In some embodiments, the SHP2 inhibitor, SOS1 inhibitor, ERK1/2 inhibitor, CDK4/6 inhibitor, AKT inhibitor, mTOR inhibitor, pan-HER inhibitor, or EGFR inhibitor and MEK inhibitor are administered in amounts (e.g., dosages) that produce a synergistic (e.g., therapeutic) effect.
In some embodiments, the SHP2 inhibitor, SOS1 inhibitor, ERK1/2 inhibitor, CDK4/6 inhibitor, AKT inhibitor, mTOR inhibitor, pan-HER inhibitor, or EGFR inhibitor and dual RAF/MEK inhibitor are administered in amounts (e.g., dosages) that produce a synergistic (e.g., therapeutic) effect.
Administration and dosage
The combination of the invention may be administered orally, parenterally, topically, rectally or by an implantable kit (implanted reservoir), preferably by oral administration or by injection. In some cases, the pH of a composition (e.g., a pharmaceutical composition) may be adjusted with a pharmaceutically acceptable acid, base, or buffer to enhance the stability or efficacy of the composition.
In some embodiments, the subject orally administers the composition (e.g., a pharmaceutical composition). In some embodiments, the composition (e.g., pharmaceutical composition) is administered orally in any orally acceptable dosage form, including, but not limited to, liquid-gel tablets or capsules, syrups, emulsions, and aqueous suspensions. The liquid-gel may contain gelatin, plasticizers and/or opacifiers as desired to achieve a suitable consistency, and may be coated with an approved-for-use enteric coating, such as shellac. When used as an oral dosage, additional thickening agents, for example, gums such as xanthan gum, starches such as corn starch or gluten, may be added to achieve the desired consistency of the composition (e.g., pharmaceutical composition). Some sweetener and/or flavoring and/or coloring agents may be added if desired.
In some embodiments, the composition (e.g., pharmaceutical composition) is administered to the subject in a form suitable for oral administration, such as tablets, capsules, pills, powders, sustained release formulations, solutions, and suspensions. The composition (e.g., pharmaceutical composition) may be in unit dosage form suitable for single administration in precise doses. In addition to the compounds described herein, the pharmaceutical compositions may also comprise a pharmaceutically acceptable carrier, and may optionally further comprise one or more pharmaceutically acceptable excipients, for example, stabilizers, diluents, binders, and lubricants. In addition, the tablets may contain other drugs or agents, carriers and/or adjuvants. Exemplary pharmaceutical compositions include compressed tablets (e.g., directly compressed tablets).
Tablets containing the active ingredient or therapeutic ingredient (e.g., a compound described herein) are also provided. In addition to the active or therapeutic ingredient, the tablet may also contain a large amount of inert material, such as a carrier. Pharmaceutically acceptable carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, sesame oil and the like. Saline solutions and aqueous dextrose may also be employed as liquid carriers. Thus, the oral dosage forms used according to the invention may be formulated in conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active ingredients into preparations which can be used pharmaceutically. Excipients can provide a pressed material with good powder flow and compaction characteristics. Examples of excipients are described, for example, in Handbook of Pharmaceutical Excipients (5 th edition) edited by Raymond C Rowe, paul j. Sheskey, and Sian C. Owen; the publisher: pharmaceutical publishers.
For oral administration, the active ingredient (e.g., a compound described herein) can be readily formulated by combining the active ingredient with pharmaceutically acceptable carriers well known in the art. These carriers are capable of formulating the active ingredients of the present invention into tablets, pills, capsules, liquids, gels, syrups, slurries, powders or granules, suspensions or solutions in water or non-aqueous medium, and the like, for oral ingestion by a subject. Solid excipients can be used to prepare pharmaceutical formulations for oral use, the resulting mixture is optionally ground, and the mixture of granules is processed after adding suitable adjuvants (if desired) to obtain, for example, tablets. Suitable excipients such as diluents, binders or disintegrants may be required.
The dosage may vary depending upon the dosage form employed and the route of administration employed. The exact dosage form, route of administration and dosage may be selected by the respective physician according to the condition of the patient (see, e.g., fingl et al, 1975, "The Pharmacological Basis of Therapeutics"). Lower or higher doses than those listed above may be required. The specific dosage and treatment regimen of any particular subject will depend upon a variety of factors including the activity of the particular compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, disorder or condition, the subject's disposition to the disease, disorder or condition, and the discretion of the attendant physician. The course of treatment may include one or more separate administrations of the compounds of the present invention. The course of treatment may include one or more cycles of a compound described herein.
In some embodiments, a cycle as used herein in the context of a drug administration cycle refers to a period of time during which a drug is administered to a patient. For example, if the drug is administered at a period of 21 days, the periodic administration is, for example, administered once daily or twice daily for 21 days. A drug may be administered for more than one period. The rest period may be between two cycles. The rest period may be 1, 2, 4, 6, 8, 10, 12, 16, 20, 24 hours, 1, 2, 3, 4, 5, 6, 7 days or 1, 2, 3, 4 weeks or longer.
If desired, the oral dosage form may be presented in a packaging or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient. The package may for example comprise a metal or plastic foil, such as a blister package. The package or dispenser device may be accompanied by instructions for administration. The package or dispenser device may also be accompanied by a notice in the form prescribed by a government agency related to the container that prescribes manufacture, use or sale of pharmaceuticals, the notice reflecting approval by the agency of the form of administration of the composition or human or veterinary. For example, such notification may be a label for prescription drugs approved by the U.S. food and drug administration or an approved product insert.
Screening
The methods provided herein also include methods for screening or identifying subjects having cancers suitable for treatment with a MEK inhibitor or dual RAF/MEK inhibitor in combination with an SHP2 inhibitor. For example, the methods are directed to identifying a subject who is likely to respond to the cancer treatments described herein. Also provided are methods for optimizing the efficacy of treatment of a subject having cancer, wherein the treatment comprises administration of a MEK inhibitor or a combination of a dual RAF/MEK inhibitor and an SHP2 inhibitor.
In one aspect, provided herein is a method of detecting the presence of a SHP2 gene mutation associated with a subject having cancer, the method comprising:
(a) Obtaining a biological sample from a subject; and
(b) Detection is performed and the samples are screened for mutations.
In one aspect, provided herein is a method of identifying a subject having a cancer with a SHP2 gene mutation, the method comprising:
(a) Obtaining a biological sample from a subject; and
(b) Detection is performed and the samples are screened for mutations.
In another aspect, provided herein are methods for screening or identifying subjects having a cancer suitable for treatment with a MEK inhibitor or a dual RAF/MEK inhibitor in combination with an SOS1 inhibitor. For example, the methods are directed to identifying a subject who is likely to respond to the cancer treatments described herein. Also provided are methods for optimizing the efficacy of treatment of a subject having cancer, wherein the treatment comprises administration of a MEK inhibitor or a combination of a dual RAF/MEK inhibitor and a SOS1 inhibitor.
In another aspect, provided herein is a method of detecting the presence of a SOS1 gene mutation associated with a subject having cancer, the method comprising:
(a) Obtaining a biological sample from a subject; and
(b) Detection is performed and the samples are screened for mutations.
In one aspect, provided herein is a method of identifying a subject having a cancer with a SOS1 gene mutation, the method comprising:
(a) Obtaining a biological sample from a subject; and
(b) Detection is performed and the samples are screened for mutations.
In another aspect, provided herein are methods for screening or identifying subjects having cancer suitable for treatment with a MEK inhibitor or dual RAF/MEK inhibitor in combination with an ERK1/2 inhibitor. For example, the methods are directed to identifying a subject who is likely to respond to the cancer treatments described herein. Also provided are methods for optimizing the efficacy of treatment of a subject having cancer, wherein the treatment comprises administration of a MEK inhibitor or a combination of a dual RAF/MEK inhibitor and an ERK1/2 inhibitor.
In another aspect, provided herein is a method of detecting the presence of an ERK1/2 gene mutation associated with a subject having cancer, the method comprising:
(a) Obtaining a biological sample from a subject; and
(b) Detection is performed and the samples are screened for mutations.
In another aspect, provided herein is a method of identifying a subject having a cancer with an ERK1/2 gene mutation, the method comprising:
(a) Obtaining a biological sample from a subject; and
(b) Detection is performed and the samples are screened for mutations.
In another aspect, provided herein are methods for screening or identifying subjects having a cancer suitable for treatment with a MEK inhibitor or dual RAF/MEK inhibitor in combination with a CDK4/6 inhibitor. For example, the methods are directed to identifying a subject who is likely to respond to the cancer treatments described herein. Also provided are methods for optimizing the efficacy of treatment of a subject having cancer, wherein the treatment comprises administration of a MEK inhibitor or a dual RAF/MEK inhibitor in combination with a CDK4/6 inhibitor.
In another aspect, provided herein is a method of detecting the presence of a CDK4/6 gene mutation associated with a subject having cancer, the method comprising:
(a) Obtaining a biological sample from a subject; and
(b) Detection is performed and the samples are screened for mutations.
In another aspect, provided herein is a method of identifying a subject having a cancer with a CDK4/6 gene mutation, the method comprising:
(a) Obtaining a biological sample from a subject; and
(b) Detection is performed and the samples are screened for mutations.
In another aspect, provided herein are methods for screening or identifying subjects having a cancer suitable for treatment with a MEK inhibitor or dual RAF/MEK inhibitor in combination with an AKT inhibitor. For example, the methods are directed to identifying a subject who is likely to respond to the cancer treatments described herein. Also provided are methods for optimizing the efficacy of treatment of a subject having cancer, wherein the treatment comprises administration of a MEK inhibitor or a combination of a dual RAF/MEK inhibitor and an AKT inhibitor.
In another aspect, provided herein is a method of detecting the presence of an AKT gene mutation associated with a subject having cancer, the method comprising:
(a) Obtaining a biological sample from a subject; and
(b) Detection is performed and the samples are screened for mutations.
In another aspect, provided herein is a method of identifying a subject having a cancer with an AKT gene mutation, the method comprising:
(a) Obtaining a biological sample from a subject; and
(b) Detection is performed and the samples are screened for mutations.
In another aspect, provided herein are methods for screening or identifying subjects having a cancer suitable for treatment with a MEK inhibitor or a dual RAF/MEK inhibitor in combination with an mTOR inhibitor. For example, the methods are directed to identifying a subject who is likely to respond to the cancer treatments described herein. Also provided are methods for optimizing the efficacy of treatment of a subject having cancer, wherein the treatment comprises administration of a MEK inhibitor or a combination of a dual RAF/MEK inhibitor and an mTOR inhibitor.
In another aspect, provided herein is a method of detecting the presence of a mutation in an mTOR gene associated with a subject having cancer, the method comprising:
(a) Obtaining a biological sample from a subject; and
(b) Detection is performed and the samples are screened for mutations.
In another aspect, provided herein is a method of identifying a subject having a cancer with a mutation in an mTOR gene, the method comprising:
(a) Obtaining a biological sample from a subject; and
(b) Detection is performed and the samples are screened for mutations.
In another aspect, provided herein are methods for screening or identifying subjects having a cancer suitable for treatment with a MEK inhibitor or dual RAF/MEK inhibitor in combination with a pan-HER inhibitor. For example, the methods are directed to identifying a subject who is likely to respond to the cancer treatments described herein. Also provided are methods for optimizing the efficacy of treatment of a subject having cancer, wherein the treatment comprises administering a MEK inhibitor or a combination of a dual RAF/MEK inhibitor and a pan-HER inhibitor.
In another aspect, provided herein is a method of detecting the presence of a pan-HER gene mutation associated with a subject having cancer, the method comprising:
(a) Obtaining a biological sample from a subject; and
(b) Detection is performed and the samples are screened for mutations.
In another aspect, provided herein is a method of identifying a subject having a cancer with a pan-HER gene mutation, the method comprising:
(a) Obtaining a biological sample from a subject; and
(b) Detection is performed and the samples are screened for mutations.
In another aspect, provided herein are methods for screening or identifying subjects having a cancer suitable for treatment with a MEK inhibitor or a dual RAF/MEK inhibitor in combination with an EGFR inhibitor. For example, the methods are directed to identifying a subject who is likely to respond to the cancer treatments described herein. Also provided are methods for optimizing the efficacy of treatment of a subject having cancer, wherein the treatment comprises administering a MEK inhibitor or a combination of a dual RAF/MEK inhibitor and an EGFR inhibitor.
In another aspect, provided herein is a method of detecting the presence of an EGFR gene mutation associated with a subject having cancer, the method comprising:
(a) Obtaining a biological sample from a subject; and
(b) Detection is performed and the samples are screened for mutations.
In another aspect, provided herein is a method of identifying a subject having cancer with an EGFR gene mutation, the method comprising:
(a) Obtaining a biological sample from a subject; and
(b) Detection is performed and the samples are screened for mutations.
Samples include, but are not limited to, tissue samples (e.g., tumor tissue samples), primary or cultured cells or cell lines, cell supernatants, cell lysates, platelets, serum, plasma, vitreous humor, lymph, synovial fluid, follicular fluid, semen, amniotic fluid, milk, whole blood, blood derived cells, urine, cerebrospinal fluid, saliva, sputum, tears, sweat, mucus, tumor lysates and tissue culture media, tissue extracts, e.g., homogenized tissue, tumor tissue, cell extracts, and combinations thereof. In some embodiments, the sample is serum, blood, urine, or plasma.
Specific mutation status of the SHP2, SOS1, ERK1/2, CDK4/6, AKT, mTOR, pan-HER or EGFR gene in a sample obtained from an individual can be identified by any of a number of methods well known to those skilled in the art. For example, the identification of the mutation may be accomplished by cloning the SHP2, SOS1, ERK1/2, CDK4/6, AKT, mTOR, pan-HER or EGFR gene or portion thereof and sequencing it using techniques well known in the art. Alternatively, the gene sequence may be amplified from genomic DNA, for example using PCR, and the product sequenced. In some embodiments, the testing comprises sequencing. In some embodiments, the test comprises a Polymerase Chain Reaction (PCR). Exemplary assays include, but are not limited to, nucleic acid sequencing (dideoxy and pyrosequencing), real-time PCR with melting curve analysis, and allele-specific PCR with various modes for distinguishing mutant and wild-type sequences. The testing may also include quantitatively or semi-quantitatively determining the amount of mutation of cell free DNA (cfDNA) in the sample.
Examples
In order that the invention described herein may be more fully understood, the following examples are set forth. The examples described in this application are for illustration of the pharmaceutical compositions and methods provided herein and should not be construed in any way to limit their scope.
Example 1 anti-tumor efficacy of Dual RAF/MEK inhibitor VS-6766 and SHP2 inhibitor
Materials and methods
In vitro 3D proliferation assay
KRAS G12C, G D or G12V mutant non-small cell lung cancer (NSCLC) and pancreatic cancer cell lines were grown under 3D conditions. Briefly, 96-well plates were coated with 50. Mu.L Matrigel (100%) and incubated at 37℃and 5% CO 2 Incubate for 30 minutes to allow Matrigel to cure. Cells were inoculated in 100. Mu.L of 2% Matrigel in medium. After overnight incubation (17-22 hours), cells were treated with VS-6766+/-SHP2i (TNO 155 or RMC-4550) for 7 days. Cell viability was measured using the cell viability CellTiter-Glo assay. Fig. 1A shows an exemplary CellTiter-Glo assay for assessing cell viability of 16 KRAS G12C, G D or G12V mutant cell lines (9 NSCLC and 7 PDACs) grown under 3D conditions in a 7 day assay. IC50 s for VS-6766, TNO155 and RMC-4550 were calculated (FIG. 1B).
And (5) collaborative analysis.
Raw data and metadata files are processed using custom R scripts (custom R-scripts) for individual agents and combined activities. Bliss, loewe, highest Single Agent (HSA) and ZIP synergy analyses were performed to generate a composite synergy score. The abbreviated graph and report is saved for visualization and further analysis. The combined synergistic results of VS-6766+TNO155 or VS-6766+RMC-4550 were summarized using a waterfall plot. Briefly, FIG. 2A shows the operation of cells in a CTG proliferation assay. The raw data and metadata files are processed using custom rscript for individual agents and combined activities. Bliss, loewe, highest Single Agent (HSA) and ZIP synergy analyses were performed to generate a composite synergy score. FIG. 2B shows an example of VS-6766+TNO155 in H2122 cells. Fig. 2C shows a waterfall plot summarizing the combined synergy of VS-6766+ tno155 in a set of KRAS mut NSCLC and PDAC cell lines.
Xenograft tumor mice study
KRAS mutant H2122 NSCLC tumor cells were obtained from ATCC and Balb/c nude mice were obtained from Shanghai Ling Biotechnology Co., ltd (Shanghai Lingchang Biotechnology). By mixing 1x 10 7 Tumor cell suspensions were inoculated subcutaneously into the right flank of recipient mice to initiate tumor challenge. Once the average tumor volume reaches 150-200mm 3 Mice were divided into 4 groups (n=10): vehicle, VS-6766 (0.3 mg/kg PO QD), RMC-4550 (10 mg/kg QD) and VS-6766+RMC-4550. In another group of study, mice were divided into 4 groups (n=10): vehicle, VS-6766 (0.3 mg/kg PO QD), TNO155 (15 mg/kg BID) and VS-6766+TNO155.
Tumor size (mm) was measured weekly during the study period 3 ) And body weight 2 times. At routine monitoring, animals were examined for any effect of tumor growth and treatment on normal behavior, such as motility, food and water consumption (by observation only), weight gain/loss, eye/hair extinction, and any other abnormal effects.
Results
The dose response matrix was used to evaluate the antiproliferative effect of VS-6766 in combination with TNO155 or RMC-4550. The synergy scores were calculated using 4 different methods (Bliss, loewe, HSA and ZIP) in combination. VS-6766, in synergy with TNO155 (FIG. 3A, FIG. 3B) or RMC-4550 (FIG. 4A, FIG. 4B), reduced the viability of a panel of 16 KRAS mutations (G12C, G D and G12V) NSCLC and pancreatic cancer cell lines.
We also investigated whether VS-6766 enhances the in vivo efficacy of the SHP2 inhibitor RMC-4550 in the KRAS mutant H2122NSCLC model (FIG. 5A). As a result, it was found that the combination of VS-6766+RMC-4550 enhanced tumor growth inhibition compared to either single agent alone. Next we studied whether VS-6766 enhances the in vivo efficacy of the SHP2 inhibitor TNO155 in KRAS mutant H2122NSCLC model (fig. 5B). As a result, it was found that the combination of VS-6766+TNO155 enhanced tumor growth inhibition compared to either single agent alone.
These results support clinical assessment of the use of VS-6766 in combination with drugs against SHP2 and potentially establish VS-6766 as a support for the treatment of RAS-driven cancers.
Example 2 anti-tumor efficacy of Dual RAF/MEK inhibitor VS-6766 and SOS1 inhibitor
Materials and methods
In vitro 3D proliferation assay
KRAS G12C, G D or G12V mutant non-small cell lung cancer (NSCLC) and pancreatic cancer cell lines were grown under 3D conditions. Briefly, 96-well plates were coated with 50. Mu.L Matrigel (100%) and incubated at 37℃and 5% CO 2 Incubate for 30 minutes to allow Matrigel to cure. Cells were inoculated in 100. Mu.L of 2% Matrigel in medium. After overnight incubation (17-22 hours), cells were treated with VS-6766+/-BI-3406 for 7 days. Cell viability was measured using the cell viability CellTiter-Glo assay. Fig. 6A shows an exemplary CellTiter-Glo assay for assessing cell viability of 16 KRAS G12C, G D or G12V mutant cell lines (9 NSCLC and 7 PDACs) grown under 3D conditions in a 7 day assay. IC50 s for VS-6766 and BI-3406 were calculated (FIG. 56).
And (5) collaborative analysis.
Raw data and metadata files are processed using custom R scripts (custom R-scripts) for individual agents and combined activities. Bliss, loewe, highest Single Agent (HSA) and ZIP synergy analyses were performed to generate a composite synergy score. The abbreviated graph and report is saved for visualization and further analysis. The combined synergistic results of VS-6766+BI3406 are summarized using a waterfall plot. Briefly, cells were run in CTG proliferation assay (fig. 7A). The raw data and metadata files are processed using custom rscript for individual agents and combined activities. Bliss, loewe, highest Single Agent (HSA) and ZIP synergy analyses were performed to generate a composite synergy score. The abbreviated graph and report is saved for visualization and further analysis. An example used in this figure is VS-6766+BI-3406 in H2122 cells (FIG. 7B). The waterfall plot summarizes the combined synergistic results of VS-6766+bi-3406 in a panel of KRAS mut NSCLC and PDAC cell lines (fig. 7C).
Xenograft tumor mice study
KRAS mutant H2122 NSCLC tumor cells were obtained from ATCC and Balb/c nude mice were obtained from Shanghai Ling Biotechnology Co., ltd (Shanghai Lingchang Biotechnology). By mixing 1x 10 7 Tumor cell suspensions were inoculated subcutaneously into the right flank of recipient mice to initiate tumor challenge. Once the average tumor volume reaches 150-200mm 3 Mice were divided into 4 groups (n=10): vehicle, VS-6766 (0.3 mg/kg PO QD), BI-3406 (50 mg/kg BID) and VS-6766+BI-3406.
Tumor size (mm) was measured weekly during the study period 3 ) And body weight 2 times. At routine monitoring, animals were examined for any effect of tumor growth and treatment on normal behavior, such as motility, consumption of food and water (by observation only) and weight gain/loss, eye/hair extinction and any other abnormal effects.
Results
The dose response matrix was used to evaluate the antiproliferative effect of the combination of VS-6766 and BI 3406. The synergy scores were calculated using 4 different methods (Bliss, loewe, HSA and ZIP) in combination. VS-6766 has synergistic effects with BI3406, and can reduce the viability of a group of 16 KRAS mutant (G12C, G D and G12V) NSCLC and pancreatic cancer cell lines. FIG. 8A shows an exemplary waterfall graph summarizing the combined synergistic results of VS-6766+BI3406 in a set of KRAS mut NSCLC and PDAC cell lines. For example, VS-6766 in combination with BI3406 may enhance the anti-tumor response of H2122 cells (FIG. 8B).
We also investigated whether VS-6766 enhances the in vivo efficacy of SOS1 inhibitor BI-3406 in KRAS mutant H2122 NSCLC model (FIG. 9). As a result, it was found that the combination of VS-6766+BI-3406 enhanced tumor growth inhibition compared to either single agent alone.
These results support clinical assessment of the use of VS-6766 in combination with drugs against SOS1 and potentially establish VS-6766 as a support for the treatment of RAS-driven cancers.
Example 3 anti-tumor efficacy of Dual RAF/MEK inhibitor VS-6766 and ERK1/2 inhibitors
Materials and methods
In vitro 3D proliferation assay
KRAS G12C, G D or G12V mutant non-small cell lung cancer (NSCLC) and pancreatic cancer cell lines were grown under 3D conditions. Briefly, 96-well plates were coated with 50. Mu.L Matrigel (100%) and incubated at 37℃and 5% CO 2 Incubate for 30 minutes to allow Matrigel to cure. Cells were inoculated in 100. Mu.L of 2% Matrigel in medium. After overnight incubation (17-22 hours), cells were treated with VS-6766+/-LY-3214996 for 7 days. Cell viability was measured using the cell viability CellTiter-Glo assay. Fig. 10A shows an exemplary CellTiter-Glo assay for assessing cell viability of 16 KRAS G12C, G D or G12V mutant cell lines (9 NSCLC and 7 PDACs) grown under 3D conditions in a 7 day assay. IC50 s for VS-6766 and LY-3214996 were calculated (FIG. 10B).
And (5) collaborative analysis.
Raw data and metadata files are processed using custom R scripts (custom R-scripts) for individual agents and combined activities. Bliss, loewe, highest Single Agent (HSA) and ZIP synergy analyses were performed to generate a composite synergy score. The abbreviated graph and report is saved for visualization and further analysis. The combined synergy of VS-6766+ ly-3214996 is summarized using a waterfall plot. Briefly, cells were run in CTG proliferation assay (fig. 11A). The raw data and metadata files are processed using custom rscript for individual agents and combined activities. Bliss, loewe, highest Single Agent (HSA) and ZIP synergy analyses were performed to generate a composite synergy score. The abbreviated graph and report is saved for visualization and further analysis. An example used in this figure is VS-6766+LY-3214996 in H2122 cells (FIG. 11B). The waterfall plot summarizes the combined synergistic results of VS-6766+LY-3214996 in a panel of KRAS mut NSCLC and PDAC cell lines (FIG. 11C).
Xenograft tumor mice study
KRAS mutant H2122 NSCLC tumor cells were obtained from ATCC and Balb/c nude mice were obtained from Shanghai Ling Biotechnology Co., ltd (Shanghai Lingchang Biotechnology). By mixing 1x 10 7 Tumor cell suspensions were inoculated subcutaneously into the right flank of recipient mice to initiate tumor challenge. Once the average tumor volume reaches 150-200mm 3 Mice were divided into 4 groups (n=10): vehicle, VS-6766 (0.3 mg/kg PO QD), LY-3214996 (60 mg/kg QD) and VS-6766+LY-3214996.
Tumor size (mm) was measured weekly during the study period 3 ) And body weight 2 times. At routine monitoring, animals were examined for any effect of tumor growth and treatment on normal behavior, such as motility, consumption of food and water (by observation only) and weight gain/loss, eye/hair extinction and any other abnormal effects.
Results
The dose response matrix was used to evaluate the antiproliferative effect of the combination of VS-6766 and LY-3214996. The synergy scores were calculated using 4 different methods (Bliss, loewe, HSA and ZIP) in combination. VS-6766 has synergistic effects with LY-3214996, and can reduce the viability of a group of 16 KRAS mutant (G12C, G D and G12V) NSCLC and pancreatic cancer cell lines. FIG. 12A shows an exemplary waterfall plot summarizing the combined synergistic results of VS-6766+LY-3214996 in a set of KRAS mut NSCLC and PDAC cell lines. For example, VS-6766 in combination with LY-3214966 enhanced the anti-tumor response of H2122 cells (FIG. 12B).
We also investigated whether VS-6766 enhances the in vivo efficacy of ERK1/2 inhibitor LY-3214996 in the KRAS mutant H2122 NSCLC model (FIG. 13). As a result, it was found that the combination of VS-6766+LY-3214996 enhanced tumor growth inhibition compared to either single agent alone.
These results support clinical assessment of the use of VS-6766 in combination with drugs against ERK1/2 and potentially establish VS-6766 as a support for the treatment of RAS-driven cancers.
Example 4 anti-tumor efficacy of Dual RAF/MEK inhibitor VS-6766 and CDK4/6 inhibitor
Materials and methods
In vitro 3D proliferation assay
KRAS G12C, G D or G12V mutant non-small cell lung cancer (NSCLC) and pancreatic cancer cell lines were grown under 3D conditions. In another set of experiments, er+ breast cancer cell lines were grown under 3D conditions. Briefly, 96-well plates were coated with 50. Mu.L Matrigel (100%) and incubated at 37℃and 5% CO 2 Incubate for 30 minutes to allow Matrigel to cure. Cells were inoculated in 100. Mu.L of 2% Matrigel in medium. After overnight incubation (17-22 hours), cells were treated with VS-6766+/-palbociclib or abbe cili for 7 days. Cell viability was measured using the cell viability CellTiter-Glo assay. Fig. 14A shows an exemplary CellTiter-Glo assay for assessing cell viability of 16 KRAS G12C, G D or G12V mutant cell lines (9 NSCLC and 7 PDACs) grown under 3D conditions in a 7 day assay. The IC50 for VS-6766, palbociclib, or abbe cili was calculated (FIG. 14B).
And (5) collaborative analysis.
Raw data and metadata files are processed using custom R scripts (custom R-scripts) for individual agents and combined activities. Bliss, loewe, highest Single Agent (HSA) and ZIP synergy analyses were performed to generate a composite synergy score. The abbreviated graph and report is saved for visualization and further analysis. The combined synergy of VS-6766+ pamoxrib or abbe-cili was summarized using a waterfall plot. Briefly, cells were run in CTG proliferation assay (fig. 15A). The raw data and metadata files are processed using custom rscript for individual agents and combined activities. Bliss, loewe, highest Single Agent (HSA) and ZIP synergy analyses were performed to generate a composite synergy score. The abbreviated graph and report is saved for visualization and further analysis. An example used in this figure is VS-6766+Pabosini in A427 cells (FIG. 15B). The waterfall plot summarizes the combined synergistic results of VS-6766+ palbociclib in a panel of KRAS mut NSCLC and PDAC cell lines (fig. 15C).
Xenograft tumor mice study
KRAS mutant H2122 NSCLC tumor cells were obtained from ATCC and Balb/c nude mice were obtained from Shanghai Ling Biotechnology Co., ltd (Shanghai Lingchang Biotechnology). By mixing 1x 10 7 Subcutaneous inoculation of tumor cell suspensions into recipientsTumor challenge was initiated in the right flank of the body mice. Once the average tumor volume reaches 150-200mm 3 Mice were divided into 4 groups (n=10): vehicle, VS-6766 (0.3 mg/kg PO QD), abeli (25 mg/kg QD) and VS-6766+Abeli.
Tumor size (mm) was measured weekly during the study period 3 ) And body weight 2 times. At routine monitoring, animals were examined for any effect of tumor growth and treatment on normal behavior, such as motility, consumption of food and water (by observation only) and weight gain/loss, eye/hair extinction and any other abnormal effects.
Results
The dose response matrix was used to evaluate the antiproliferative effect of the VS-6766+ palbociclib or abbe cilib combination. The synergy scores were calculated using 4 different methods (Bliss, loewe, HSA and ZIP) in combination. VS-6766, acting synergistically with palbociclib (fig. 16A, 16B) or abeyanili (fig. 17A, 17B), reduced the viability of a panel of 16 KRAS mutations (G12C, G D and G12V) NSCLC and pancreatic cancer cell lines.
We also investigated whether VS-6766 enhanced the in vivo efficacy of the CDK4/6 inhibitor arbelide in the KRAS mutant H2122 NSCLC model (fig. 18). As a result, it was found that the combination of VS-6766+Abeli enhanced tumor growth inhibition compared to either single agent alone.
Next, the dose response matrix was used to evaluate the antiproliferative effect of the VS-6766+ Abeli combination in ER+ breast cancer cell lines. The synergy scores were calculated using 4 different methods (Bliss, loewe, HSA and ZIP) in combination. FIG. 19A shows Bliss, loewe, HSA and ZIP synergy analysis was performed to generate a composite synergy score. VS-6766 has synergistic effects with Abeli and can reduce the viability of a group of 3 ER+ breast cancer cell lines. FIG. 19B shows Bliss synergy scores in MCF7ER+ breast cancer cell lines, and FIG. 19C shows Bliss synergy scores in ZR-75-1ER+ breast cancer cell lines.
These results support clinical assessment of the use of VS-6766 in combination with drugs directed against CDK4/6 and potentially establish VS-6766 as a support for the treatment of RAS-driven cancers.
Example 5 anti-tumor efficacy of Dual RAF/MEK inhibitor VS-6766 with AKT or mTOR inhibitors
Materials and methods
In vitro 3D proliferation assay
KRAS G12C, G D or G12V mutant non-small cell lung cancer (NSCLC) and pancreatic cancer cell lines were grown under 3D conditions. Briefly, 96-well plates were coated with 50. Mu.L Matrigel (100%) and incubated at 37℃and 5% CO 2 Incubate for 30 minutes to allow Matrigel to cure. Cells were inoculated in 100. Mu.L of 2% Matrigel in medium. After overnight incubation (17-22 hours), cells were treated with VS-6766+/-patatide, M2698 or everolimus for 7 days. Cell viability was measured using the cell viability CellTiter-Glo assay. The CellTiter-Glo assay was used to evaluate the cell viability of 16 KRAS G12C, G D or G12V mutant cell lines (9 NSCLC and 7 PDACs) grown under 3D conditions in a 7 day assay (fig. 20A). IC50 s for VS-6766, patadine, M2698, and everolimus were calculated (FIG. 20B).
And (5) collaborative analysis.
Raw data and metadata files are processed using custom R scripts (custom R-scripts) for individual agents and combined activities. Bliss, loewe, highest Single Agent (HSA) and ZIP synergy analyses were performed to generate a composite synergy score. The abbreviated graph and report is saved for visualization and further analysis. The combined synergy of VS-6766+ patadine, M2698, or everolimus was summarized using a waterfall plot. Briefly, cells were run in CTG proliferation assay (fig. 21A). The raw data and metadata files are processed using custom rscript for individual agents and combined activities. Bliss, loewe, highest Single Agent (HSA) and ZIP synergy analyses were performed to generate a composite synergy score. The abbreviated graph and report is saved for visualization and further analysis. An example used in this figure is VS-6766+M2698 in SW1573 cells (FIG. 21B). The waterfall plot summarizes the combined synergistic results of VS-6766+m2698 in a panel of KRAS mut NSCLC and PDAC cell lines (fig. 21C).
Results
The dose response matrix was used to evaluate the antiproliferative effect of the combination of VS-6766+ patatide, M2698, or everolimus. The synergy scores were calculated using 4 different methods (Bliss, loewe, HSA and ZIP) in combination. VS-6766 synergistically acts with patadine (fig. 22A, 22B), M2698 (fig. 23A, 23B) or everolimus (fig. 24A, 24B) to reduce the viability of a panel of 16 KRAS mutations (G12C, G D and G12V) NSCLC and pancreatic cancer cell lines.
These results support clinical assessment of the use of VS-6766 in combination with drugs directed against AKT/mTOR and potentially establish VS-6766 as a support for the treatment of RAS-driven cancers.
Example 6 anti-tumor efficacy of Dual RAF/MEK inhibitor VS-6766 with pan-HER or EGFR inhibitor
Materials and methods
In vitro 3D proliferation assay
KRAS G12C, G D or G12V mutant non-small cell lung cancer (NSCLC) and pancreatic cancer cell lines were grown under 3D conditions. Briefly, 96-well plates were coated with 50. Mu.L Matrigel (100%) and incubated at 37℃and 5% CO 2 Incubate for 30 minutes to allow Matrigel to cure. Cells were inoculated in 100. Mu.L of 2% Matrigel in medium. After overnight incubation (17-22 hours), cells were treated with VS-6766+/-afatinib for 7 days. Cell viability was measured using the cell viability CellTiter-Glo assay. The CellTiter-Glo assay was used to evaluate the cell viability of 16 KRAS G12C, G D or G12V mutant cell lines (9 NSCLC and 7 PDACs) grown under 3D conditions in a 7 day assay (fig. 25A). IC50 s for VS-6766 and afatinib were calculated (FIG. 25B).
And (5) collaborative analysis.
Raw data and metadata files are processed using custom R scripts (custom R-scripts) for individual agents and combined activities. Bliss, loewe, highest Single Agent (HSA) and ZIP synergy analyses were performed to generate a composite synergy score. The abbreviated graph and report is saved for visualization and further analysis. The combined synergy of VS-6766+ afatinib was summarized using a waterfall plot. Briefly, cells were run in CTG proliferation assay (fig. 26A). The raw data and metadata files are processed using custom rscript for individual agents and combined activities. Bliss, loewe, highest Single Agent (HSA) and ZIP synergy analyses were performed to generate a composite synergy score. The abbreviated graph and report is saved for visualization and further analysis. An example used in this figure is VS-6766+ afatinib in H2122 cells (FIG. 26B). The waterfall plot summarizes the combined synergistic results of VS-6766+ afatinib in a panel of KRAS mut NSCLC and PDAC cell lines (fig. 26C).
Xenograft tumor mice study
KRAS mutant H2122 NSCLC tumor cells were obtained from ATCC and Balb/c nude mice were obtained from Shanghai Ling Biotechnology Co., ltd (Shanghai Lingchang Biotechnology). By mixing 1x 10 7 Tumor cell suspensions were inoculated subcutaneously into the right flank of recipient mice to initiate tumor challenge. Once the average tumor volume reaches 150-200mm 3 Mice were divided into 4 groups (n=10): vehicle, VS-6766 (0.3 mg/kg PO QD), afatinib (10 mg/kg QD) and VS-6766+afatinib.
EGFR mutant H1975 NSCLC tumor cells were obtained from ATCC, EGFR mutant H1975 octenib resistant NSCLC tumor cells were produced by Wuxi AppTec, and Balb/c nude mice were obtained from Peking Vitolihua laboratory animal technologies Co., ltd (Beijing Vital River Laboratory Animal Technology). By mixing 5x 10 6 Tumor cell suspensions were inoculated subcutaneously into the right flank of recipient mice to initiate tumor challenge. Once the average tumor volume reaches 150-200mm 3 Mice were divided into 4 groups (n=10): vehicle, VS-6766 (0.3 mg/kg PO QD), orientinib (2.5 mg/kg QD) and VS-6766+Orientinib.
Tumor size (mm) was measured weekly during the study period 3 ) And body weight 2 times. At routine monitoring, animals were examined for any effect of tumor growth and treatment on normal behavior, such as motility, consumption of food and water (by observation only) and weight gain/loss, eye/hair extinction and any other abnormal effects.
Results
The dose response matrix was used to evaluate the antiproliferative effect of the combination of VS-6766 and afatinib. The synergy scores were calculated using 4 different methods (Bliss, loewe, HSA and ZIP) in combination. VS-6766 has a synergistic effect with afatinib, reducing the viability of a panel of 16 KRAS mutant (G12C, G D and G12V) NSCLC and pancreatic cancer cell lines (FIG. 27A, FIG. 27B).
We investigated whether VS-6766 enhances the in vivo efficacy of the pan-HER inhibitor afatinib in the KRAS mutant H2122 NSCLC model (FIG. 28). As a result, it was found that the combination of VS-6766+afatinib enhanced tumor growth inhibition compared to either single agent alone.
We also investigated whether VS-6766 enhanced the in vivo efficacy of the EGFR inhibitor of octreotide in EGFR mutant H1975, parental and octreotide resistant NSCLC models (fig. 29, fig. 30). In the H1975 parental model, tumor regression occurred with VS-6766+octtinib, but no tumor regression occurred with either drug alone (fig. 29). Furthermore, an increase in survival was observed in the combination treatment group compared to either single drug alone. In the H1975 octenib resistance model, VS-6766 increased tumor growth inhibition and survival compared to the octenib single agent (FIG. 30).
These results support clinical assessment of the use of VS-6766 in combination with drugs against EGFR, and potentially establish VS-6766 as a support for the treatment of RAS-driven cancers.
Equivalents and scope
In the claims, articles such as "a/an" and "the" may mean one or more than one unless indicated to the contrary or otherwise apparent from the context. Unless indicated to the contrary or otherwise apparent from the context, a claim or specification that includes an "or" between one or more members of a group is considered satisfied if one, more than one, or all of the group members are present, used in, or otherwise relevant to a given product or method. The present invention includes implementations in which exactly one member of the group is present, used in, or otherwise related to a given product or process. The present invention includes embodiments in which more than one or all of the group members are present, used in, or otherwise related to a given product or process.
Furthermore, the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims are introduced into another claim. For example, any claim that is dependent on another claim may be modified to include one or more limitations found in any other claim that is dependent on the same base claim. When elements are presented in a manifest form (e.g., in Markush group (Markush group)), each subset of the elements is also disclosed, and any elements may be removed from the group. It should be understood that, in general, where the invention or aspects of the invention are referred to as comprising particular elements and/or features, certain embodiments of the invention or aspects of the invention consist of or consist essentially of such elements and/or features. For simplicity, those embodiments have not been set forth herein exclusively in these words. It should also be noted that the terms "comprising" and "including" are intended to be open-ended and allow for the inclusion of additional elements or steps. Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values expressed as ranges may employ any particular value or subrange within the range in different embodiments of the invention, reaching one tenth of the unit of the lower limit of the range unless the context clearly dictates otherwise.
This application mentions various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. If there is a conflict between any of the incorporated references and this specification, the present specification shall control. In addition, any particular embodiment of the invention that falls within the prior art may be explicitly excluded from any one or more of the claims. Because such embodiments are considered to be known to those of ordinary skill in the art, they may be excluded even if the exclusion is not explicitly set forth herein. Any particular embodiment of the invention may be excluded from any claim for any reason, whether or not related to the presence of prior art.
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described herein. The scope of the embodiments of the invention described herein is not intended to be limited by the foregoing description, but is instead set forth in the following claims. Those skilled in the art will appreciate that various changes and modifications may be made to the invention without departing from the spirit or scope thereof as defined in the appended claims.
Claims (94)
1. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a) an effective amount of a CDK4/6 inhibitor; and b) an effective amount of a dual RAF/MEK inhibitor, thereby treating the subject.
2. A method according to claim 1, wherein the CDK4/6 inhibitor is GLR2007, roniciclib, RP-CDK4/6, TQB3303, trazoyside, SHR-6390, ly Luo Xili, FCN-437c, azoxystrobin, PF-06873600, XZP-3287, ON-123300, ETH-155008, HEC-80797, JS-104, PF-07220060, RMC-4550, SRX-3177, VS-2370), palbociclib, rebaudinib, letrozole+rebabociclib, or abbe's, or a pharmaceutically acceptable salt thereof.
3. A method according to claim 1 or 2, wherein the CDK4/6 inhibitor is abbe, pamoxnib or rebamiphene, or a pharmaceutically acceptable salt thereof.
4. A method according to any one of claims 1 to 3 wherein the CDK4/6 inhibitor is administered at least once daily.
5. A method according to any one of claims 1 to 4 wherein the CDK4/6 inhibitor is administered once daily.
6. A method according to any one of claims 1 to 4 wherein the CDK4/6 inhibitor is administered twice daily.
7. A method according to any one of claims 1 to 6 wherein the CDK4/6 inhibitor is administered orally.
8. A method according to any one of claims 1 to 7 wherein the CDK4/6 inhibitor is administered at about 1mg to about 1000mg per administration.
9. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a) an effective amount of an SOS1 inhibitor; and b) an effective amount of a dual RAF/MEK inhibitor, thereby treating the subject.
10. The method according to claim 9, wherein the SOS1 inhibitor is BMS-SCH, SDGR5, BI-3406, BAY-293, RMC-5845, SDGR5 or BI-1701963, or a pharmaceutically acceptable salt thereof.
11. The method according to claim 9 or 10, wherein the SOS1 inhibitor is SDGR-5, BI-3406 or BI-1701963, or a pharmaceutically acceptable salt thereof.
12. The method according to any one of claims 9-11, wherein the SOS1 inhibitor is administered at least once daily.
13. The method according to any one of claims 9-12, wherein the SOS1 inhibitor is administered once daily.
14. The method according to any one of claims 9-12, wherein the SOS1 inhibitor is administered twice daily.
15. The method according to any one of claims 9-14, wherein the SOS1 inhibitor is administered orally.
16. The method according to any one of claims 9-15, wherein the SOS1 inhibitor is administered at about 1mg to about 1000mg per administration.
17. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a) an effective amount of an ERK1/2 inhibitor; and b) an effective amount of a dual RAF/MEK inhibitor, thereby treating the subject.
18. The method according to claim 17, wherein the ERK1/2 inhibitor is AZ6197, BI ERKi, CC-90003, erat-007, HMPL-295, IPN-ERK, KO-947, LTT462, SCH772984, TK216, ASTX-029, HH-2710, LY-3214996, ulitinib, ASN-007, ATG-017, BPI-27336, JSI-1187, MK-8353, JRP-890 or JRF-108, or a pharmaceutically acceptable salt thereof.
19. The method of claim 17 or 18, wherein the ERK1/2 inhibitor is LY-3214996, or a pharmaceutically acceptable salt thereof.
20. The method according to any one of claims 17-19, wherein the ERK1/2 inhibitor is administered at least once daily.
21. The method according to any one of claims 17-20, wherein the ERK1/2 inhibitor is administered once daily.
22. The method according to any one of claims 17-20, wherein the ERK1/2 inhibitor is administered twice daily.
23. The method according to any one of claims 17-22, wherein the ERK1/2 inhibitor is administered orally.
24. The method according to any one of claims 17-23, wherein the ERK1/2 inhibitor is administered at about 1mg to about 1000mg per administration.
25. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a) an effective amount of an SHP2 inhibitor; and b) an effective amount of a dual RAF/MEK inhibitor, thereby treating the subject.
26. The method according to claim 25, wherein the SHP2 inhibitor is erat-601, TNO-155, SHP099, RMC-4630, RMC-4550, IACS-13909, JAB-3068, JAB-3312, rle-1971, BBP-398, HBI-2376 or ICP-189, BR790, ETS-001, PF-07284892, RX-SHP2i, SH3809, TAS-ASTX, X-37-SHP2, or a pharmaceutically acceptable salt thereof.
27. The method according to claim 25 or 26, wherein the SHP2 inhibitor is JAB-3068, RMC-4630, TNO-155, JAB-3312, rli-1971, BBP-398, HBI-2376, ICP-189 or RMC-4550, or a pharmaceutically acceptable salt thereof.
28. The method according to any one of claims 25-27, wherein the SHP2 inhibitor is administered at least once daily.
29. The method according to any one of claims 25-28, wherein the SHP2 inhibitor is administered once daily.
30. The method according to any one of claims 25-28, wherein the SHP2 inhibitor is administered twice daily.
31. The method according to any one of claims 25-30, wherein the SHP2 inhibitor is administered orally.
32. The method according to any one of claims 25-31, wherein the SHP2 inhibitor is administered at about 1mg to about 1000mg per administration.
33. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a) an effective amount of an AKT inhibitor; and b) an effective amount of a dual RAF/MEK inhibitor, thereby treating the subject.
34. The method according to claim 33, wherein the AKT inhibitor is capigaservib, patatide, LY-2503029, afuresertib hydrochloride, COTI-2, miranservib mesylate, MK-2206, MK-2206+ semtinib sulfate, ONC-201, PTX-200, TAS-117, trimetinib dimethyl sulfoxide + jeponatide, ARQ-751, AT-13148, M2698, ALM-301, BAY-1125976, borussertib, DC-120, FXY-1, JRP-890, KS-99, NISC-6, RX-0201, or RX-0301, or a pharmaceutically acceptable salt thereof.
35. The method according to claim 33 or 34, wherein the AKT inhibitor is M2698 or patatine, or a pharmaceutically acceptable salt thereof.
36. The method according to any one of claims 33-35, wherein the AKT inhibitor is administered at least once daily.
37. The method according to any one of claims 33-36, wherein the AKT inhibitor is administered once daily.
38. The method according to any one of claims 33-36, wherein the AKT inhibitor is administered twice daily.
39. The method according to any one of claims 33-38, wherein the AKT inhibitor is administered orally.
40. The method according to any one of claims 33-39, wherein the AKT inhibitor is administered at about 1mg to about 1000mg per administration.
41. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a) an effective amount of an mTOR inhibitor; and b) an effective amount of a dual RAF/MEK inhibitor, thereby treating the subject.
42. The method according to claim 41, wherein the mTOR inhibitor is everolimus, zortress, sirolimus, temsirolimus, albumin-bound sirolimus, dactolisib tosylate, onatasertib, DTRMWXHS-12+ everolimus+pomalidomide, bimiralisib, CC-115, monetel, sha Pase, sirolimus, valdecolonite, dierotigotine, FP-208, HEC-68498, LXI-15029, ME-344, PTX-367, WXFL-10030390, XP-105, paclitaxel+sirolimus+tamsulosin, AL-58805, AL-58922, AUM-302, CA-102, CA-103, CT-PQF-529, DHM-25, QFT-1518, NSC-765844, omipalisib, OSU-53, OT-043, PQR-514, pramipexole mesylate, QR-213, RMC-5552, SN-202, OSI-965, TAM-03, or a pharmaceutically acceptable salt thereof.
43. The method according to claim 41 or 42, wherein the mTOR inhibitor is everolimus, or a pharmaceutically acceptable salt thereof.
44. The method according to any one of claims 41-43, wherein the mTOR inhibitor is administered at least once daily.
45. The method according to any one of claims 41-44, wherein the mTOR inhibitor is administered once daily.
46. The method according to any one of claims 41-44, wherein the mTOR inhibitor is administered twice daily.
47. The method according to any one of claims 41-46, wherein the mTOR inhibitor is administered orally.
48. The method according to any one of claims 41-47, wherein the mTOR inhibitor is administered at about 1mg to about 1000mg per administration.
49. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a) an effective amount of a pan-HER inhibitor; and b) an effective amount of a dual RAF/MEK inhibitor, thereby treating the subject.
50. The method of claim 49, wherein the pan-HER inhibitor is ZW49, PB 357, MP 0274, VRN 07, BDTX 189, saprotinib, zetolizumab, wave Ji Tini, mo Bo tib, valitinib, pyrroltinib, lapatinib, afatinib, lenatinib, or dacatinib, or a pharmaceutically acceptable salt thereof.
51. The method of claim 49 or 50, wherein the pan-HER inhibitor is saprotinib, zetuzumab, boscalid Ji Tini, mo Bo tinib, valitinib, pyrroltinib, lapatinib, afatinib, lenatinib, or dacatinib, or a pharmaceutically acceptable salt thereof.
52. The method according to any one of claims 49-51, wherein the pan-HER inhibitor is administered at least once daily.
53. The method of any one of claims 49-52, wherein the pan-HER inhibitor is administered once daily.
54. The method according to any one of claims 49-52, wherein the pan-HER inhibitor is administered twice daily.
55. The method according to any one of claims 49-54, wherein the pan-HER inhibitor is administered orally.
56. The method of any one of claims 49-55, wherein the pan-HER inhibitor is administered at about 1mg to about 1000mg per administration.
57. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a) an effective amount of an EGFR inhibitor; and b) an effective amount of a dual RAF/MEK inhibitor, thereby treating the subject.
58. A method according to claim 57, wherein the EGFR inhibitor is doxorubicin + erlotinib, votuximab + zatuximab, evelutinib (abvirtinib) (e.g., evelutinib maleate), ABP-1119, ABP-1130, afatinib (e.g., afatinib dimaleate), AG-101, AL-6802, almitinib (almonetinib) (e.g., ametinib mesylate), evelutinib (Evelutinib maleate), evelutinib (Evelutinib acetate) AM-105, amelimumab, E Mo Tuoshan antibody, AMX-3009, APL-1898, ASK-120067, AST-2818, BBT-176, BDTX-189, BEBT-108, BEBT-109, BH-2922, BLU-4810, BMX-002, BO-1978, BPI-15086, BPI-7711, buntinib, C-005, cetuximab, CK-101 CLM-29, CLM-3, CMAB-017, CR-13626, CSHEGF-29, D-0316, D2C7-it+pvsripo, dabrafenib mesylate+panitumumab+trimetinib dimethyl sulfoxide, daccotinib, DBPR-112, rituximab, DGD-1202, doxitinib (e.g., doxitinib mesylate), DZD-9008, EO-1001, ai Peiti ni, erlotinib (e.g., erlotinib hydrochloride), ES-072, FCN-411, FHND-9041, FLAG-001, FLAG-003, fmpl-2, GB-263, GC-1118A, gefitinib, GS-03+octtinib, HA-12128, HMPL-309, HMPL-813, HS-627, icotinib (e.g., icotinib hydrochloride) JMT-101, JRF-103, JZB-29, KBP-5209, KNP-501, KU-004, lapatinib (e.g., lapatinib ditosylate), lagrantinib, razitinib, lifrafenib (e.g., lifrafenib maleate), MCLA-129, MCLA-158, MDC-22, mo Bo tinib, mRX-7, MTX-211, MVC-101, naquotinib (e.g., naquotinib mesylate), naquotinib (e.g., nazatinib mesylate), cetuximab, lenatinib, nimustinab, NRC-2694, NT-004, NT-113, OBX-1012, omatinib (e.g., omatinib hydrochloride), octenib (e.g., octenib mesylate), panitumumab, PB-357, lamitinib, and pharmaceutical compositions containing the same wave Ji Tini, pyrroltinib, QL-1105, QL-1203, RXDX-105, SAH-EJ1, saprotinib, SCT-200, selatinib (e.g., selatinib di-p-toluenesulfonate), cerotinib, SKLB-1028, SKLB-1206, SPH-118811, SYN-004, TAS-6417, tervaltinib (tervaltinib) (e.g., tervaltinib p-toluenesulfonate), TGRX-360, toxib mab, TQB-3804, UBP-1215, vandetanib, varlitinib, VRN-071918, VRN-6, WBP-297, WJ-13404, WSD-0922, XZP-5809, inlittinib, YZJ-0318, ZNE-4, ZLitinib, ZR-2002, ZSP-0391, ORIC-114, JS-2087 b, 111, LL-191, BI-4020 or Y-2476568, or a pharmaceutically acceptable salt thereof.
59. The method of claim 57 or 58, wherein the EGFR inhibitor is afatinib or octeninib, or a pharmaceutically acceptable salt thereof.
60. The method according to any one of claims 57-59, wherein the EGFR inhibitor is administered at least once daily.
61. The method according to any one of claims 57-60, wherein the EGFR inhibitor is administered once daily.
62. The method according to any one of claims 57-60, wherein the EGFR inhibitor is administered twice daily.
63. The method according to any one of claims 57-62, wherein the EGFR inhibitor is administered orally.
64. The method of any one of claims 57-63, wherein the EGFR inhibitor is administered at about 1mg to about 1000mg per administration.
65. The method according to any one of claims 1-64, wherein the dual RAF/MEK inhibitor is a compound of formula (I):
66. the method according to claim 65, wherein the dual RAF/MEK inhibitor is a compound of formula (I):
67. the method according to claim 65, wherein the dual RAF/MEK inhibitor is a potassium salt of the compound of formula (I).
68. The method according to any one of claims 1-67, wherein the dual RAF/MEK inhibitor is administered orally to the subject.
69. The method according to any one of claims 1-68, wherein the dual RAF/MEK inhibitor is administered twice a week.
70. The method according to any one of claims 1-69, wherein the dual RAF/MEK inhibitor is administered at a dose of 0.5mg to about 10mg per administration.
71. The method according to claim 70, wherein the dual RAF/MEK inhibitor is dosed at 3.2mg per administration.
72. The method according to claim 70, wherein the dual RAF/MEK inhibitor is dosed at 4mg per administration.
73. The method according to any one of claims 1-72, wherein the dual RAF/MEK inhibitor is administered as a cycle comprising administering the dual RAF/MEK inhibitor for three weeks followed by discontinuing the administration of the dual RAF/MEK inhibitor for one week.
74. The method according to any one of claims 1-73, wherein the cancer is lung adenocarcinoma, non-small cell lung carcinoma, colorectal carcinoma, endometrioid carcinoma, bladder urothelial carcinoma, breast invasive lobular carcinoma, cervical squamous cell carcinoma, cutaneous melanoma, cervical adenocarcinoma, hepatocellular carcinoma, pancreatic carcinoma, bipolar pleural mesothelioma, renal clear cell carcinoma, gastric adenocarcinoma, tubular gastric adenocarcinoma, uterine sarcoma, or uterine malignancy mixed Mullerian tumor.
75. The method according to any one of claims 1-73, wherein the cancer is pancreatic cancer, gynaecological cancer (e.g., cervical cancer, ovarian cancer, uterine cancer, vaginal cancer, endometrial cancer or vulvar cancer), liver cancer, prostate cancer, mesothelioma, breast cancer, bladder cancer, melanoma, lung cancer, colorectal cancer, thyroid cancer, glioblastoma or renal cancer.
76. The method according to any one of claims 1-73, wherein the cancer is melanoma, lung cancer, colorectal cancer, ovarian cancer, thyroid cancer, glioblastoma, or renal cancer.
77. A method according to claim 76, wherein said lung cancer is non-small cell lung cancer.
78. A method according to claim 76, wherein said lung cancer is metastatic non-small cell lung cancer.
79. The method according to claim 76, wherein the melanoma is unresectable melanoma.
80. The method according to claim 76, wherein the melanoma is metastatic melanoma.
81. The method according to claim 76, wherein the cancer is colorectal cancer.
82. The method according to claim 76, wherein the cancer is ovarian cancer.
83. The method according to any one of claims 1-82, wherein the cancer is identified as having a RAS mutation.
84. The method according to any one of claims 1-83, wherein the cancer is identified as having a KRAS, NRAS or HRAS mutation.
85. The method of claim 84, wherein the KRAS mutation is a mutation in KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S or KRAS G12C.
86. The method of claim 84, wherein the KRAS mutation is a mutation in KRAS G13V, KRAS G13D, KRAS G13A, KRAS G13R, KRAS G13S, KRAS G13E, KRAS G12 dup, or KRAS G13C.
87. The method of claim 84, wherein the KRAS mutation is a mutation in KRAS Q61H, KRAS Q61K, KRAS Q61L, KRAS Q61R, KRAS Q61P or KRAS Q61E.
88. The method according to any one of claims 1-87, wherein the cancer is identified as having a RAF mutation.
89. The method according to any one of claims 1-88, wherein the cancer is identified as having a BRAF, ARAF or CRAF mutation.
90. The method according to claim 89, wherein the BRAF mutation is a BRAF V600 mutation.
91. The method according to any one of claims 1-90, wherein the cancer is identified as having a MEK1 and/or MEK2 mutation.
92. The method of any one of claims 1-91, wherein the cancer is identified as having NF1 alterations, KRAS amplification and/or NRAS amplification.
93. The method according to any one of claims 1-92, wherein the cancer is identified as having positive phosphorylated ERK protein expression (e.g. ≡10%, ≡20% or ≡30% cells) by immunohistochemical detection.
94. The method according to any one of claims 1-93, wherein the cancer is identified as having an EGFR change.
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63/146,352 | 2021-02-05 | ||
US63/146,395 | 2021-02-05 | ||
US63/146,349 | 2021-02-05 | ||
US63/146,369 | 2021-02-05 | ||
US63/146,357 | 2021-02-05 | ||
US63/146,376 | 2021-02-05 | ||
US202163185704P | 2021-05-07 | 2021-05-07 | |
US63/185,695 | 2021-05-07 | ||
US63/185,704 | 2021-05-07 | ||
US63/185,672 | 2021-05-07 | ||
US63/185,651 | 2021-05-07 | ||
PCT/US2022/015262 WO2022170060A1 (en) | 2021-02-05 | 2022-02-04 | Combination therapy for treating abnormal cell growth |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117729923A true CN117729923A (en) | 2024-03-19 |
Family
ID=90209300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280026743.9A Pending CN117729923A (en) | 2021-02-05 | 2022-02-04 | Combination therapy for the treatment of abnormal cell growth |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117729923A (en) |
-
2022
- 2022-02-04 CN CN202280026743.9A patent/CN117729923A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20230142757A (en) | Combination therapy to treat abnormal cell growth | |
TWI609012B (en) | Aminoquinazoline derivatives and their salts and methods of use thereof | |
KR20230011908A (en) | Combination therapy to treat abnormal cell growth | |
US20120316137A1 (en) | Methods and Compositions for Treating Cancer | |
CN112472699A (en) | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | |
KR20140025434A (en) | Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use | |
CN118510505A (en) | Combination therapy for the treatment of abnormal cell growth | |
KR20230011277A (en) | Methods of treating abnormal cell growth | |
JP2020507566A (en) | Benzothiophene estrogen receptor modulator | |
WO2023147297A2 (en) | Combination therapy for treating abnormal cell growth | |
EP4444310A2 (en) | Combination therapy for treating abnormal cell growth | |
CN118647382A (en) | Methods for treating abnormal cell growth | |
CN115414480A (en) | Dianhydrogalactitol in combination with radiation for treatment of non-small cell lung cancer and glioblastoma multiforme | |
KR20230039684A (en) | Combination therapy to treat abnormal cell growth | |
KR20230057384A (en) | combination therapy | |
CN117729923A (en) | Combination therapy for the treatment of abnormal cell growth | |
TW202320792A (en) | Combination therapy comprising an fgfr inhibitor and a kras inhibitor | |
CN111840289A (en) | Quinoline compound or pharmaceutically acceptable salt thereof for treating giant cell tumor of bone | |
WO2023235356A1 (en) | Combination therapy for treating abnormal cell growth | |
EA046076B1 (en) | CSF1R INHIBITORS FOR CANCER TREATMENT | |
WO2024130344A1 (en) | Transient receptor potential vanilloid 6 inhibitors | |
CN117440813A (en) | EGFR degrading agents for treating brain or CNS cancer metastasis | |
TW202432142A (en) | Combination therapy for treating cancer | |
JP2024537550A (en) | Methods of Treatment for Patients with Cancer Associated with Dysregulation of the MAPK and/or PI3K Pathways | |
WO2024033513A1 (en) | Compounds for treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |